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The MBD2-NuRD co-repressor complex is an epigenetic regulator of the developmental 
silencing of embryonic and fetal β-type globin genes in adult erythroid cells as well as 
aberrant methylation-dependent silencing of tumor suppressor genes in neoplastic 
diseases. Biochemical characterization of the MBD2-NuRD complex in chicken 
erythroid cells identified RbAp46/48, HDAC1/2, MTA1/2/3, p66α/β, Mi2α/β and MBD2 to 
comprise this multi-protein complex.
In the work presented in Chapter 2, we have pursued biophysical and molecular studies 
to describe a previously uncharacterized domain of human MBD2 (MBD2IDR). 
Biophysical analyses show that MBD2IDR is an intrinsically disordered region (IDR). 
Despite this inherent disorder, MBD2IDR increases the overall binding affinity of MBD2 
for methylated DNA. MBD2IDR also recruits the histone deacetylase core components 
(RbAp48, HDAC2 and MTA2) of NuRD through a critical area of contact requiring two 
contiguous amino acid residues, Arg286 and Leu287. Mutation of these critical residues 
abrogates interaction of MBD2 with the histone deacetylase core and impairs the ability 
of MBD2 to repress the methylated tumor suppressor gene Prostasin in MDA-MB-435 
breast cancer cells. These findings expand our knowledge of the multi-dimensional 
interactions of the MBD2-NuRD complex that govern its function. 
    In Chapter 3, we have discussed a novel mechanism for MBD2-mediated silencing of 
the fetal γ-globin gene. Through microarray expression analyses in adult erythroid cells 
of MBD2-/- mice, we identified ZBTB32 and miR-210 as downstream targets of MBD2.  
Over-expression of ZBTB32 and miR-210 in adult erythroid cells causes increased 
expression of the silenced fetal γ-globin gene. Thus, our results indicate that MBD2 may 
regulate γ-globin gene expression indirectly though ZBTB32 and miR-210 in adult 
erythroid cells. 
  1 
CHAPTER 1: Introduction 
 
 
 
 
I. Hemoglobin and the hemoglobin switch: 
 
 
A. Hemoglobin 
Hemoglobin is the oxygen carrying metalloprotein in the red blood cells in our body. 
Hemoglobin carries oxygen from the lungs to other tissues in the body. Although there 
are many variants of hemoglobin in normal embryonic, fetal and adult life as well as 
different pathologic conditions, each hemoglobin molecule is a tetramer consisting of 
four subunits including two α-like chains and two β-like globin chains. In humans, the 
genes coding the α-chains are located on the short arm of chromosome 16 (16p13.3). 
The α-globin locus contains one functional embryonic ζ-globin gene and two adult α-
globin genes (α1 and α2). The genes coding for the β-globin chains are located on the 
short arm of chromosome 11 (11p15.5) and it determines different types of hemoglobin 
chains that are expressed in different stages of development (David G. Nathan, David 
Ginsburg, Stuart H. Orkin, A. Thomas Look, 2003).  
   In adult humans, the most common form of hemoglobin is HbA (α2β2) which comprises 
~95% of the total hemoglobin. HbA2 (α2δ2) comprises about 1.5-3.5% of the total 
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hemoglobin whereas the fetal hemoglobin HbF (α2γ2) comprises <2% of the total 
hemoglobin in adults (David G. Nathan, David Ginsburg, Stuart H. Orkin, A. Thomas 
Look 2003). 
 
B. The β-globin gene locus and the hemoglobin switch:  
The human β-globin gene cluster lies on the short arm of chromosome 11 (11p15.5) 
and consists of different genes that code for the β-globin subunit of hemoglobin. This 
cluster includes a pseudogene (ψβ) and 5 functional genes: 5’ - epsilon(ε) - gamma 
G(Gγ) - gamma A(Aγ) - delta(δ) - beta(β) which are expressed in the order of their 
arrangement within the locus (Stamatoyannopoulos et al. 2001). All of the expressed β-
type globin gene products have 146 amino acids and consist of two introns and 3 
exons.  
   The earliest hemoglobin to be expressed is the embryonic hemoglobin (ζ2ε2) which 
consists of the ε-globin subunit from the β-globin gene cluster and the ζ-globin subunit 
from the α-globin gene cluster. The ε-globin gene is expressed in the first wave of 
primitive erythropoiesis from the yolk sac during the first 5-7 weeks of gestation.  
   At 5-7 weeks post gestation, the primitive erythroid lineage is replaced by the 
definitive erythroid lineage and undergoes maturational globin switching at which time 
the ε-globin gene expression ceases and the fetal γ-globin gene expression begins. 
This first major “hemoglobin switching” event coincides with the changes in the sites of 
erythropoiesis from the embryonic yolk sac to the developing fetal liver. Fetal 
hemoglobin (α2γ2) consists of the fetal β-type globin subunits, 
Gγ and 
Aγ, and the α-
globin subunit from the α-globin gene cluster (Figure 1). The γ-chains arose due to gene 
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duplications in primate evolution and differ only in the presence of glycine or alanine, 
respectively, at position 136. The Gγ subunit is produced three times higher than the Aγ 
subunit in these fetal erythrocytes.  
    The second major “hemoglobin switch” occurs perinatally in humans and Old World 
primates around 32 weeks post-gestation when the fetal γ-globin subunits are gradually 
replaced by two adult β-globin subunits forming the adult hemoglobin: α2β2. By six 
months of age, adult hemoglobin HbA1 (α2β2) is the primary hemoglobin that is 
expressed. The adult bone marrow is now the primary site of erythropoiesis for the adult 
erythrocytes (Figure 1) (Boyer et al. 1975; Ley et al. 1989; Peschle et al. 1985).  
       The first “hemoglobin switch” occurring in the primitive embryonic erythroid cells to 
give way to the definitive erythroid cells is found among all vertebrates. However the 
second “hemoglobin switch” leading from fetal-to-adult definitive erythroid cells occurs 
only in the primates and humans and is believed to be due to the unique expression of 
the γ genes during the fetal period - an event which took place around 35 to 55 million 
years ago during primate evolution. Although the γ- and β-globin chains are highly 
homologous, there are significant structural differences between them which confer 
different functional properties to HbF and HbA. HbF has higher average affinity for 
oxygen compared to HbA; this property is physiologically relevant since the maternal O2  
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Figure 1. The hemoglobin switch. (A) Hemoglobin switching in man. Around week 6 of gestation, 
embryonic globin (ε) is silenced and fetal globin (γ) starts to be expressed. Perinatally the switch to adult 
globin (β) occurs. For the α-like globins, a single switch from the embryonic (ζ) to adult (α) globin occurs 
(not shown). (B) Major anatomical sites of hematopoiesis during development. Erythropoiesis occurs in 
the blood islands of the yolk sac in the first 8 weeks of gestation, then in the fetal liver between 8 and 32 
weeks, and finally in the bone marrow from 32 weeks on. Around birth the spleen serves as a transient 
erythropoietic organ (not shown). (C) Structure of the main human hemoglobins expressed during 
development. Embryonic globin (ζ2ε2; HbE Gower-1); fetal hemoglobin (α2γ2; HbF) and adult 
hemoglobin (α2β2, HbA).  Adapted from Cantu and Philipsen, 2014.  
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needs to diffuse to the fetal circulation and the higher O2 affinity of HbF ensures that 
some of the maternal O2 will be trapped by the fetal circulatory system. Also, the lower 
O2 affinity of adult hemoglobin (maternal hemoglobin) readily allows transfer of its O2 to 
fetal hemoglobin (Bell 1999). 
       
II. Erythropoiesis:  
Erythropoiesis is the process by which red blood cells are formed from erythroid 
precursor cells. There are two types of erythropoiesis in humans, primitive 
erythropoiesis and definitive erythropoiesis. Primitive erythropoiesis occurs from the 
“blood islands” in the yolk sac early on during embryonic development and gives rise to 
large, nucleated erythroid cells which mature and enucleate in circulation. Definitive 
erythropoiesis occurs during late fetal life and throughout adulthood when the sites of 
erythropoiesis are the fetal liver and postnatal bone marrow respectively, giving rise to 
mature, enucleated erythroid cells. Unlike primitive erythropoiesis, definitive 
erythropoiesis occurs within erythroblastic islands, composed of erythroblasts physically 
attached to central macrophage cells. (McGrath and Palis 2008; Palis 2014).  
   Hematopoietic stem cells differentiate into a common myeloid progenitor which gives 
rise to the lineage-committed, definitive erythroid progenitors called burst forming unit-
erythroid (BFU-E) and colony forming unit-erythroid (CFU-E). These give rise to the 
morphologically identifiable, nucleated precursors that progress from pro erythroblasts 
(ProE) to basophilic erythroblasts (BasoE), polychromatophilic erythroblasts (PolyE) and 
orthochromatophilic erythroblasts (OrthoE) to reticulocyte. Reticulocytes are released 
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Figure 2. Human erythropoiesis. Hematopoiesis begins in the bone marrow with the multi-potent 
hematopoietic stem cell. This cell gives rise to a common myeloid progenitor (MEP), followed by a 
megakaryotic/erythroid pluripotent progenitor. In erythropoiesis, the MEP goes through a series of 
morphological changes culminating in the formation of a Hb-filled and organelle-lacking erythrocyte. 
These stages include the Burst forming unit-erythroid (BFU-E), Colony forming unit-erythroid (CFU-E), 
proerythroblast, basophilic erythroblast, polychromatophilic and orthochromatophilic erythroblasts which 
loses the nucleus and differentiates into the reticulocyte. The reticulocyte is released into bloodstream 
and matures in RBC. Adapted from Cantu and Philipsen, 2014 
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into the bloodstream and comprise about 1% of circulating red blood cells (Figure 2). 
The reticulocytes mature into erythrocytes after one to two days in circulation. These 
different stages of erythropoiesis can be visualized by staining with Wright staining and 
examination by light microscopy. Progressive erythroid maturation is characterized by 
erythroblast expansion through a limited set of symmetric cell divisions, accumulation of 
hemoglobin, decrease in cell size, nuclear pyknosis and decrease in RNA content. As 
erythrocytes age, surface area and volume, but not the hemoglobin content, are 
progressively lost which leads to increased erythrocyte cell density. Senescent 
erythrocytes are ultimately cleared by splenic macrophages (Palis 2014).  
 
III. β-hemoglobinopathies:  
Disorders of the β-globin gene (β-hemoglobinopathies) are single gene disorders which 
are inherited as autosomal recessive traits. According to a recent estimate by the World 
Health Organization, about 0.7% of the world’s population is carrier of sickle cell 
disease, affecting over 275,000 babies and of β-thalassemia, affecting around 56,000 
babies every year (Weatherall and Clegg 2001). About 60% of total and 70% of all 
pathological cases are found in Africa. β-hemoglobinopathies are most common in the 
ethnic populations from Africa, the Mediterranean basin and South-east Asia. 
Hemoglobinopathies provide a selective advantage to heterozygous populations for 
survival against malaria, hence these variant alleles have been evolutionarily selected  
in geographical areas where malaria is endemic (Weatherall and Clegg 2001). The β-
hemoglobinopathies can be characterized into two groups.  The first group is 
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characterized by structurally abnormal β-globin chains most commonly caused by 
missense mutations. Over 900 qualitative structural variants of hemoglobin have been 
reported, although most of them are rare and benign. Most of these are caused due to 
amino acid substitutions, although some are also brought about by insertions and 
deletions of amino acids, elongation of globin chains and poly-peptide fusions as a 
result of recombination between globin chains (Examples, Hb S, E, Dpunjab, C, Lepore 
etc.) (Weatherall and Clegg 2001). Sickle cell disease is the most common type of β-
hemoglobinopathy in this group. The second group is characterized by the production of 
abnormally low amounts of the β-globin chains, through mutations as well as deletions  
that affect regulation of the gene. β-thalassemias comprise this second group of 
disorders.  
 
A. Sickle Cell Disease (SCD) 
Sickle cell disease is one of the most common severe monogenic disorders worldwide. 
It is a multi-system disorder that is caused by inheritance of the mutated β-globin chain 
and involves periods of acute illness and progressive organ damage arising from 
hemoglobin polymerization. Sickle cell anemia is the most common form of sickle cell 
disease and results from a single base-pair mutation which causes substitution of a 
valine in place of glutamic acid in the 6th position in the adult β-globin gene (βs). This 
mutation produces a hydrophobic motif in the deoxygenated HbS tetramer such that it 
results in binding between the β1 and β2 chains of two hemoglobin molecules. The 
crystallization produces a polymer nucleus which fills the erythrocyte, disrupting its 
architecture and flexibility and promoting cellular dehydration with physical and oxidative 
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stress (Figure 3). A normal red cell typically functions for 90-120 days, whereas sickle 
cells only last 10-20 days.  
Sickle cell anemia manifests as two major pathophysiological processes: vaso-
occlusion with ischemia-reperfusion injury, and hemolytic anemia. Acute vaso-occlusion 
pain is caused by entrapment of erythrocytes and leucocytes in the microcirculation, 
causing vascular obstruction and tissue ischemia. Restoration of blood flow further 
promotes tissue damage by reperfusion. These cycles of ischemia and reperfusion 
 lead to oxidative stress. Hemolysis causes anemia and fatigue; cutaneous leg 
ulcerations, priapism and pulmonary hypertension are also associated with hemolysis. 
The release of hemoglobin in the plasma during hemolysis also produces reactive 
oxygen species which inhibit endothelial nitric oxide signaling, leading to endothelial cell 
dysfunction and nitric oxide resistance (David G. Nathan, David Ginsburg, Stuart H. 
Orkin, A. Thomas Look 2003).  
The prevalence of sickle cell disease is the highest in the sub-Saharan population; a 
recent estimate suggests about 230,000 affected children are born every year in this 
region. In comparison, the number of affected children in North America is 2600, with 
1300 in Europe every year. Due to the adaptive advantage to heterozygotes, the 
occurrence of SCD is highest in people with ancestry from regions where malaria has 
been endemic, including Africa, the Mediterranean, Indian and the middle-east 
(Weatherall and Clegg 2001). In USA, 1 in 500 African-American children and 1 in 
36,000 Hispanic children are born with SCD every year. It is estimate that 2.5 million 
Americans are heterozygous carriers of the sickle disease trait, occurring among 1:12 
African-Americans and 1:100   
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Figure 3. Pathophysiology of sickle cell disease. The HbS mutation, HBB glu6val, leads to β-globin 
chains that, when incorporated into hemoglobin tetramers with normal α-globin chains, produce a 
hemoglobin, HbS, which can undergo reversible polymerization when deoxygenated. The sickle polymer 
injures the erythrocyte and eventually produces irreversible membrane damage. The cells have a 
shortened life-span due to hemolysis. Adapted from Steinberg MH, 2008 
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Hispanic-Americans.  About 90% patients with SCD survive to the age of 20 years and 
about 50% survive beyond their fifth decade. In the USA, the mean survival age for 
male patients with SCD is 53 years and that for female patients is 58 years.  
 
B. β-thalassemias 
β-thalassemias are one of the most common autosomal recessive monogenic disorders 
worldwide. β-thalassemias are characterized by reduced or absent production of the β-
globin chains of hemoglobin that leads to microcytic anemia.  
   β-thalassemias are highly heterogenous at the molecular level; more than 200 
different disease-causing mutations have been identified so far. The majority of 
mutations are single base-pair substitutions, deletions or insertions of few base-pairs 
leading to a frameshift. Mutations leading to deficient production of β-globin chains are 
categorized as: 1. Mutations causing defective β-globin gene transcription which 
includes mutations in the promoter and 5’-UTRs; 2. Mutations that cause affect its 
mRNA processing which includes splice-junction and consensus sequence mutations, 
polyadenylation and 3’-UTR mutations; 3. Mutations resulting in abnormal mRNA 
translation including non-sense, frameshift and initiation codon mutations 
(Stamatoyannopoulos et al. 2001).  
    β0-thalassemias are characterized by mutations that cause complete absence of 
production of the β-globin chains whereas β+-thalassemias results from reduced 
production of β-globin chains. The three clinically recognized forms of β-thalassemias in 
the order of increasing severity include: β-thalassemia trait (carrier status), β-
thalassemia intermedia and β-thalassemia major. β-thalassemia minor (also β-
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thalassemia trait) results from heterozygocity for the β-thalassemia mutations (β0 or β+) 
and is clinically asymptomatic. β-thalassemia intermedia consists of a genetically and 
clinically heterogenous group of thalassemia-like disorders with severity ranging from 
asymptomatic to severe transfusion-dependent anemia. These individuals could be 
heterozygous or homozygous for any of the β-thalassemia genotypes. β-thalassemia 
major (also called Cooley’s anemia for Thomas Cooley who first described it in 1925) is 
the most severe form of the disease leading to severe transfusion-dependent anemia 
and is caused by homozygosity for the β0 alleles or compound heterozygosity for mild β-
thalassemia alleles (Stamatoyannopoulos et al. 2001).               
   The clinical severity of β-thalassemias depend on the extent of imbalance between 
the alpha globin and non-alpha globin chains. In red blood cell precursors, the absent or 
reduced amounts of  β-globin chains causes the unassembled alpha-globin chains to 
precipitate, which in turn leads to oxidative damage to the red cell membranes and 
apoptosis due to ineffective erythropoiesis. Anemia stimulates the production of 
erythropoietin leading to intensive but ineffective expansion of the bone marrow, which 
results in bone deformities. Prolonged anemia and increased erythropoietin stimulation 
in turn results in hepatosplenomegaly and extra-medullary hematopoiesis (Figure 4).   
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Figure 4. Pathophysiology of β-thalassemia. Reduced production of β-globin causes aggregation of 
the excess -globin which leads to an abnormal erythroblast. This causes ineffective erythropoiesis leading 
to anemia, bone marrow expansion and skeletal deformities. Organ damage causes liver cirrhosis, 
cardiomyoptahy and organ damage due to iron deposits. Iron overload due to blood transfusions leads to 
secondary hemochromatosis. Adapted from Pathologic basis of blood diseases, Aster JC 2003. 
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Individuals with β-thalassemia major usually come to medical attention within 1-2 years 
of age and require regular blood transfusions for survival. If a regular transfusion 
program is maintained, the growth and development of infants is normal till 10-11 years 
of age. After the age of 10-11 years, there is an increased risk for developing 
complications due to iron overdose, however it can be managed with adherence to iron 
chelation therapy. Complications of iron overload affect the heart (myocardiopathy and 
pericarditis), liver (chronic hepatitis, fibrosis and cirrhosis) and endocrine glands 
(resulting in diabetes and insufficiency of the thyroid and pituitary glands) and causes 
hypersplenism, osteoporosis and lung hypertension (Figure 4) (Weatherall and Clegg 
2001).  
   Patients who undergo regular blood transfusions and iron chelation therapy survive 
well beyond 40 years of age. Myocardial disease is the major life-limiting complication of  
iron toxicity in β-thalassemias. An estimate suggests that 71% of deaths in patients with 
β-thalassemia major are caused by cardiac complications.      
    β-thalassemias are prevalent in Africa, the Mediterranean, the Middle-east, central 
Asia, India, Southern China and the Far East, with incidences as high as 10% in these 
regions presumably due to the adaptive association with malaria. Estimates indicate 
that about 1.5% of the global population are carriers of β-thalassemias and about 1 in 
every 100,000 people is symptomatic for the beta-thalassemia disease, with majority of 
the cases being recorded in developing countries (Weatherall and Clegg 2001).  
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C. Management of β-hemoglobinopathies: 
 
i. Therapeutic options for β-hemoglobinopathies: 
    Management of sickle cell disease involves symptomatic treatment of acute events 
like vaso-occlusive crises and acute chest crises; prevention of bacterial infections; iron 
chelation to reduce the iron overload; folic acid supplementation; management of 
different forms of organ damage and stroke and controlling complications, if and when 
they occur.  Newer therapeutic options include: 5-hydroxymethyl-2-furfural (5-HMF) 
which is a natural compound that binds to red blood cells and increases their oxygen , 
thus preventing the red blood cells from sickling (Abdulmalik et al. 2005). Adenosine 
A2A receptor antagonists have potent anti-inflammatory activity and are used for 
relieving pain-related symptoms due to vaso-occlusive crises in sickle cell disease 
(Field et al. 2013).  
Treatment options for β-thalassemia disorders include regular blood transfusions, iron 
chelation therapy, splenectomy and folic acid supplementation. The primary focus of 
these therapies is to alleviate the symptoms of the illness.  
Allogenic bone marrow or cord blood transplantation is the only curative therapy 
available for small number of patients with severe β-hemoglobinopathies. The overall 
survival following matched sibling donor hematopoietic stem cell transplants is excellent 
in children, with disease-free survival rates greater than 80%, and a graft failure rate of 
about 10% (Angelucci 2010; Shenoy 2013). However its therapeutic application is 
limited by the inability to find an HLA-identical sibling donor for the patients and also the 
concerns of morbidity and mortality related to the high risk procedure.    
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ii. Fetal Hemoglobin Stimulants: 
 
Hereditary persistence of fetal hemoglobin (HPFH) is a naturally occurring condition in 
which the fetal γ-globin gene continues to be expressed well into adulthood without any 
pathological manifestations. Many deletion mutations resulting from large deletions at 
the β-globin gene cluster and non-deletion mutations resulting from single base 
mutations in the promoters of the Gγ and Aγ genes have been characterized in HPFH, 
however how some of these mutations affect γ-globin gene expression remains 
unknown.  Rare individuals with β-hemoglobinopathies and HPFH do not manifest the 
disease because the fetal γ-globin gene can substitute for the functionally impaired 
adult β-globin gene. This phenomenon was first observed in infants with sickle cell 
disease who had fewer symptoms and their deoxygenated erythrocytes took longer to 
sickle; Watson attributed this effect to the presence of fetal hemoglobin in these cells 
(WATSON 1948). However, this effect lasted only for a few months after birth until adult 
β-globin gene expression became pre-dominant. The ameliorating effect of HbF was 
later noted in individuals who were co-inherited sickle cell disease and hereditary 
persistence of fetal hemoglobin. These individuals were clinically asymptomatic despite 
the presence of HbS (Edington and Lehmann 1955).   
   The protective effect of HbF was understood through studies which postulated that 
varying amounts of HbF would be beneficial in different complications of sickle cell 
disease. It was accepted that higher amounts of HbF had ameliorating effects in those 
symptoms of the disease that were associated with sickle vaso-occlusion and blood 
viscosity (Kato, Gladwin, & Steinberg, 2007). However, any increase in HbF had a 
beneficial effect on mortality (Platt et al. 1994; Powars et al. 1984). The pathophysiology 
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of sickle cell disease depends on the polymerization of the deoxygenated HbS, but HbF 
interferes with this process. Importantly, the Hb tetramer composed of both HbF and 
HbS (α2β
sγ) cannot enter the polymerized sickle state on deoxygenation. Also, the 
hybrid tetramer containing βs and βA globin chains have only half the probability of 
entering the polymer to form HbS. The anti-polymerization effect of HbF resides in its 
two critical residues: glycine γ87 and aspartic acid γ80. HbF prevents the tendency of 
deoxy sickle hemoglobin to polymerize, which in turn retards the many downstream 
pathophysiological effects caused by cellular damage due to HbS (Steinberg 2008). 
Cell based therapies for induction of fetal hemoglobin as a therapeutic strategy for β-
hemoglobinopathies began in the 1970s after cloning of the human globin genes and in 
the 1980s once the mechanisms regulating globin gene expression were elucidated. 
Epigenetic mechanisms like DNA methylation and histone deacetylation gained 
increased importance in developmental silencing of the fetal globin gene in adult 
erythrocytes. 5-azacytidine was the first agent to be used to induce HbF in adults 
patients. The rationale for using a DNA methylation inhibitor came from the fact that 
actively transcribed adult β-globin gene is hypomethylated whereas the non-transcribed 
fetal γ-globin gene is hypermethylated in adult life. DNA methylation of genes was 
shown to be inversely proportional to gene expression. 5-azacytidine was shown to 
induce very high levels of HbF in anemic baboons, which led to treatment of patients 
with sickle cell disease and β-thalassemias with 5-azacytidine (Charache et al. 1983; 
Ley et al. 1982; Lowrey and Nienhuis 1993). Although the adult patients with β-
hemoglobinopathies showed promising induction of fetal hemoglobin, azacytidine was 
never tested in large-clinical trials due to concerns about potential carcinogenicity and 
  
 18 
toxicity. Recently, decitabine (5-aza-2-deoxycytidine) - a newer and safer analog of 5-
azacytidine, has been introduced in small scale clinical trials for patients with SCD and 
has shown promising results in inducing HbF and ameliorating the pathophysiology of 
SCD. However, larger long-term trials are required to confirm its safety and efficacy 
(Saunthararajah et al. 2003).   
 Hydroxyurea, an S-phase specific ribonucleotide reductase inhibitor and an approved 
chemotherapeutic agent has demonstrated great success in induction of HbF in adult 
patients with SCD (Charache et al. 1995; Dover and Charache 1992; Steinberg et al. 
1997). Induction of HbF by hydroxyurea has been proposed to occur through various 
different mechanisms:  perturbation of erythroid differentiation through stress 
erythropoiesis pathways, stimulation of cyclic GMP signaling pathway, increase in 
cAMP levels, induction of small GTP-binding protein and RAS-related (SAR) protein and 
induction of soluble guanylate cyclase through its nitrosylation (Atweh and Fathallah 
2010). Currently, hydroxyurea is the only FDA approved treatment for adults with 
moderate or severe sickle cell disease, however its effects are highly variable (Ma et al. 
2007).  
Butyrate, a short chain fatty acid that inhibits histone deacetylases, was also 
investigated as a fetal hemoglobin stimulating agent in chicken, mice and baboons. 
Treatment of SCD patients with arginine butyrate also showed sustained stimulation of 
HbF. However, due to difficulty in the mode of administering large volumes of this drug 
its therapeutic use has been limited (Atweh and Fathallah 2010; Perrine et al. 1993). 
Recently, an oral butyrate derivative sodium 2,2-dimethyl butyrate (HQH-1001) was 
shown to induce γ-globin expression and was tolerated in phaseI/II clinical trials in 
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patients with β-thalassemia (Fucharoen et al. 2013). Although butyrates and its 
derivatives have promising results, the effect is often variable among patients.  
 
iii. Futuristic therapeutic options: 
 
The lack of effective treatments for β-hemoglobinopathies has encouraged efforts to 
investigate newer therapeutic options. Gene therapy has been promising in correcting 
many immunodeficiency diseases like X-linked severe combined immunodeficiency (X-
SCID), Wiskott-Aldrich syndrome (WAS) and chronic granulomatous disease (CGD). 
Gene therapy for β-hemoglobinopathies is in the early phases of development and 
preliminary results have been encouraging. The first successful gene-therapy for a 
transfusion-dependent patient with hemoglobin-E-β-thalassemia  was done using a self-
inactivating lentivirus (SIN-LV)-based βT87Q vector and reported in a French trial 
(Cavazzana-Calvo et al. 2010). Synthetic β-globin (βT87Q) has anti-sickling properties.  
An initial safety concern was raised due to activation of the HMGA2 locus in the 
erythroid cells, however it gradually reduced to only 2% to 3% of the circulating 
nucleated cells. At 5 years after gene therapy, this patient is transfusion-independent. 
One more patient has been enrolled in the program and results are awaited. In the 
United States, a phase 1 to 2 β-thalassemia gene therapy trial was started by Sadelain 
and colleagues at Memorial Sloan Kettering Institute in 2011; 2 patients received gene-
corrected CD34+ cells and results are awaited. Following successes in β-thalassemia 
gene-therapy, similar studies were begun for sickle cell disease. Townes et al. 
developed anti-sickling β-globin by introducing three substitutions to the normal β-globin 
(T87Q, E22A, and G16D); the recombinant β-globin designated βAS3 inhibits sickling of 
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deoxygenated hemoglobin and also provides a competitive advantage compared with β-
globin for its interaction with alpha-globin (Levasseur et al. 2004). Correction of the SCD 
phenotype in a murine model by expressing βT87Q with an LV vector was reported for the 
first time by Pawlik and colleagues (Levasseur et al. 2003). Recently, Romero and 
group used a LV carrying the recombinant βAS3  to show consistent expression of the 
modified β-globin and reversal of RBC properties in red cells differentiated from CD34+ 
cell derived from the bone marrow of a sickle cell disease patient (Romero et al. 2013). 
Malik and group will be initiating clinical trials for patients with SCD using a LV vector 
carrying the γ-globin gene driven by the β-globin LCR and a 130-bp β-globin promoter 
(Perumbeti et al. 2009; Pestina et al. 2009).     
Induced pluripotent stem cells (iPSCs) combined with the powerful tool of genome 
editing offers many exciting avenues for correcting genetic disorders using autologous 
somatic cells. iPSCs offer the advantage of an endless supply of stem cells for genome 
editing followed by the possibility to select the ideal clone with safe integration and high-
efficiency expression (Papapetrou et al. 2011). Zinc-finger nucleases (ZFNs), 
transcription-activator like nucleases (TALENS) and clustered regulatory interspersed 
short palindromic repeat (CRISPR/Cas) endonuclease systems have been used for 
genome editing. Proof-of-concept studies have showed ZFN-mediated correction of β-
thalassemia in human iPSCs (Chang and Bouhassira 2012),  in situ ZFN and TALEN 
enabled correction of SCD mutation in iPSCs derived from an SCD patient (Sebastiano 
et al. 2011) and correction of the sickle cell mutation in HBB gene in human iPSCs 
using TALENs and piggyBac transposon (Sun and Zhao 2014). A very recent study 
published correction of β-thalassemia causing HBB mutations in patient-derived iPSCs 
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using CRISPR/Cas9 and piggyBac technologies (Xie et al. 2014). Although the genome 
editing approach is very promising, more work is needed to establish the safety and 
efficacy of these methods in gene therapy.  
IV. Human β-globin gene regulation 
 
Molecular therapies which target developmental silencing of the fetal γ-globin gene are 
also promising because they pose less toxicity and better effectiveness, which 
necessitates a detailed understanding of the process of hemoglobin switching. Various 
regulators of the human β-globin gene locus are discussed in detail.  
 
 
A. Cis-acting sequences 
The locus control region was first identified as DNase-I hypersensitive sites located 
approximately 6 to 20 kb upstream of the β-globin genes and necessary for expression 
of the β-globin genes. The LCR consists of 5 DNAse-I hypersensitive sites and each HS 
has a core sequence approximately 250 bp long which contains motifs for binding of 
various transcriptional factors. It was initially proposed through studies in transgenic 
mice that the LCR was required for opening the β-globin gene locus and for its active 
transcription (Grosveld et al. 1987), however it was later shown that the LCR is primarily 
required for high level expression of the β-globin genes (Bender et al. 2000). The LCR 
confers lineage-specific expression of the β-globin genes while also acting as an 
enhancer of the β-globin locus promoting its high expression and serving as an insulator 
for the locus to protect it from surrounding heterochromatin (Grosveld et al. 1987). Of 
the 5 HSs, HS2 is important for the position independent activity of the LCR (Collis, 
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Antoniou, Grosveld 1990), whereas HS3 is essential for its enhancer activity (Ellis et al. 
1996). 
Studies in transgenic mice have identified  two potential mechanisms for the function of 
LCR in regulating expression of the β-globin gene locus: Gene competition (Behringer 
et al. 1990; Enver et al. 1990) and Autonomous silencing. The competitive mechanism 
(also called chromosome looping) suggests that specific genes from the β-globin gene 
locus preferentially interact with the LCR at a given developmental stage depending on 
its proximity to the LCR, leading to its active transcription. The γ- and β-globin genes 
compete with the LCR during fetal and adult erythropoiesis such that during the fetal 
stage there is preferential interaction between the γ-globin gene and the LCR whereas 
in the adult stage the LCR interacts with the β-globin gene, silencing the γ-globin gene.         
The autonomous silencing mechanism suggests that all factors necessary for turning off 
gene expression are available within the canonical gene or nearby sequences (Raich et 
al. 1990). The ε-globin gene is highly regulated by autonomous gene silencing by 
various stage-specific factors (Raich et al. 1990). Autonomous silencing is the primary 
mechanism that turns off γ-globin gene expression in adult erythropoiesis; competition 
by the β-globin gene also has a contributory effect (Dillon and Grosveld 1991). The β-
globin gene is mainly regulated by chromatin looping leading to its robust expression in 
adult erythropoiesis (Dillon and Grosveld 1991).  
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B. Trans-acting factors:  
 
 
GATA1 and FOG1:  
GATA1 is a central regulator of essential genes involved in erythropoiesis. GATA1 
knockout mice die during gestation at E12.5 due to ineffective hematopoiesis in the yolk 
sac (Takahashi et al. 1997); GATA1 null-cells of primitive or definitive lineage fail to 
develop beyond the pro erythroblast stage (Fujiwara et al. 1996). GATA1 was among 
the first factors to be identified to have a role in hemoglobin switching through its 
binding at the β-globin gene locus (Evans and Felsenfeld 1989; Martin, Tsai, Orkin 
1989; Tsai et al. 1989). GATA1 may be involved in hemoglobin switching through 
facilitating a chromatin loop formation between Kit and β-globin gene (Jing et al. 2008; 
Vakoc et al. 2005).  
A SNP located 567 base-pairs 5’ to the Gγ globin gene was identified in an Iranian-
American family that showed heredity persistence of fetal hemoglobin (Chen et al. 
2008). This SNP disrupted the GATA-binding motif in the far upstream promoter of the 
Gγ-globin gene, and a similar SNP is also present in the Aγ-globin gene located at 566 
base-pairs upstream (5’) to Aγ-globin start site (Harju-Baker et al. 2008). Disruption of 
the -566 Aγ GATA-binding site in β-YAC transgenic mice caused elevated expression of 
fetal hemoglobin in adult mice. Later, Mi2β was identified to be an essential component 
for gene repression at this site (Costa et al. 2012). GATA1 has been shown to function 
as a transcriptional activator as well repressor in erythroid cells through interaction with 
its cofactor Friend of GATA1 (FOG1) and the MeCP1 complex (Miccio et al. 2010; 
Miccio and Blobel 2010; Rodriguez-Paredes and Esteller 2011). 
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FOG1 is a zinc finger protein which is critical to the function of GATA1 and important for 
the normal differentiation and maturation of megakaryocytic and erythroid precursor 
cells (Tsang et al. 1998). Fog1 knockout mice die due to fatal anemia at E10.5-11.5, 
similar to GATA1 knockout mice (Tsang et al. 1998). The functional interaction between 
GATA1 and FOG1 is highlighted by a mutation in the N-terminal zinc-finger of GATA1 
that impairs FOG1 binding; patients and mice with this mutation suffer from severe 
anemia (Hong et al. 2005). The N-terminal region of FOG1 recruits the NuRD co-
repressor complex to mediate the transcriptional repression by GATA1; mutation of the 
residues critical for interaction between FOG1 and NuRD impairs its gene repression 
activity as well repression by GATA1 (Hong et al. 2005).  
 
BCL11A , HBS1L-MYB and miRNAs-15a and 16-1: 
 Because hereditary persistence of fetal hemoglobin is a quantitative trait, genome-wide 
association studies were applied in subjects with and without β-hemoglobinopathies, to 
identify novel regulators of the γ-globin gene. These studies identified common variation 
at two loci beyond the β-globin gene cluster, BCL11A on chromosome 2 (Lettre et al. 
2008; Menzel et al. 2007; Uda et al. 2008) and the HBS1L-MYB intergenic region on 
chromosome 6 (Thein et al. 2007; Thein et al. 2009). Variants at these two loci are also 
associated with severity of the β-globin disorders, with higher levels HbF associated 
with milder phenotypes. BCL11A is a zinc finger protein and functions as a 
transcriptional repressor. Bcl11a knockout mice show impaired silencing of endogenous 
murine embryonic globin genes and the transgenic human fetal globin genes (Sankaran 
et al. 2009). Knockdown of BCL11A in primary human erythroid cells show elevated 
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expression of the γ-globin gene, thus establishing a role for BCL11A  in maintaining 
repression of the γ-globin gene in adult erythroid cells (Sankaran et al. 2008). BCL11A 
interacts with many transcriptional regulators like GATA1, FOG1, SOX6, other erythroid 
transcription factors and the NuRD complex to bring about silencing of the murine 
embryonic and human fetal globin genes (Xu et al. 2010). BCL11A exerts its repressive 
effects in part by occupying critical sites  in the β-globin gene locus (intergenic δ-β 
sequences which are deleted in HPFH), which promote long-range interactions between 
the LCR and the β-globin gene, at the expense of the γ-globin genes (Xu et al. 2010). 
Recent studies have identified a developmental stage-specific erythroid-lineage 
restricted enhancer of BCL11A through analysis of SNPs in regulatory DNA elements 
such that loss of this enhancer results in absence of BCL11A expression in erythroid 
cells. Common genetic variants of this enhancer display modestly reduced BCL11A 
expression, transcription factors GATA1 and TAL1 binding and increased HbF (Bauer et 
al. 2013).  
 The HBS1L-MYB locus regulates the γ-globin gene primarily through the effect of MYB 
(Jiang et al. 2006; Wahlberg et al. 2009). c-MYB is a hematopoietic transcription factor 
essential for definitive hematopoiesis, is highly expressed in hematopoietic stem cells 
and progenitors and its expression reduces as the erythroid cells mature (Vegiopoulos 
et al. 2006). Knockdown of MYB in primary adult human erythroid cells has been shown 
to increase HbF expression, possibly through its activation of KLF1/BCL11A and 
TR2/TR4 pathways (Suzuki et al. 2013). A recent study analyzed several HBS1L-MYB 
intergenic variants and showed that these variants reduce critical transcription factor 
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binding, affecting long-range interactions by MYB and also MYB expression levels 
(Stadhouders et al. 2014).   
Trisomy of chromosome 13 is one of the few viable trisomies and is associated with a 
delayed fetal-to-adult hemoglobin switch and persistent elevated expression of HbF. 
Analysis of cases of partial trisomy 13 using an integrated genomic approach identified 
a precursor RNA (DLEU2) for two microRNAs, 15a and 16-1, with identical seed 
targeting sequences as the top candidate in the region of 13q14. Increased expression 
of miR-15a/16-1 in hematopoietic progenitor cells caused a modest increase in γ-globin 
gene expression. This effect was shown to be mediated via the MYB gene, wherein 
MYB was identified as a direct target of the miR-15a/16-1(Sankaran et al. 2011). 
 
SOX6: 
SOX6 is a member of the Sry-related high-mobility-group (HMG) box transcription 
factors which serve as important regulators of cell fate and differentiation in various 
lineages. The role of SOX6 in globin gene regulation was first identified in Sox6 
knockout mice; these mice show increased expression of embryonic εy-globin gene in 
the fetal livers, while the βh1 gene was rapidly down-regulated. Sox6 represses the  εy-
globin gene by directly binding at its promoter region (Yi et al. 2006). Sox6 has been 
suggested to enhance erythroid differentiation by stimulating erythroid survival, 
proliferation and terminal maturation (Dumitriu et al. 2006). A role for SOX6 in human 
globin gene regulation has not been elucidated yet, however recent studies in human 
erythroid progenitors has suggested a correlation between varying levels of SOX6 and 
the expression of the γ-globin gene (Sripichai et al. 2009). SOX6 has also been shown 
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to co-occupy the β-globin gene locus with BCL11A and silence the expression of γ-
globin gene in adult erythroid cells (Xu et al. 2010). Knockdown of SOX6 in these adult 
erythroid cells demonstrated that SOX6 has a modest contribution in maintaining 
silencing of the γ-globin gene in the adult erythroid cells (Xu et al. 2010). The exact 
mechanism of transcriptional repression of the γ-globin gene by SOX6 is not known, 
however the Sox family of transcription factors interact with the minor groove of DNA 
and may effect conformational changes in DNA. Thus SOX6 may function as an 
architectural protein by enabling long range DNA interactions along the β-globin locus 
and assembling local chromatin structures with multi-protein complexes.         
 
KLF1:  
KLF1 (Krüppel-like factor 1), also known as EKLF (Erythroid Krüppel-like factor), 
belongs to the Krüppel-like zinc-finger containing family of transcription factors. KLF1 
was first identified in a subtractive hybridization screen for genes highly expressed in 
erythroid vs. myeloid lineages (Miller and Bieker 1993). KLF1 has been shown to play 
critical roles in erythropoiesis and β-globin gene regulation (Miller and Bieker 1993; 
Nuez et al. 1995; Perkins, Gaensler, Orkin 1996; Wijgerde et al. 1996). KLF1-/- mice 
show severe anemia and death in utero at E14.5 during development (Nuez et al., 
1995). KLF1 has been shown to bind the CACCC binding motif in the proximal promoter 
of the β-globin gene and the HS sites, HS1, HS2 and HS4, in the β-globin LCR in vivo 
(Miller and Bieker 1993).  Studies by Borg et al. linked a mutation in the first C2H2 zinc-
finger of KLF1 to HPFH in a Maltese family; individuals heterozygous for this mutation 
showed up to 19.5% expression of HbF into adulthood (Borg et al. 2010). Other 
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mutations in the KLF1 gene promoter and another mutation affecting its splicing have 
been identified, both of which cause haploinsufficiency of KLF1 and elevated expression 
of HbF, suggesting a critical role of KLF1 in hemoglobin switching (Gallienne et al. 
2012; Radmilovic et al. 2013; Satta et al. 2012; Singleton, Frayne, Anstee 2012). 
Haploinsufficient Klf1 transgenic mice carrying the human β-globin gene locus show 
elevated HbF without a significant change in β-globin expression and erythropoiesis, an 
effect that is mediated by Klf1 binding the Bcl11a promoter and acting as a positive 
regulator of Bcl11a (Zhou et al. 2010). Interestingly, Klf1(wt/ko)::Bcl11a(cko/cko) mice 
also show increased expression of murine embryonic genes and human γ-globin gene 
during fetal development. However, after birth these fetal and embryonic globin genes 
show a significant reduction in expression, being maintained at modestly higher levels 
than control mice during adult life, possibly because of a role of other transcriptional 
repressors of the embryonic and fetal β-type globin genes in adulthood (Esteghamat et 
al. 2013). Thus, two possible mechanisms have been suggested for regulation the fetal-
to-adult hemoglobin switch by KLF1: a) Preferential activation of the adult β-globin 
genes by establishing an adult stage-specific three-dimensional locus configuration 
through chromatin looping; and  b) Indirect repression of the fetal γ-globin gene by 
activation of transcription factors like BCL11A which serve as repressors of γ-globin 
gene expression. 
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NF-E4:  
NF-E4 was identified as a regulator of the chicken β-globin gene through its interaction 
with the stage specific element (SSE) in the chicken β-globin gene promoter (Zhou et 
al., 2004). It was later characterized as a member of the stage selector protein (SSP) 
heterodimeric complex which also contains the ubiquitous transcription factor CP2 
(Zhou et al. 2004). Several SSP binding sites were identified in the HS2, HS3, ε-globin 
promoter and in an HPFH point mutation, which implicated a role for p22-NF-E4 (human 
homologue of chicken NF-E4) in human γ-globin gene regulation. Enforced expression 
of p22-NF-E4 in β-YAC transgenic mice caused a delay in the switch from fetal to adult 
glob in genes, however the switch was eventually completed in the adult bone-marrow. 
Enforced expression of a short isoform of NF-E4 (p14-NF-E4) in human erythroid 
progenitor cord blood cells was reported to reduce the expression of the fetal γ-globin 
gene (Zhao et al. 2006).   
 
PRMT1/5:  
Protein arginine methyltransferase 5 (PRMT5) induces a repressive histone mark 
H4R3me2s, which serves as a template for binding of DNMT3A and subsequent DNA 
methylation (Zhao et al. 2009a). Reduction of PRMT5 or its enzymatic activity leads to 
increased expression of the γ-globin gene (Rank et al. 2010a). PRMT5 has also been 
reported to occupy the γ-globin gene promoter and its enzymatic activity is critical in 
recruiting a multi-protein repressive complex to the γ-globin promoter, an event which 
induces various repressive epigenetic marks. Disruption of this multi-protein complex 
results in reactivation of the fetal γ-globin gene (Rank et al. 2010a).   
  
 30 
FOP:  
Friend of PRMT1 (FOP) is a chromatin factor important in transcriptional regulation, 
including estrogen-dependent gene induction in breast cancer cells (van Dijk et al. 
2010). It is a target of methylation by PRMT1 and PRMT5 arginine methyltransferases. 
Knockdown of FOP in murine fetal liver cells and human erythroid progenitor cells 
shows increased expression of the γ-globin gene (van Dijk et al. 2010). The exact 
mechanism of action of FOP in γ-globin expression is not clear, although it is presumed 
to function as a target for PRMT mediated regulation of the γ-globin gene. 
 
DRED, TR2/TR4 and LSD1: 
 The embryonic and fetal globin genes, but not the adult β-globin genes, contain direct 
repeat (DR) elements in their promoters which serve as binding sites for non-steroidal 
nuclear receptors. Numerous mutations in the Gγ and Aγ globin gene promoter DR 
elements have been associated with specific HPFH phenotypes. Introduction of these 
DR element promoter mutations in β-YAC transgenic mice leads to increased 
expression of the respective ε- and γ-globin genes. In an attempt to identify potential 
repressive proteins that may bind these DR cis elements, the DR-element binding 
protein was identified as a complex between the erythroid-specific transcription factor 
NF-E3 and a member of the COUP transcription family member COUP-TFII. Named the 
DR-element erythroid specific (DRED) complex hereafter, this complex was 
characterized to be composed of a heterodimer of the orphan nuclear receptors 
TR2/TR4 (Tanimoto et al. 2000). TR2 and TR4 bind the DR1 sites in the embryonic ε-
globin gene promoter and the single DR1 site in the fetal γ-globin gene promoter 
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(Tanabe et al. 2002). Silencing of the embryonic and fetal globin genes was shown to 
be delayed in Tr2 and Tr4 null mice (Tanabe et al. 2007), however paradoxically, forced 
over expression of TR2 and TR4 in mice also lead to induction of the fetal globin gene 
and a modest alleviating effect in the phenotype of SCD mouse model (Campbell et al. 
2011; Tanabe et al. 2007). The mechanism of action underlying this phenomena is yet 
unknown, but two possible explanations have been proposed:    1. The over-expression 
of TR2 and TR4 may inhibit formation of the DRED complex due to limited availability of 
one or more of the DRED complex co-factors 2. TR2 and TR4, in addition to being 
repressors, may function as activators of the fetal gamma-globin gene by association 
with other cellular activators like PGC-1.  
TR2 and TR4 associate with co-repressors DNMT1 and LSD1 (lysine-specific 
demethylase 1) which form a core heterotetrameric complex (Cui et al. 2011). LSD1 
removes methyl-groups from mono- and dimethyl histone H3 lysine 4 which is an 
activating epigenetic mark. Knockdown of LSD1 in primary adult human erythroid cells 
can modestly activate γ–globin gene expression, however LSD1 is important for normal 
erythroid differentiation and LSD1 knockdown erythroid cells show delayed erythroid 
differentiation (Xu et al. 2013). Pharmacologic inhibition of LSD1 by Tranylcypromine 
(TCP)- a monoamine oxidase inhibitor was also shown to induce γ–globin gene 
expression in vitro and in vivo (Shi et al. 2013), however it poses the risk of 
hematopoietic toxicity and significant side effects. Next generation TCP compounds 
such as  could be tested for better efficiency in γ–globin gene induction with fewer side 
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effects. However, its application may be limited due to the importance of LSD1 in 
normal hematopoiesis. 
 
Ikaros:   
The transcription factor Ikaros (also known as Lyf-1) is a nuclear regulator that has been 
implicated in control of early hematopoiesis. Ikaros is associated with the chromatin 
remodeling PYR complex which binds the intergenic region between γ- and β-globin 
genes that is involved in regulating the fetal-to-adult hemoglobin switch (O'Neill et al. 
2000). The PYR complex consists of the NuRD and SWI/SNF chromatin remodeling 
complexes (O'Neill et al. 2000). Ikaros null mice show a modest delay in silencing of the 
murine embryonic globin genes and the human fetal globin genes in transgenic mice 
carrying the human β-globin mini locus, possibly due the absence of the PYR complex 
(Lopez et al. 2002). Mice carrying a specific mutation in Ikaros in the third zinc finger of 
its N-terminal domain show severe anemia and die between E15.5 to E17.5 due to 
failure in normal erythroblast growth and differentiation (Dijon et al. 2008).    
 
Mi2β: 
Mi2β, the chromatin remodeling component of the NuRD complex, belongs to the SNF2 
family of DNA helicases (Eisen, Sweder, Hanawalt 1995). In addition to the NuRD 
complex, it is also a component of the PYR complex which has been associated in 
regulating the hemoglobin switch (O'Neill et al. 2000). Recent studies by our lab 
established a role for Mi2β in regulation of the fetal γ-globin gene, in part through the 
NuRD complex, but largely as a positive regulator of KLF1 and BCL11A proteins such 
  
 33 
that even a partial knockdown of Mi2β in primary adult erythroid cells results in ~25% to 
30% γ/(γ+β) globin gene expression and 13.2% HbF protein levels as compared to 
control cells expressing <1% γ/(γ+β) globin gene (Amaya et al. 2013). A following study 
by another group also identified Mi2β as one of the most potent regulators of HbF in 
adult erythroid cells (Xu et al. 2013). However, the therapeutic potential of Mi2β may be 
limited by its important roles in normal development. 
   As can be noted, a complex interplay of several different factors is involved in the 
developmental silencing of the fetal γ–globin gene in adult erythroid cells. Epigenetics 
comprises another layer of regulation of γ–globin gene expression.   
V. Epigenetics:  
Epigenetics (Greek: epi - beyond; genetics) is defined as changes in heritable gene 
expression brought about by mechanisms other than the canonical changes in the DNA 
sequence. These changes can involve chemical modifications to DNA or the proteins 
that closely interact with the DNA and a newly emerging field of functional non-coding 
RNA has also gained recognition as an epigenetic mechanism. Epigenetic mechanisms 
have been implicated in various biological processes, including both normal 
developmental processes like genomic imprinting, X-chromosome inactivation and 
cellular differentiation and pathological phenomena like imprinting disorders, cancer and 
developmental abnormalities. DNA methylation and histone modifications are the most 
extensively studied mechanisms; many therapeutics like 5-azacytidine and HDAC 
inhibitors targeted at these mechanisms have been clinically explored.  
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Figure 5. Trans-acting factors regulating hemoglobin switch. The switch from fetal (HbF) to adult 
(HbA) hemoglobin is regulated by various transcription factors and cofactors. Regulators of this process 
constitute potential therapeutic targets for patients with major hemoglobin disorders. Positive and 
negative interactions are denoted by printed and blunt arrows, respectively. Adapted from Xu, Bauer and 
Orkin 2011.  
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A. DNA Methylation:  
DNA methylation involves addition of a methyl moiety to the 5th carbon of a cytosine 
residue in the DNA backbone. DNA methyl transferase enzymes are the epigenetic 
writers that establish the DNA methylation signature of genes and include the well 
characterized DNMT1 and DNMT3A and DNMT3B. DNMT1 is the maintenance 
methylase which adds a methyl moiety to the symmetric CpG on hemimethylated DNA 
during DNA replication. DNMT3A and DNMT3B are de novo methylases which 
symmetrically add a methyl group to unmethylated DNA (Kim, Samaranayake, Pradhan 
2009). CpG dinucleotides are methylated throughout the genome at ~70-80% of CpG 
cytosines (Jabbari and Bernardi 2004), however there are clusters of non-methylated 
“CpG-islands” which are present in the promoter regions of 60-70% of all human genes 
(Saxonov, Berg, Brutlag 2006). Differential methylation of these CpG islands plays a 
regulatory role in developmental as well as tissue-specific genes (Deaton and Bird 
2011). Aberrant methylation of CpG islands of tumor suppressor genes also has been 
shown to lead to carcinogenesis (Esteller 2008).       
 
i. Methyl Cytosine Binding Proteins: 
The DNA methylation signature of chromatin is read by the methyl-CpG binding domain 
(MBD) containing family of proteins. These proteins bring about repression of their 
target genes by recruiting associated co-repressor complexes containing histone 
deacetylase and nucleosome remodeling activities or by directly inhibiting interaction 
with the transcriptional machinery (Figure 6). MeCP2 was the founding member of the 
MBD family of proteins; later MBD1, MBD2, MBD3 and MBD4 were also identified as 
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members of this family of proteins (Hendrich and Bird 1998; Lewis et al. 1992). The 
structures of these proteins bear little resemblance to each other outside of their ~75 
amino acid MBD motif. Another group of proteins known as the Kaiso and Kaiso-like 
proteins (ZBTB4 and ZBTB38) recognize and bind methyl cytosine residues through 
their conserved zinc finger motifs in a sequence specific manner (Filion et al. 2006; 
Prokhortchouk et al. 2001).   
   MeCP2: MeCP2 has been characterized to be an intrinsically disordered protein and  
mutations in all of its 6 domains are known to cause the X-linked condition Rett 
syndrome (Miltenberger-Miltenyi and Laccone 2003). The MBD of MeCP2 can 
recognize and bind even a single methylated CpG and through its transcriptional 
repression domain (TRD) it recruits the SIN3A co-repressor complex containing histone 
deacetylases (Jones et al. 1998; Nan et al. 1998). Although MeCP2 plays a vital role in 
neurological development, Mecp2-/- female mice are viable and born normal but 
progressively develop symptoms of Rett syndrome (Guy et al. 2001).  
   MBD1: MBD1 has been shown to bind mCpG residues as well as unmethylated DNA 
based on its alternatively spliced  isoform and has been shown to interact with co-
repressor proteins SETDB1, MCAF, HDAC3 and MPG through its TRD (transcriptional 
repression domain) (Fujita et al. 2003; Nakao et al. 2001; Sarraf and Stancheva 2004). 
MBD1 null mice also have no developmental defects except minor neural defects and 
reduced genomic stability (Zhao et al. 2003). The C-terminus of MBD1 (MBD1-c) was 
recently shown to be intrinsically disordered but it governs selective interaction of MBD1 
with its co-repressors proteins (Hameed et al. 2014).  
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   MBD2 and MBD3: Early studies of the MBD2 and MBD3 proteins in transgenic mice 
revealed that Mbd2-/- mice were viable and fertile with a defect in maternal nurturing 
whereas Mbd3-/- mice were embryonic lethal, indicating non-overlapping functions of 
the MBD2 and MBD3 proteins in developmental gene regulation (Hendrich et al. 2001). 
MBD2 and MBD3 proteins share ~70% sequence homology and both proteins are 
highly expressed across various tissues types in adult mice as well as during 
embryogenesis (Hendrich and Bird 1998). MBD2 specifically binds to methylated DNA 
in vitro and in vivo (Hendrich and Bird 1998) and its binding orientation and affinity is 
influenced by the DNA sequence adjacent to the central mCpG (Scarsdale et al. 
2011a). All MBD proteins except MBD3 have been shown to bind methyl-CpG residues, 
although with varying affinities; MBD3 has a sequence variation in its conserved MBD 
which impairs its ability to interact with methylated DNA (Hendrich and Bird 1998). 
MBD3 was shown to have high affinity for hydroxy-methylated DNA, however these 
studies may require further work to draw a stronger conclusion (Baubec et al. 2013; 
Yildirim et al. 2011). Recent work has shown that MBD3 preferentially localizes to 
methylated CpGs and to a lesser extent to non-methylated CpGs, while it does not 
distinguish between hydroxy-methylated and non-methylated DNA (Cramer et al. 2014).  
   MBD4: MBD4 binds to methylated DNA but is primarily involved in identifying  T:G 
mismatches caused by deamination of the cytosine residue in mCpG dinucleotides and 
brings about DNA repair through its DNA glycosylase activities (Hendrich et al. 1999; 
Petronzelli et al. 2000). MBD4 deficient mice are viable and fertile, but display increased 
mutability in CG -> TA transitions at CpG sites (Millar et al. 2002).  
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Figure 6. The role of DNA methylation in gene silencing. During development, a number of CpG rich 
promoter regions are methylated by DNMT enzymes. DNA methylation hampers RNA Pol II from 
advancing. DNA methylation also recruits methyl-binding domain proteins such as MBD2 and silencing 
complexes such as NuRD complex, which in turn alter histone modification patterns, further preventing 
gene expression. Adapted from Ginder, Gnanapragasam and Mian 2008.  
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Mutations in MBD4 have been reported in 26 to 43% of human colorectal tumors that 
show micro satellite instability (Bader, Walker, Harrison 2000; Riccio et al. 1999). 
Likewise, MBD4 deficient mice heterozygous for Min allele of adenomatous  
polyposis coli gene (ApcMin) show increased mutagenesis due to genomic instability 
(Millar et al. 2002).  
 
B. Histone Modifications 
Histones are alkaline proteins that package and order DNA into structural units called 
nucleosomes. There are five major categories of histones: H2A, H2B, H3 and H4 are 
core histones while H1 and H5 are linker histones. Histones allow regulation of gene 
expression by undergoing various histone modifications like acetylation, methylation, 
phosphorylation, SUMOylation, ubiquitination and ADP-ribosylation. These 
modifications are added to the N-terminal tails of histones through post translational 
modifications by specific enzymes. Histone acetylation and methylation are among the 
most well characterized modifications. Trimethylation of H3K4, H3K36 and H3K79 are 
associated with actively transcribed genes whereas trimethylation of H3K9, H3K27 and 
H4K20 have been associated with transcriptionally silenced genes. Similarly, histone 
acetylation is a mark of euchromatin where histone deacetylation is associated with 
heterochromatin. Combinations of such modifications are known to constitute the 
histone code. The histone code is recognized by large number of multi-protein 
complexes which are involved in functions like DNA repair, gene regulation, 
chromosome condensation and others.  
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    In regulation of the β-globin gene locus, histone methyltransferases PRMT1 (van Dijk 
et al. 2010) and PRMT5 (Rank et al. 2010b; Zhao et al. 2009b) have been extensively 
studied. Lysine-specific demethylase 1 (LSD1) has also been identified as a silencer of 
the γ-globin gene in adult erythroid cells (Shi et al. 2013). Histone deacetylase inhibitors 
have a promising role in reactivation of HbF and recent studies have identified specific 
inhibitors of HDAC1 and HDAC2 as γ-globin gene inducers (Bradner et al. 2010). 
 
C. MicroRNAs 
MicroRNAs are endogenous ~22 nucleotide non-coding RNAs that have functional roles 
in gene regulation through mRNA cleavage or translational repression. The human 
genome codes for over 1000 miRNAs which may target about 60% of human protein-
coding genes. miRNAs identify their target genes through a complementary 6-8 
nucleotide sequence known as the “seed sequence”. The seed sequence may lie in the 
5’-UTR, 3’-UTR or the coding region of the target gene. Several target prediction 
algorithms have been developed to identify putative targets of the currently known 
miRNAs in different species. Recently discovered functions of miRNAs include DNA 
repair, cell proliferation and cell death, modulation of hematopoietic lineage 
differentiation in mammals and others.   
MiRNA biogenesis and processing are represented in Figure 7. miRNA genes are often 
intergenic; about 40% of miRNA genes may lie in the introns of protein and non-protein 
coding genes and are often transcribed together with their host gene. About 42-48% 
miRNAs are transcribed from a polycistronic unit encoding multiple discrete loops for  
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Figure 7. MicroRNA Biogenesis. MicroRNA (miRNA) genes are generally transcribed by RNA 
Polymerase II (Pol II) in the nucleus to form large pri-miRNA transcripts, which are capped (
7
MGpppG) 
and polyadenylated (AAAAA). These pri-miRNA transcripts are processed by the RNase III enzyme 
Drosha and its co-factor, Pasha, to release the 70-nucleotide pre-miRNA precursor product. RAN–GTP 
and exportin 5 transport the pre-miRNA into the cytoplasm. Subsequently, another RNase III enzyme, 
Dicer, processes the pre-miRNA to generate a transient 22-nucleotide miRNA:miRNA
*
 duplex. This 
duplex is then loaded into the miRNA-associated multiprotein RNA-induced silencing complex (miRISC) 
(light blue), which includes the Argonaute proteins, and the mature single-stranded miRNA (red) is 
preferentially retained in this complex. The mature miRNA then binds to complementary sites in the 
mRNA target to negatively regulate gene expression in one of two ways: 1. miRNAs that bind to mRNA 
targets with imperfect complementarity block target gene expression at the level of protein translation 
(lower left). Complementary sites for miRNAs using this mechanism are generally found in the 3' 
untranslated regions (3' UTRs) of the target mRNA genes. 2. miRNAs that bind to their mRNA targets 
with perfect (or nearly perfect) complementarity induce target-mRNA cleavage (lower right). miRNAs 
using this mechanism bind to miRNA complementary sites that are generally found in the coding 
sequence or open reading frame (ORF) of the mRNA target. Adapted from Winter et al, 2009. 
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several mature miRNAs to be processed. Most miRNA genes are transcribed by RNA 
polymerase II and undergo processing stages from primary miRNA in the nucleus to 
precursor miRNA in the nucleus and precursor-miRNA to mature miRNA in the  
cytoplasm. This miRNA processing is mediated by the RNA-induced silencing complex 
(RISC) containing Drosha and many other proteins. MiRNA expression is also subject to 
various transcriptional regulatory mechanisms and its dysregulation has been reported 
to be causative for several pathophysiological conditions; cancer, heart disease, 
nervous disorders, obesity and also inherited disorders are some examples (Ardekani 
and Naeini 2010). 
 
D. NuRD complex:  
The nucleosome remodeling and histone deacetylase complex is an epigenetic 
regulator of gene expression. It is one of the four major types of ATP-dependent 
chromatin remodeling complexes. The NuRD complex was first purified over a decade 
ago in cells of different species and is the only multi-protein complex that couples two 
independent chromatin modifying enzymatic activities: 1) nucleosome remodeling 
brought by the chromodomain-helicase-DNA-binding protein 3 (CHD3; Mi2α) and CHD4 
(Mi2β) subunits which have ATPase-dependent chromatin remodeling activity and 
which fall within the subclass of the SWI/SNF family and 2) protein deacetylation 
brought about by the histone deacetylases HDAC1 and HDAC2. Other non-enzymatic 
subunits of the complex include the retinoblastoma-binding protein 4 (RBBP4, also 
known as RbAp48) and RBBP7 (also known as RbAp46) which directly bind core 
histones; the GATAD2A (p66α) and GATAD2B (p66β) proteins which interacts with 
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MBD2/3 and also recruits Mi2α/β proteins to the NuRD complex; both RbAp46/48 and 
p66α/β proteins serve important roles as structural units of the complex too. The MTA 
family of proteins - MTA1/2/3 are also core components of the NuRD complex with 
potentially unique roles in transcriptional regulation, given cell- and tissue-type 
specificity (Figure 8). All of these components associate with a member of the MBD 
family of proteins, MBD2 or MBD3. The MBD2 and MBD3 subunits have been shown to 
associate with mutually exclusive NuRD complexes and have recently been implicated 
in fundamentally different transcriptional regulatory processes. Early studies of the 
MBD2 and MBD3 proteins in transgenic mice revealed that Mbd2-/- mice were viable 
and fertile with a defect in maternal nurturing whereas Mbd3-/- mice were embryonic 
lethal, indicating  non-overlapping functions of the MBD2/3 proteins in developmental 
gene regulation (Hendrich et al. 2001). 
In addition to these six core subunits, a large number of proteins have been shown to 
interact with the NuRD complex, such as GATA1/FOG1, BCL11A, LSD1 etc (Sankaran, 
Xu, Orkin 2010a; Xu et al. 2013). Such a combinatorial assembly of non-enzymatic 
subunits in the NuRD complex has been proposed to be the fundamental mechanism 
conferring functional specificity to the NuRD complex.  
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Figure 8. The MBD2/NuRD co-repressor complex. Densely methylated DNA is able to recruit methyl-
binding domain protein 2 (MBD2) as well as the NuRD complex. Mi2 confers chromatin remodeling 
function to the complex. MTA2 and p66 act as transcriptional repressors. The histone deacetylase activity 
is mediated by HDAC1 and RbAp48 which is a histone-binding protein.  
 
 
 
 
 
Densely methylated DNA 
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i. MBD2-NuRD Complex in normal development 
MBD2 recruits the nucleosome remodeling and deacetylase (NuRD) complex which 
was first identified as a multi-protein complex known as MeCP1 (Ng et al. 1999). 
MeCP1 was shown to bind >12 methylated CpG dinucleotides, irrespective of the 
sequence context and its transcriptional repression was found to be correlated with 
methylation density. MBD2 was identified to be the methyl-DNA binding component of 
MeCP1 (Feng and Zhang 2001; Ng et al. 1999). The MBD2-NuRD complex has been 
isolated from cell lines and primary cells and consists of at least one component each of 
RbAp46/48, HDAC1/2, MTA1/2/3, p66α/β, Mi-2α/β and MBD2 (Feng and Zhang 2001; 
Kransdorf et al. 2006). MBD3 was also identified as a part of this complex initially, 
however later studies identified MBD2-NuRD and MBD3-NuRD as distinct complexes 
(Le Guezennec et al. 2006).  
Studies of MBD2-/- knockout mice suggested that MBD2 was not required for 
embryonic development since MBD2-/- mice are viable, fertile and of normal 
appearance,  although MBD2-/- mothers display abnormal nurturing behavior (Hendrich 
et al. 2001). They do not show any defects in DNA methylation or imprinting of genes, 
however cell lines generated from MBD2-/- knockout mice were unable to repress 
methylated reporter genes as effectively as wild-type and heterozygous mice.  
Kersh et al. showed MBD2 plays a role in the differentiation of naive CD8+ T cells into 
effector and memory cells (Kersh 2006). MBD2-/- knockout mice also display 
disoriented differentiation of helper T-cells which show mis-expression of interleukin 4 
and interferon γ; interleukin 4 and interferon γ are expressed mutually exclusively in Th1 
and Th2 populations, however Mbd2-/- mice show simultaneous expression of both 
cytokines in their T helper cells, which ultimately leads to altered immune responses in 
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the Mbd2-/- mice. Gene expression analysis of differentially regulated genes in the gut 
of Mbd2-/- mice identified abnormally high expression of exocrine pancreatic genes in 
the colon of these animals. The exocrine pancreatic genes code for digestive enzymes 
which are normally expressed in the duodenum and pancreas only (Berger et al. 2007).  
MBD2 deficiency also causes slightly elevated expression of Xist in SV-40 transformed 
fibroblast cell lines derived from the tail of knockout mice and add back of exogenous 
Mbd2 was able to recover the repression of the Xist gene (Barr et al. 2007). The Xist 
gene produces a non-translated RNA that localizes to the inactive X-chromosome from 
which it is transcribed and is responsible for cis-inactivation of the X-chromosome.    
     MBD2 has also been shown to affect the development of olfactory receptor neurons 
by controlling the expression of differentiation stage specific genes. Loss of Mbd2 
results in the dysregulation of adult olfactory epithelium progenitor-driven neurogenesis, 
compromised olfactory receptor neuron survival, and prolonged deficits in the 
organization of olfactory receptor neurons synaptic fields (Macdonald et al. 2010). 
 
ii. MBD2-NuRD Complex in Tumorigenesis: 
Loss of MBD2 has been shown to strongly suppress adenoma formation in Apcmin/+ mice 
(Sansom et al. 2003). Apcmin/+ mice are heterozygous for a mutation in the tumor 
suppressor APC (adenomatous polyposis coli) which leads them to develop multiple 
intestinal neoplasias. MBD2 binds to and silences the expression of the Lect2 gene 
whose product is a negative regulator  of the Wnt signaling pathway. Thus loss of MBD2 
attenuates Wnt signaling and up regulates the Lect2 gene product, which in turn 
suppresses formation of intestinal neoplasms in Apcmin/+ mice (Phesse et al. 2008). 
  
 47 
MBD2 has been shown to bind to 5’ upstream regulatory regions and repress the 
expression of tumor suppressor genes p16 and p14 in human colon cancer cell lines 
(Magdinier and Wolffe 2001). p16 is a cyclin-dependent kinase inhibitor found to be 
hypermethylated in various malignant tissues and p14/ARF (ARF- alternative reading 
frame), a gene located 20kb upstream on chromosome 9p21, has also been found to be 
methylated in many carcinomas. Both of these gene products are critical in of major cell 
cycle regulatory pathways of p53 and retinoblastoma protein, Rb, respectively. MBD2 
also silences the expression of GSTP1 gene in MCF-7 breast cancer cells; GSTP1 
encodes the pi-class glutathione S-transferase and is known to be hypermethylated in 
cancers of the breast, prostate and liver (Lin and Nelson 2003a). Studies in our lab 
identified a direct role of MBD2 in methylation-mediated silencing of tumor suppressor 
genes, DAPK1 and KLK10 in MCF-7 breast cancer cells as well as growth suppression 
of MBD2 deficient mammary epithelial cell lines in in vivo xenograft tumors in mice 
(Mian et al. 2011).  
 
iii. MBD2-NuRD complex in hemoglobin switching:  
   
Globin genes were among the first set of genes in which DNA methylation was shown to 
be inversely proportional to gene expression. Previous studies in our lab identified a 
critical role for MBD2 in the developmental regulation of the chicken embryonic ρ-globin 
gene and human embryonic ε-globin and fetal γ-globin genes. The chicken embryonic 
ρ-globin gene becomes highly methylated at the same time that it is transcriptionally 
silenced (Singal et al. 1997). Also, a protein complex containing MBD2 was purified 
from primary chicken erythrocytes and it was shown to bind the methylated DNA 
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sequences proximal to the ρ-globin gene (Singal et al. 2002).  Further purification and 
characterization of this complex showed the presence of MBD2, but not MBD3 in the 
complex (Kransdorf et al. 2006). These studies were the first to identify a direct role of 
the MBD2/NuRD complex in developmental regulation of the β-type globin genes.  
   These results were followed by crossing transgenic mice bearing a yeast artificial 
chromosome with the entire human β-globin gene locus (β-YAC) with MBD2 knockout 
mice. Absence of MBD2 led to ~20 to 40% increase in the human fetal γ-globin gene 
expression (Rupon et al. 2006a) as well as the embryonic ε-globin gene (Rupon et al. 
2011a) in adult mice. Given that the human β-globin gene locus is CpG sparse, we also 
showed that MBD2 does not directly interact with the γ-globin gene promoter, thereby 
suggesting that MBD2 regulates the expression of this locus via an indirect mechanism.  
     The role of MBD2 in developmental regulation of the γ-globin gene was also studied 
in primary adult human erythroid cells. Stable knockdown of MBD2 by ~75% reactivated 
expression of the fetal γ-globin gene to about 10% of the total β-type globin genes 
expressed in terminally differentiated erythroid cells (Amaya et al. 2013). These 
promising results reinforced MBD2/NuRD as a potential target for therapeutic 
reactivation of the γ-globin gene for treatment of β-hemoglobinopathies. A proof-of-
concept study was conducted by our lab to examine the repressive function of MBD2 by 
disrupting its interaction with components of the NuRD complex. A small peptide that 
interfered with the coiled-coil interaction between MBD2 and p66α dissociated the p66α 
and Mi2β proteins from the NuRD complex, resulting in increased expression of the γ-
globin gene in adult mouse bone marrow erythroid cells bearing the human β-globin 
gene locus (Gnanapragasam et al. 2011a). These results encouraged studies to disrupt 
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other protein-protein interactions within the MBD2/NuRD complex with the potential of 
designing similar inhibitory small peptides.           
 
VI.  Primary adult human erythroid cells as a model to study hemoglobin 
switching : 
Cultured primary human erythroid cells derived from CD34+ progenitors serve as a 
powerful model to study developmental regulation of the globin genes because they 
recapitulate normal adult erythropoiesis at the molecular level (Fibach and Prus 2005; 
Pope et al. 2000). A two phase liquid culture differentiation system allows for extensive 
proliferation and terminal differentiation of the mobilized bone marrow cells harvested 
from the peripheral blood (Amaya et al. 2013). A major challenge in using hematopoietic 
stem cells for the study of regulators of the hemoglobin switch is their limited 
proliferative capacity, asynchronous differentiation manner and lack of ability to achieve 
terminal differentiation of these cells without significantly affecting cell viability in culture.  
Human induced pluripotent stem cells (hiPSCs) derived erythroid cells are also being 
developed which may overcome the limitations of limited life span and viability of the 
primary human erythroid cells and may be used for mass production of erythroid 
progenitor cells to study the hemoglobin switch in adult erythropoiesis. Although 
significant advances have been made in generating iPSCs from adult somatic cells, the 
system is challenged by the fact that iPSC-derived erythroid cells express mainly 
embryonic (ε) and fetal (γ) globins (Chang et al. 2006). Further studies are required to 
understand the transcriptional profiles of iPSC-derived hematopoietic cells and their 
application in studying human erythropoiesis.  
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VII. Scope of the thesis 
The MBD2-NuRD complex was biochemically characterized in erythroid cells by our lab 
and found to contain RbAp46/48, HDAC1/2 and MTA1/2/3 components which form the 
histone deacetylase core of the complex and the p66α/β and Mi2α/β proteins which 
comprise the chromatin remodeling components of the NuRD complex, together with 
MBD2 which recruits the NuRD complex to sites of dense CpG methylation in the 
genome (Kransdorf et al. 2006). Little is known about the structural properties and 
functional interactions of various components within the MBD2/NuRD complex. The 
work presented in Chapter 2 characterizes the structure and function of an intrinsically 
disordered region of MBD2, MBD2IDR, and identifies its important roles in modifying 
kinetics of DNA binding and interaction with the histone deacetylase core of the NuRD 
complex. A critical contact region for this interaction comprising two contiguous amino 
acid residues, Arg286 and Leu287 was identified and its functional significance was 
examined.   
 Studies in our lab have also demonstrated a critical role of MBD2 in developmental 
silencing of the fetal γ-globin gene in adult erythroid cells. However, it is not yet clear 
how MBD2, in concert with the NuRD complex, brings about this silencing of the fetal γ-
globin gene. The MBD2/NuRD complex requires sites of dense CpG methylation for its 
interaction with methylated DNA and the human β-globin gene cluster lacks regions of 
high CpG density. In continuation of previous work in our laboratory that identified 
potential downstream regulators of MBD2 through a microarray screen, the studies 
detailed in Chapter 3 of this thesis functionally validate one of these candidate target 
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genes and a newly identified miRNA in the transcriptional activation of the fetal γ-globin 
gene in a human primary adult erythroid model system.  
VIII. Significance 
Currently, not many treatment options are available for patients with β-
hemoglobinopathies. Blood transfusions and bone marrow transplants are 
recommended for a small percentage of patients because of the associated high risks 
and complications. Reactivation of fetal hemoglobin (HbF) in adult patients has been 
pursued as a therapeutic avenue because of its ameliorating effects in SCD and β-
thalassemia. The DNA methylation inhibitor 5-azacytidine was tested in preclinical 
studies to induce HbF but was abandoned later due to concerns of potential 
carcinogenicity. Hydroxyurea - an S-phase specific agent without a primary 
hypomethylating effect and tolerable side effects, was later tested in clinical trials and 
presently it is the only therapeutic agent available for treatment of sickle cell anemia, but 
its effect varies highly in the patients. 
Considering the limited efficacy of available treatment options, understanding of the 
molecular mechanism of hemoglobin switching will prove rewarding in the development 
of targeted therapies for stimulating HbF in adult patients with β-hemoglobinopathies.  
Previous work in the lab has identified MBD2 to be involved in developmental silencing 
of fetal hemoglobin. The therapeutic significance of MBD2 as a target is underscored by 
the observation that MBD2 has a minimal role in normal mammalian development  
as seen in MBD2 knockout mice which are viable, fertile and have a minimally abnormal 
phenotype.  
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Understanding the mechanistic role of MBD2 and delineating its functional interactions 
with the NuRD co-repressor complex will facilitate its research as an effective 
therapeutic target. Disrupting MBD2-mediated functions will have therapeutic potential 
not only in fetal hemoglobin induction in adult patients with β-hemoglobinopathies but 
also in the treatment of wide array cancers by de-repression of tumor suppressor genes 
targeted by MBD2.   
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CHAPTER 2: An Intrinsically Disordered Region of MBD2 recruits the Histone 
Deacetylase Core of the NuRD Complex 
 
 
 
I. Introduction: 
Epigenetic regulation comprises heritable changes in gene expression most commonly 
brought about by DNA methylation and histone modifications. The predominant form of 
DNA methylation in mammals involves addition of a methyl moiety to the C5 carbon of 
the cytosine residue in a cytosine-guanine dinucleotide (CpG) through the enzymatic 
activity of DNA methyl-transferases, DNMT1, DNMT3A and DNMT3B (Kim, 
Samaranayake, Pradhan 2009). Regions of high CpG density are often associated with 
gene promoters (Illingworth and Bird 2009), which remain unmethylated except for a 
subset of tissue-specific genes involved in normal differentiation and development 
(Berger et al. 2007; Kransdorf et al. 2006; Rupon et al. 2006a; Straussman et al. 2009).  
Aberrant hypermethylation of tumor suppressor gene promoters is associated with 
oncogenesis in a wide array of tissues (Jones and Baylin 2007). The methyl-CpG 
binding domain (MBD) family proteins recognize this methylated mark and repress the 
associated genes by recruiting different co-repressor complexes. The MBD family of 
proteins 
  
 54 
include the first identified MeCP2 (Meehan et al. 1989) and MBD1, MBD2, MBD3 and 
MBD4 (Hendrich and Bird 1998). With the exception of mammalian MBD3, all MBD 
proteins bind to methylated DNA although with varying affinities (Cramer et al. 2014). 
MBD2 binds densely methylated CpG islands and represses transcription of the 
associated genes through recruitment of the NuRD co-repressor complex (Feng and 
Zhang 2001). The MBD2-NuRD co-repressor complex from both cell lines and primary 
cells has been characterized and is comprised of at least one copy each of the 
MTA1/2/3, HDAC1/2, RbAp46/48, p66α/β, and Mi-2α/β and MBD2 proteins (Feng and 
Zhang 2001; Kloet et al. 2014; Kransdorf et al. 2006; Smits et al. 2013).  Recent studies 
have evaluated the stoichiometry of protein interactions in the NuRD complex (Kloet et 
al. 2014; Smits et al. 2013). However much remains to be explored about the nature 
and assembly of protein-protein interactions within this complex.  Previous work in our 
laboratory identified MBD2 as a silencer of the chicken ρ–globin gene (Gnanapragasam 
et al. 2011b; Kransdorf et al. 2006; Singal et al. 2002) as well as murine and human 
embryonic and fetal β–type globin genes in adult erythroid cells (Gnanapragasam et al. 
2011b; Rupon et al. 2006a). In addition, MBD2 has been implicated in aberrant 
silencing of methylated tumor suppressor genes in carcinogenesis (Esteller 2008; Lin 
and Nelson 2003b; Magdinier and Wolffe 2001; Mian et al. 2011; Sansom et al. 2003; 
Stefanska et al. 2013).   
The MBD2 protein consists of an N-terminal glycine-arginine repeat region (GR), a 
methyl-binding domain (MBD) which binds in vivo to densely methylated DNA 
(Brackertz et al. 2006), an uncharacterized domain of MBD2 (MBD2IDR) and a coiled-coil 
domain. In previous work we showed that the C-terminal coiled-coil of MBD2 binds to 
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the p66α/β components of NuRD, which contributes to the recruitment of the Mi-2α/β 
proteins and gene silencing. Consistent with these findings, the p66α coiled-coil domain 
peptide can bind to native MBD2 in cells and relieve MBD2-mediated repression of 
target genes such as the embryonic and fetal β–type globin genes in adult erythroid cell 
culture systems (Gnanapragasam et al. 2011b). This proof-of-concept study 
underscored the biological significance of functional disruption of the MBD2-NuRD co-
repressor complex and led us to pursue characterization of other MBD2 mediated 
interactions within the NuRD complex.  
Intrinsically disordered proteins (IDPs) are a rapidly advancing area of research due to 
their importance in human biology. Although IDPs lack a stable three-dimensional 
structure under physiological conditions, they can serve as hubs of multi-protein 
interactions for diverse cellular functions like transcription regulation, chromatin 
remodeling and cell signaling because the intrinsic disorder permits transient, low 
affinity but high specificity protein-protein and nucleic acid-protein interactions (Tompa 
2012). Among the MBD protein family members, the transcription repression domain of 
MBD1 (Hameed et al. 2014) and 60% of full-length MeCP2 protein have been identified 
to be intrinsically disordered (Adams et al. 2007), even in the presence of their binding 
partners.  
Having previously determined the structures of the MBD and coiled-coil domains of 
MBD2, we present here the unique structural and functional features of the previously 
uncharacterized MBD2IDR in collaboration with Dr. David Williams at UNC Chapel Hill 
(All biophysical studies were conducted by Dr. David Williams and his research group, 
whereas I was involved in biological assays presented in this work). We show that this 
  
 56 
region is intrinsically disordered in isolation and in the context of the full-length protein 
bound to DNA; we identify its role in modifying kinetics and affinity of DNA-binding, and 
map the critical sites needed for MBD2IDR to recruit the histone deacetylase core 
complex within the context of the intact MBD2 protein in cells. We anticipate these 
results will facilitate efforts for further biochemical and structural characterization of the 
MBD2-NuRD complex and open up avenues to target co-repressor activities of MBD2-
NuRD via disruption of MBD2IDR-mediated interactions with the NuRD complex. 
 
II. Methods: 
Protein expression and purification: Various MBD2 constructs were cloned into a 
modified pET32a vector (Cai et al. 2003) including: the MBD2IDR of human (amino acids 
238-356) and mouse (amino acids 241-359) MBD2; a single-chain coiled-coil domain 
construct (scMBD2-p66α) comprised of the MBD2 coiled-coil domain (amino acids 361-
393), a short GGSG linker, and the p66α coiled-coil domain (amino acids 137-178); and 
a full-length MBD2 single-chain construct (MBD2FLsc) comprised of MBD2 (amino 
acids 150-393) and the scMBD2-p66α.   The resulting plasmids were transformed into 
the Rosetta II (DE3) (Invitrogen) E. coli strain, grown in either Luria Bertani medium 
(unlabeled) or M9 minimal media (13C, 15N labeled) and induced with 1mM isopropyl-β-
d-thiogalactopyranoside at an A600 ~ 0.8 for 2 or 4 hours, respectively.   Bacterial pellets 
from 1L of growth media were lysed with 30 mL of the B-PER reagent (Thermo 
Scientific) and the expressed fusion protein purified by Nickel affinity chromatography.   
For analytical ultracentrifugation studies, the fusion protein was further purified by gel 
filtration chromatography (Superdex-75 26/60, GE Healthcare).   For CD and NMR 
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studies, the MBD2IDR was separated from the thioredoxin fusion domain by thrombin 
cleavage at room temperature overnight, and further purified by gel filtration (Superdex-
75 26/60, GE Healthcare) and ion exchange (MonoS 10/100, GE Healthcare) 
chromatography.   The final protein concentration was determined by UV absorbance at 
280 nm. 
 
Analytical ultracentrifugation: Protein was buffer exchanged in to 20mM Tris pH 8.0, 
150 mM NaCl and sedimentation velocity analyzed at 40,000 rpm, 20 ºC on a Beckman 
Optima XL-I analytical ultracentrifuge (Beckman Coulter Inc.) equipped with a four and 
eight-position AN-60Ti rotor. The sample partial specific volume, buffer density and 
viscosity were calculated with the SEDNTERP (Lebowitz, Lewis, Schuck 2002) software 
and the effective molecular weight determined by fitting the data to a continuous size 
distribution with the SEDFIT (Schuck 2000) software. 
 
Circular dichroism: The MBD2IDR was buffer exchanged into 10 mM NaPO4, pH 6.5 at 
a final concentration of ~33 μg/mL protein.  CD spectra were collected from 190-260 nm 
(0.5 nm interval, 50 nm/min, 1 cm path length, 20 ºC) on a JASCO J-715 CD 
spectrometer (JASCO Corp). Helical content for each peptide was calculated as 
described previously (Kumita, Smart, Woolley 2000; Walavalkar, Gordon, Williams 
2013).  
 
Nuclear magnetic resonance: Uniform 13C, 15N labeled protein was buffered 
exchanged into 10 mM NaPO4, pH 6.5, 0.02% sodium, 1mM dithiothreitol, and 10% 
  
 58 
2H2O and concentrated to 0.5-1 mM.   NMR spectra were collected on a Bruker Avance 
III 700 MHz instrument, and data processed and analyzed with NMRPipe (Delaglio et al. 
1995) and CcpNmr (Vranken et al. 2005), respectively.   Standard double and triple 
resonance experiments (15N-HSQC, HNCO, HNCACB, CBCA(CO)NH, HBHA(CO)NH, 
HN(CA)NNH, HNCACO, CCH-TOCSY, (H)CC(CO)NH, 15N-NOESY-HSQC) were 
collected and the backbone and sidechain Hα/β resonances assigned for mouse 
MBD2IDR.  Given the sequence identity and similar 15N-HSQC spectra, only HNCO, 
HNCACB, and HBHA(CO)NH triple resonance spectra were necessary to propagate 
backbone and sidechain Hα/β resonance assignments to human MBD2IDR. Chemical 
shift index analyses were performed with the TALOS-N software to predict secondary 
structure formation and order parameters (Cornilescu, Delaglio, Bax 1999; Shen et al. 
2009; Shen and Bax 2013).  
 
Cell culture: Human embryonic kidney 293T cells were maintained in Dulbecco’s 
modified Eagle’s Medium (DMEM) containing 10% heat inactivated fetal bovine serum 
(Hyclone), 2mM L-glutamine and 100 U/mL penicillin and streptomycin. MDA-MB-435 
breast cancer cells were maintained in DMEM supplemented with 10% heat inactivated 
fetal bovine serum and 100 U/mL penicillin and streptomycin. Cells were cultured at 
37ºC and 5% CO2.  
 
Co-immunoprecipitation: Various MBD2 constructs were cloned into the pCMVTag2B 
(Stratagene) vector in frame with an N-terminal flag-tag sequence. HEK 293T cells were 
transfected with the constructs (18 ug plasmid DNA) by calcium phosphate precipitation 
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method (Kingston, Chen, & Okayama, 2003) and harvested after 48 hours. Cells were 
lysed and immunoprecipitated with anti-flag M2 antibody (Sigma) and mouse IgG 
(Santa Cruz) controls according to the Sigma Flag-IPT kit protocol (Sigma-Aldrich, Inc., 
St. Louis, MO). The precipitated proteins were then analyzed for different components 
of the MBD2-NuRD complex by western blot using antibodies against RbAp48 (Abcam 
ab79416), HDAC2 (Millipore #05-814) and MTA2 (Santa Cruz sc-28731).  
For full-length MBD2 pull downs, the cells were lysed in micrococcal nuclease (MNase) 
digestion buffer (25mM HEPES-KOH pH 7.6, 100mM NaCl, 5mM MgCl2, 3mM CaCl2, 
10% glycerol, 0.2% NP40 and 1X EDTA-free protease inhibitor cocktail (Roche)) 
followed by MNase digestion using 1500 U/mL of MNase (Worthington Biochemical, 
Lakewood, NJ) for 2 hours on ice. Ethidium bromide was then added to the lysate at 
300 ug/mL followed by a spin at 10,000xg for 15 mins at 4ºC. The supernatant was then 
subjected to immunoprecipitation as previously described.  
 
Site-directed mutagenesis: Mutant oligonucleotides targeting the conserved residues 
of the 1st and 2nd region of MBD2IDR were designed using the QuikChange Primer 
Design Program (www.agilent.com/genomics/qcpd). Primers used for mutagenesis are 
listed in Table 1. Mutagenesis was carried out per manufacturer’s protocol using the 
Quikchange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa 
Clara, CA). Clones were verified by sequencing and used for transfections. 
Sequence Alignments: Protein-coding sequences of MBD2 for different species were 
obtained from the NCBI Protein database and aligned using the PRALINE software 
(http://www.ibi.vu.nl/programs/pralinewww/). 
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Local isoelectric point calculation: Each residue (i) in the protein was assigned a 
local isoelectric point (pI) calculated from the amino acid sequence (Bjellqvist et al. 
1993) for residues spanning i±7.  The pI was calculated using the 
SeqUtils.IsoelectricPoint module in the  Bio package from the Biopython Project 
(www.biopython.org).  For those residues less than seven from the N- or C-termini, the 
isoelectric point was calculated from the amino acid sequence for residues spanning i ± 
n where n is the number of residues between i and the N- or C- terminus.  
 
Lentiviral knockdown and expression of MBD2: The shMBD2 (5’ - 
GGGTAAACCAGACTTGAA - 3’) sequence was cloned into the pRRL.H1.shRNA 
vector. Full-length wild-type and mutant MBD2 gene sequences were cloned in the 
pLV203 vector with a flag-tag added to the C-terminus (Genecopoeia, Rockville, MD). 
Both full-length MBD2 genes contain a single silent mutation introduced into the MBD2 
shRNA target sequence to confer shRNA resistance. The vectors were packaged into a 
lentivirus by calcium phosphate transfections of HEK 293T cells.  MDA-MB-435 breast 
cancer cells were transduced with packaged virus and grown in vitro for 7 days post-
transduction before quantitative PCR and western blot analyses. Primers used for 
qPCR analysis are listed in Table 2. Antibodies used for MBD2 and Flag epitope protein 
detection were from Santa Cruz (sc1244) and Abcam (ab1162) respectively. 
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Table 1. List of primers used for mutagenesis 
 
 
FORWARD REVERSE 
P244G GAAAATTGATGCTGTTTGTCTAATTC
CCAATGTTGTATTCAAGTCTGGTTTA 
TAAACCAGACTTGAATACAACATTG
GGAATTAGACAAACAGCATCAATTT
TC 
R246E CCAGACTTGAATACAACATTGCCAAT
TGAGCAAACAGCATCAATTTTCAAA
CAACC 
GGTTGTTTGAAAATTGATGCTGTTTG
CTCAATTGGCAATGTTGTATTCAAGT
CTGG 
T248A GACTTGAATACAACATTGCCAATTAG
ACAAGCAGCATCAATTTTCAA 
TTGAAAATTGATGCTGCTTGTCTAAT
TGGCAATGTTGTATTCAAGTC 
R246E_T2
48A 
GGTTGTTTGAAAATTGATGCTGCTTG
CTCAATTGGCAATGTTGTATTCAAGT
CTGGTTTACC 
GGTAAACCAGACTTGAATACAACAT
TGCCAATTGAGCAAGCAGCATCAAT
TTTCAAACAACC 
P255A GACAAACAGCATCAATTTTCAAACA
AGGGGTAACCAAAGTCACAAATCAT 
ATGATTTGTGACTTTGGTTACCCCTT
GTTTGAAAATTGATGCTGTTTGTC 
V256A CATCAATTTTCAAACAACCGGCAACC
AAAGTCACAAATCATCC 
GGATGATTTGTGACTTTGGTTGCCGG
TTGTTTGAAAATTGATG 
P278G ACAACGAATGAATGAACAGGGACGT
C 
CTCCCAGAAAAGCTGACGTCCCTGTT 
Q280A CGAATGAATGAACAGCCACGTGCGC
T 
CTTCTCCCAGAAAAGCGCACGTGGC
T 
W283A AGCCACGTCAGCTTTTCGCGGAGAA
G 
CTTGTAGCCTCTTCTCCGCGAAAAGC 
R286E TCAGCTTTTCTGGGAGAAGGAGCTAC TGCACTAAGTCCTTGTAGCTCCTTCT 
L287A GCTTTTCTGGGAGAAGAGGGCACAA TGATGCACTAAGTCCTTGTGCCCTCT 
R286E_L2
87A 
CACGTCAGCTTTTCTGGGAGAAGGA
G 
CATCTGATGCACTAAGTCCTTGTGCC 
L290A GGAGAAGAGGCTACAAGGAGCTAGT TGTTACATCTGATGCACTAGCTCCTT 
For full-length MBD2 mutagenesis of specific residues, following primers were used: 
R286E_L2
87A 
TTT TCT GGG AGA AGG AGG CAC 
AAG  
 CTT TTC TGG GAG AAG GAG CTA 
CAA G 
R286E  CTT TTC TGG GAG AAG GAG CTA 
CAA G 
 CTT TTC TGG GAG AAG GAG CTA 
CAA G 
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Table 2. List of primers used for qPCR in Chapter 2  
 FORWARD REVERSE PROBE 
MBD2 AAG AGC GAG TAC 
AGC AAG TAC GCA 
TTC TGT ATC AGC 
AGC TCG CGA CAA 
TGG AAG AAG CAC 
TGA TGG CAG ACA 
TC 
GAPDH TCG ACA GTC AGC 
CGC ATC TTC TTT 
ACC AAA TCC GTT 
GAC TCC GAC CTT 
AGC CAC ATC GCT 
CAG ACA CCA TGC 
PRSS8 ACGCCTTCATAGGT
GATGCT 
ATCTTGGATTACTC
CGGTCG 
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III. Results: 
 
A. The MBD2IDR region is intrinsically disordered   
We cloned, expressed and purified from bacteria the MBD2IDR from both the human 
(amino acids 238-356) and mouse (amino acids 241-359) MBD2 proteins. The 2D 15N-
HSQC spectra of each (Figure 9a) show features characteristic of a disordered peptide.   
The amide backbone resonances are quite sharp, the 1H(N) chemical shifts fall between 
7.5-8.5 ppm, and the sidechain amide resonances are highly degenerate. In particular, 
the 1H-15Nε resonances of two Trp residues completely overlap (red dashed oval, Figure 
9a), while seven Asn and ten Gln sidechain 15N-1H2 resonances overlap extensively 
(blue dashed oval, Figure 9a).  These findings indicate that the MBD2IDR domain 
remains largely disordered in solution.  
We further characterized this region by CD and analytical ultracentrifugation.   The CD 
spectra are consistent with a highly disordered peptide comprised of only 7% helix at 
298 K and 12% helix at 368 K (Figure 9b) based on mean residue ellipticity (MRE) at 
222nm.  Thermal melting did not show a cooperative transition typical of a folded 
domain (blue curve, Figure 9b).   Sedimentation velocity by analytical ultracentrifugation 
analysis is consistent with a monomeric protein at 20 μM with a tendency to aggregate 
at higher concentrations (Figure 9c).  
B. A polypeptide linkage stabilizes the MBD2-p66α coiled-coil complex 
These observations raise the possibility that the MBD2IDR depends on the MBD or 
coiled-coil domains to adopt a regular structure.  A polypeptide including the MBD, 
MBD2IDR and coiled-coil domains of MBD2 has proven difficult to purify from bacterial 
expression systems.   We recently designed and tested a remarkably stable and well-
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Figure 9. The MBD2IDR of MBD2 is intrinsically disordered in isolation. (a) An overlay of 
15
N-HSQC 
spectra for the MBD2IDR of HsMBD2 (black) and MmMBD2 (green) shows a lack of chemical shift 
dispersion with highly degenerate Gln and Asn 
15
N-
1
H2 (blue circle) and Trp 
15
N-
1
Hε (red circle) 
resonances.  (b) CD spectra of the MBD2IDR at 293 K for HsMBD2 (black) and MmMBD2 (purple) and at 
368 K for HsMBD2 (red) shows little evidence of secondary structure formation while a thermal melt for 
HsMBD2 MBD2IDR fails to reveal a cooperative transition characteristic of folded domains.  (c) Analytical 
ultracentrifugation sedimentation velocity analysis for 20 μM (black) and 100 μM (red) HsMBD2 MBD2IDR 
indicates that the MBD2IDR is largely monomeric at 20 μM but does show evidence of aggregation at 
higher concentration. 
(By Dr. David Williams et al.) 
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behaved single chain construct of the coiled-coil domains from MBD2 and p66α (Figure 
10a).  This single-chain construct (scMBD2-p66α) comprises the MBD2 coiled-coil 
domain (amino acids 361-393), a short GGSG linker, and the p66α coiled-coil domain 
(amino acids 137-178).   The scMBD2-p66α retains helical content as measured by CD 
analysis up to 95°C (Figure 10b) and the 2D 15N-HSQC spectrum remains dispersed 
and similar to that of the p66α-MBD2 coiled-coil complex previously studied, even at 
80°C (Figure 10c).  Adding the scMBD2-p66α to the MBD and MBD2IDR of MBD2  
(MBD2FLsc, amino acids 212-356) stabilizes the protein for bacterial expression and 
purification.   
 
C. NMR analysis of intrinsically disordered MBD2IDR 
 A 2D 15N-HSQC spectrum of the MBD2FLsc protein bound to methylated DNA contains 
broadened and dispersed resonances traceable to the MBD and coiled-coil domains, 
while most resonances from the MBD2IDR remain quite sharp and restricted in 
1H 
chemical shift similar to the isolated MBD2IDR (Figure 11a).  These findings show that 
the MBD2IDR region remains largely disordered even in the context of full-length protein 
and while bound to DNA and does not appear to affect the structures of the MBD and 
coiled-coil domains. Although the backbone resonances of the MBD2IDR lack significant 
chemical shift dispersion, we were able to assign these resonances using standard 3D 
heteronuclear  techniques.  The mouse domain was particularly well-behaved, such that 
we first assigned mouse MBD2IDR and then carried those assignments over to the 
human protein where possible.  Predicting the backbone order parameter and  
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Figure 10. A polypeptide linkage stabilizes the MBD2-p66α coiled-coil complex.  (a) A ribbon 
diagram depicts the the scMBD2-p66α construct comprised of the MBD2 coiled-coil domain (cyan), a 
short GGSG linker (yellow), and the p66α coiled-coil domain (blue).  (b) CD analysis shows that the 
scMBD2-p66α contains similar helical content at 298 K and 368 K, while a thermal melt shows that the 
coiled-coil complex does not undergo a cooperative unfolding transition.   (c) An overlay of 
15
N-HSQC 
spectra for the scMBD2-p66α (gray) with the MBD2 (red) and p66α (blue) coiled-coil complex peptides 
shows similar dispersion and chemical shifts.  This finding indicates that the single-chain peptide adopts a 
similar structure to the coiled-coil complex of the individual peptides.  (d) The 
15
N-HSQC spectra of the 
scMBD2-p66α remains well dispersed at 298 K (gray), 323 K (blue) and 353 K (orange) showing that the 
scMBD2-p66α resists thermal denaturation. (By Dr. David Williams et al.) 
  
 67 
secondary structure by chemical shift indexing as implemented in Talos-N (Shen and 
Bax 2013) (Figure 11b) shows that the entire MBD2IDR lacks a propensity to form 
structure in isolation.   Several small regions (amino acids 275-280, 290-300, and 320-
330) do show chemical shift perturbations suggestive of helical content (Figure 11b), but 
the predicted order parameters remain below 0.6 consistent with a lack of regular 
structure formation. 
 
D. The MBD2IDR modifies DNA binding kinetics and overall binding affinity:   
To determine if the MBD2IDR affected interaction with DNA, we measured binding to 
methylated DNA by surface plasmon resonance.  As described previously (Scarsdale et 
al. 2011a), the isolated MBD shows rapid on and off-rates, which requires steady state 
analysis to determine the overall binding affinity (KD = 330 nM, Figure 12a).   In contrast, 
the MBD2FLsc shows a dramatic reduction in off-rate leading to a 100-fold increase in 
affinity (KD = 2 nM).   Inspection of the MBD2IDR reveals that the region just C-terminal 
to the MBD contains positively charged Arg and Lys residues, which could contribute to 
DNA binding through non-specific electrostatic interactions.   Therefore we calculated a 
theoretical isoelectric point for a sliding window of 15 amino acids along the length of 
the protein.  The results of this analysis for the MBD2IDR homologous regions of human 
(Hs) MBD2 paralogs (MBD2, MBD3, MBD3-L1, and MBD3-L2) as well as Bombyx mori 
(Bm) and Amphimedon queenslandica (Aq) MBD2 orthologs are plotted in Figure 12b.  
Each of the MBD2 orthologs contains a positively charged region just following the MBD 
and at the N-terminus of the MBD2IDR   (Figure 12b).   
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Figure 11 NMR analysis of intrinsically disordered MBD2IDR.  (a) An overlay of 
15
N-HSQC spectra for 
the MBD2 MBD (gray), scMBD2-p66α (blue), and MBD2FLsc (red) indicates the MBD2IDR remains 
disordered in the context of full-length protein and while bound to DNA.   As highlighted in the expanded 
regions, broadened and dispersed resonances in the MBD2FLsc spectrum align with resonances from 
the MBD and coiled-coil domains.  Resonances from the MBD2IDR lack chemical shift dispersion and are 
highly degenerate consistent with a lack of regular structure.  (b) Based on NMR chemical shift 
indexing(36, 37, 38), order parameters (S
2
, upper bar graphs) and secondary structure probabilities 
(lower graphs) for helix (red), sheet (blue) and loop (black) are plotted for the MBD2IDR of MmMBD2a and 
HsMBD2a.  The NMR chemical shifts indicate a lack of regular structure formation throughout the region. 
(By Dr. David Williams et al.) 
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To test whether this region  is sufficient to modify DNA binding, we measured binding 
kinetics by surface plasmon resonance for an MBD2 construct that includes the MBD 
and the first 20 amino acids of the MBD2IDR (residues 150-260).  Similar to MBD2FLsc, 
this protein shows reduced on- and off-rates and increased binding affinity (KD = 20 nM) 
compared to the isolated MBD (Figure 12a).  Therefore the MBD2IDR contains a 
positively charged region that modifies binding kinetics and affinity despite a lack of 
regular structure formation.  Similar positively charged disordered regions adjacent to 
DNA binding domains have been described previously and referred to as “fuzzy” 
domains (Fuxreiter 2012; Fuxreiter and Tompa 2012; Uversky 2011). 
E. The MBD2IDR binds the histone deacetylase core complex of NuRD:  
 In previous studies we showed that the coiled-coil domain of MBD2 recruits the p66 
and Mi2 proteins to NuRD.  To investigate whether the MBD2IDR and coiled-coil 
domains interact with the remaining core components of NuRD (MTA1/2/3, HDAC1/2, 
and RbAp46/48), the MBD2IDR was expressed in 293T cells as a flag-tagged construct, 
with and without the scMBD2-p66α coiled-coil domains (Figure 13a and 13b 
respectively).  Cell lysates were immunoprecipitated with an anti-flag antibody followed 
by western blot analysis to identify the NuRD components interacting with the flag-
tagged MBD2IDR. Figure 13a shows that the MBD2IDR of MBD2 strongly interacts with 
the RbAp48, HDAC2, and MTA2 components of NuRD while the scMBD2-p66α does 
not. The MBD2IDR does not interact with p66α and Mi2β proteins (Figure 14) as 
expected, which uniquely maps the interaction of MBD2 with the histone deacetylase 
and chromatin remodeling components of the NuRD complex into two distinct functional 
domains, the MBD2IDR and the MBD2 coiled-coil domain, respectively.  
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Figure 12 The MBD2IDR modifies DNA binding kinetics and affinity.  (a) Surface plasmon analysis of 
DNA binding shows that both MBD2FLsc (upper panel), and MBD2(150-260) (second panel) bind with 
slower on and off rates and higher affinity than the isolated MBD (third panel).  As seen previously(41), 
the rapid on and off-rates for the MBD preclude accurate fitting of the kinetic data.  Steady-state analysis 
of the isolated MBD binding to methylated (red) and unmethylated (blue) DNA is shown in the fourth 
panel.   (b) The local isoelectric point, calculated as described in the text, is plotted for the MBD2IDR from 
HsMBD2, HsMBD3, HsMBD3-L1, HsMBD3-L2, BmMBD2/3, and AqMBD2/3.  This analysis shows that a 
positively charged region at the N-terminus of the MBD2IDR is conserved across the animal kingdom. 
(By Dr. David Williams et al.) 
 
 
  
 71 
Segments of intrinsically disordered proteins can fold upon interacting with target 
proteins to adopt regular secondary structure. These segments, referred to as molecular 
recognition features (MoRFs) (Mohan et al. 2006; Uversky 2011; Vacic et al. 2007), may 
be identified as regions with low disorder propensity by disorder prediction algorithms.   
Based on analysis from the disorder prediction algorithm PONDR® VLXT (Predictor of 
Naturally Disordered Regions) (Li et al. 1999; Romero, Obradovic, Dunker 1997), three 
separate sub-regions with low disorder propensity were identified within MBD2IDR 
(amino acids 212-273, 274-316 and 317-360, Figure 13c). We tested each of these 
ordered regions separately and in combination for binding to components of the histone 
deacetylase core complex of NuRD. As can be seen in Figure 13d, none of these three 
sub-regions interact with the core complex in isolation.  However, the first and second 
sub-regions of MBD2IDR in combination (amino acids 212-316) were sufficient to bind 
RbAp48, HDAC2, and MTA2, albeit with a somewhat weaker interaction with MTA2 as 
compared to the entire MBD2IDR (Figure 13b).    
F. Key residues within minimal MBD2IDR are Evolutionarily Conserved:  
Full-length protein sequences of HsMBD2 orthologs from across the animal kingdom, 
(Aq, Trichoplax adhaerans (Ta), Bm, Danio rerio (Dr), Gallus gallus (Gg), Mus musculus 
(Mm)),  and Hs paralogs MBD3, MBD3-like 1 and 2 (MBD3-L1, MBD3-L2) were 
obtained from the NCBI protein database. The protein sequences of individual domains 
of MBD2 were aligned using the default settings of the PRALINE online server.  An 
alignment of the MBD (Figure 15a) for orthologs (Aq, Bm, Dr, Gg, and Mm) and a 
paralog (MBD3) that contain a recognizable MBD shows a high degree of conservation  
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Figure 13. The MBD2IDR binds the histone deacetylase core complex of NuRD. (a) The MBD2IDR 
with scMBD2-p66α was transfected in high-transfection-efficiency HEK 293T cells. Immunoprecipitation 
and western blot analysis of the transfected cells indicates that the MBD2IDR binds the histone 
deacetylase core components RbAp48, HDAC2 and MTA2, whereas the scMBD2-p66α construct does 
not. The flag-IP lane shows pull down of the histone deacetylase core components by 
immunoprecipitation using an anti-flag antibody directed against the flag-tagged MBD2IDR.  IgG and 
expression vector pCMV serve as negative controls while the input lane shows 2% of the input. (b) The 
region of MBD2IDR from amino acids 240-316 comprising the first and second ordered sub-regions in 
combination can bind to RbAp48, HDAC2 and MTA2, although a weaker interaction with MTA2 was 
observed. (c) PONDR® VLXT analysis of the MBD2IDR identified three sub-regions of low disorder 
propensity within this intrinsically disordered region (amino acids 240-262, 280-308 and 347-364). (d) The 
three ordered sub-regions of MBD2IDR were expressed individually in HEK 293T cells and 
immunoprecipitated, but failed to bind to either of the histone deacetylase core complex components. 
Note that a non-specific band appears in the IgG lane when blotted with anti-MTA2 that runs just below 
the MTA2 protein in the input and flag IP lanes. 
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from sponge to human (AqMBD2 and HsMBD2 proteins share 64% identity in their 
MBDs).  Critical residues known to influence DNA binding affinity and methylation 
selectivity (Tyr178 and Lys174 of HsMBD2) (Cramer et al. 2014; Fraga et al. 2003; Saito 
and Ishikawa 2002) are highly conserved indicating that methylation specificity 
developed with the first multi-cellular organisms. Notably, several homologs (Ta 
MBD2/3, Hs MBD3-L1 and L2) lack an MBD, yet previous studies have shown that both 
the MBD3-L1 and L2 paralogs interact with NuRD and compete with MBD2 and MBD3 
for complex formation (Jiang et al. 2002; Jiang, Jin, Pfeifer 2004; Jin et al. 2005). 
Therefore, NuRD complex recruitment and DNA binding represent distinct and 
separable functions of MBD2. 
An alignment of the MBD2IDR and coiled-coil regions (Figure 15b), shows much less 
conservation with large insertions (i.e. TaMBD2/3 and AqMBD2/3) and smaller deletions 
as compared to HsMBD2. Nonetheless, specific individual residues are absolutely 
conserved across species suggesting that these amino acids are critical to function. 
Highly conserved residues were identified within the first two ordered regions of 
MBD2IDR implicated in binding to the NuRD histone deacetylas core complex.  We 
mutated these conserved residues individually or in pairs as follows: 1) P244G, 2) 
R246E, 3) P255A, 4) V256A, 5) P278G, 6) Q280A, 7) R286E, 8) L287A, 9) 
R246E/T248A and 10) R286E/L287A (see asterisks below sequence alignment in 
Figure 15b). Flag-tagged MBD2IDR mutants were expressed in 293T cells followed by 
immunoprecipitation and blotting for the histone deacetylase core components. Of the 
ten conserved residues tested, only two contiguous amino acids from the second 
ordered region of MBD2IDR, Arg
286 and Leu287, when mutated effectively eliminated  
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Figure 14. MBD2IDR does not interact with p66α and Mi2β subunits of NuRD. Immunoprecipitation of 
MBD2IDR and the MBD2IDR minimal binding region in transfected HEK293T cells shows that the MBD2IDR 
does not interact with p66α and Mi2β subunits of the NuRD complex, thus delineating unique points of 
contact associating MBD2IDR with the histone deacetylase core subunits and in conjunction with our 
previous data, the coiled-coil domain with the chromatin remodeling component(s) of the NuRD complex 
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Figure 15. Evolutionary conservation of key residues within minimal MBD2IDR. (a) Alignment of the 
protein sequence of the MBD of MBD2 for orthologs (Aq, Bm, Dr, Gg and Mm) and a paralog (MBD3) was 
done using the PRALINE program online. The software color codes the most conserved residues on a 
scale of 0 to 10 with 10 being the most conserved residue. Most residues within the MBD show high 
degree of conservation including critical residues known to influence DNA binding affinity and methylation 
selectivity. (b) Alignment of the protein sequence of MBD2IDR and the coiled-coil domain shows much less 
conservation with large insertions (TaMBD2/3 and AqMBD2) and smaller deletions as compared to 
HsMBD2. However, absolute conservation of specific residues in the minimal MBD2IDR suggests 
functional importance. These conserved residues identified for functional analysis (with a conserved 
score of 8 out of 10) are depicted by an (*) under the sequence alignment and are as follows: Pro
244
, 
Arg
246
, Thr
248
, Pro
255
, Val
256
, Pro
278
, Gln
280
, Trp
283
, Arg
286
, Leu
287
, and Leu
290
.  (Part B on next page) 
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binding to the core complex (Figure 16a). Interestingly neither of these mutations in 
isolation nor any of the other mutations disrupt binding to the histone deacetylase core 
components.   Next, we introduced the double mutation R286E/L287A into the full-
length human MBD2 gene by site-directed mutagenesis.  Since MBD2-NuRD contains 
several potential DNA binding proteins, the immunoprecipitation protocol for full length 
MBD2Flag constructs was modified to eliminate contamination through non-specific 
DNA binding.  The cell lysate from transfected cells was treated with micrococcal 
nuclease, which cleaves both single- and double-stranded DNA and RNA, and with 
ethidium bromide, which intercalates between stacked bases in the double helix.  As 
expected, immunoprecipitation of the NuRD complex by the mutant full length MBD2 
revealed impaired interaction with the histone deacetylase core components: RbAp48, 
HDAC2 and MTA2, with the effect being most pronounced for MTA2 (Figure 16b). 
Together these observations indicate that Arg286 and Leu287 comprise a critical 
interaction surface necessary but not sufficient for recruiting the histone deacetylase 
core complex of NuRD.  
 
G. Functional biological assay of double mutant MBD2: 
To determine if interaction with the histone deacetylase core components is necessary 
for methylation dependent gene silencing by MBD2, we expressed the R286E/L287A 
double mutant MBD2Flag construct in a background of partial knockdown of 
endogenous MBD2 in MDA-MB-435 breast cancer cells.  The RNA expression level of 
the endogenous gene PRSS8 was used as a reporter of MBD2-NuRD mediated 
transcriptional repression.  We previously showed that stable knockdown of MBD2 by   
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Figure 16. Two conserved residues from minimal MBD2IDR are necessary to bind the histone 
deacetylase core of NuRD. (a) Mutating five residues from the first region of minimal MBD2IDR (P244G, 
R246E, P255A, V256A, and R246E/T248A) does not affect immunoprecipitation of the histone 
deacetylase core complex. Similarly, mutating four residues from the second ordered region of minimal 
MBD2IDR  (P278G, Q280A, R286E, and L287A) does not affect immunoprecipitation of the histone 
deacetylase core complex.  However, combined mutation of two adjacent residues (R286E/L287A) 
significantly abrogates the ability of MBD2IDR to recruit the histone deacetylase core components.  
Strikingly, the individual mutants R286E and L287A have no effect on interaction of the MBD2IDR with the 
histone deacetylase core. Three additional mutations (T248A, W283A and L290A) do not affect binding of 
MBD2IDR to the histone deacetylase core complex (data not shown). (b) Full length flag-tagged MBD2 
carrying the double mutation R286E/L287A also displays a disrupted interaction with RbAp48, HDAC2 
and MTA2. The interaction of the double mutant MBD2 with MTA2 is completely lost whereas its 
interaction with RbAp/HDAC shows significant reduction. 
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shRNA in MDA-MB-435 cells increased PRSS8 expression, demonstrating that MBD2 
mediates transcriptional repression of PRSS8 in these cells (Mian et al. 2011).  
Simultaneous knockdown of endogenous MBD2 and enforced expression of wild-type 
or R286E/L287A double mutant MBD2Flag was achieved by lentivirus mediated 
delivery of anti-MBD2 shRNA and wild-type and R286E/L287A double mutant 
MBD2Flag mRNA resistant to knockdown (Mian et al. 2011). Blotting with anti-MBD2 
antibody (Figure 17a), which recognizes both endogenous (lower band) and lentivirally 
expressed MBD2Flag (top band), shows about 50% knockdown of the endogenous 
protein in SH+WT and SH+Double mutant cells as compared to the negative control 
(SC + LV).  Detection of the exogenously expressed MBD2Flag proteins with an anti-
flag antibody demonstrates similar expression levels in SH+WT and SH+Double mutant 
transduced cells (Figure 17b). Taking into account both knockdown of endogenous 
MBD2 and expression of MBD2Flag proteins, the total amount of MBD2 protein in both 
groups (SH+WT and SH+Double mutant) remains constant and represents ~50% more 
MBD2 protein than that in the negative control. Knockdown of endogenous MBD2 and 
add back of wild type MBD2, shows repression of PRSS8 expression beyond the 
baseline due to increased total expression of wild-type MBD2. However, in the case of 
enforced expression of the R286E/L287A double mutant MBD2, PRSS8 gene 
expression is not statistically significantly reduced compared to the baseline level 
although there is a suggestion of a slight decrease (Figure 17c). PRSS8 gene 
expression is consistently >2 fold lower (p-value<0.01) in SH+WT cells than in 
SH+Double mutant cells, which we attribute to the inability of mutant MBD2 to 
effectively recruit the histone deacetylase core components of the NuRD complex. 
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Figure 17. Double mutant MBD2 shows reduced transcriptional repression of its methylated target 
gene PRSS8. Western blot analysis of MDA-MB-435 cells infected with MBD2 knockdown and 
expression lentiviruses shows (a) ~50% and ~40% knockdown of endogenous MBD2 in SH+WT and 
SH+Double mutant cells respectively and (b) Equivalent expression of wild-type MBD2Flag and 
R286E/L287A double mutant MBD2Flag across both SH+WT and SH+Double mutant cells respectively. 
Therefore, SH+Double mutant cells contain 60% mutant MBD2Flag as compared to SH+WT cells. (c) 
SH+WT cells show increased repression of PRSS8 as compared to the baseline expression level set by 
SC+LV control. However, SH+Double mutant cells express PRSS8 at levels close to the baseline, due to 
the inability of double mutant MBD2 to effectively repress its target gene PRSS8. SC+LV control 
represents cells transduced with empty backbone lentiviral vectors for both shRNA knockdown (SC) and 
gene expression (LV). PRSS8 gene expression is normalized to GAPDH expression. Error bars denote 
standard deviation of 3 independent experiments. *signifies p-value<0.005, ** signifies p-value<0.01. 
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IV. Discussion:  
Research over the past two decades has challenged the traditional structure-function 
paradigm of proteins.   Instead of adopting a well-folded three-dimensional structure in 
solution, many proteins are entirely disordered or contain functionally important 
intrinsically disordered regions (IDR). Estimates indicate that from 15-45% of eukaryotic 
proteins have long (>30 amino acid) regions of disorder (Tompa 2012). These regions 
can function either by folding upon binding to a target ligand or through dynamic  
interactions involving rapidly exchanging conformations of the disordered state 
(Fuxreiter and Tompa 2012; Fuxreiter 2012; Tompa 2012; Uversky 2011).    
Here we show that a large segment (~145 amino acids) between the conserved MBD 
and coiled-coil domains of MBD2 behaves as an intrinsically disordered region in 
isolation and in the context of the full-length protein.  This region does not adopt a 
regular structure even when bound to methylated DNA.  Nonetheless incorporating the 
MBD2IDR affects the binding kinetics and overall affinity for DNA, functioning as a 
"fuzzy" domain (Fuxreiter 2012). The N-terminal portion of the MBD2IDR has a net 
positive charge that is conserved across evolution and likely contributes to this fuzzy 
interaction with the DNA (see Figure 12b). IDRs flanking functional DNA-binding 
domains have been shown to influence DNA recognition and potentially rates of 
association and lifetime of the DNA-protein interactions (Ghosh et al. 2010; Pontius 
1993). 
IDRs are often found in proteins that serve as hubs of one-to-many protein interactions 
(Dunker et al. 2005; Haynes et al. 2006; Patil and Nakamura 2006). In this report we 
demonstrate that the MBD2IDR of MBD2 binds the histone deacetylase core complex of 
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NuRD comprised of the MTA1/2, HDAC1/2, and RbAp46/48 proteins.   To map this 
interaction, we divided the MBD2IDR into three potential MoRFs based on disorder 
propensity as predicted by the PONDR® VLXT algorithm (Li et al. 1999; Romero, 
Obradovic, Dunker 1997). We found that the first two segments of the MBD2IDR are 
necessary and sufficient to bind the histone deacetylase core complex (Figure 13b). 
Interestingly, this region also incorporates the positively charged segment that 
contributes to DNA binding. We were unable to identify sub-regions of MBD2IDR that 
selectively bind to different components of the histone deacetylase core complex, which 
suggests cooperative all-or-none formation of this complex (Figure 13c). This 
observation indicates that either the MBD2IDR forms a large contact surface for binding 
each of the proteins cooperatively or that the MBD2IDR binds to one of the core 
components which in turn interacts with other components. In support of the latter 
interpretation, recent structural analyses have shown that the ELM2 and SANT domains 
of MTA1 bind directly to HDAC1 (Millard et al., 2013) and a small peptide from the C-
terminal region of MTA1 binds RbAp48 (Alqarni et al. 2014). The MTA proteins may 
provide a common point of contact such that MBD2IDR binding directly to either of 
RbAp, HDAC, or MTA would be sufficient to recruit all of the histone deacetylase core 
components.  
   Intrinsic disorder in MBD2 appears to be under selective pressure as evidenced by 
conservation of numerous residues within the MBD2IDR across several paralogs and 
distantly related orthologs, despite large insertions and sequence variability (Figure 15). 
Using this evolutionary conservation as a guide, we designed point mutations in the first 
and second segments of the MBD2IDR and found that two highly conserved residues 
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(Arg286 and Leu287) are critical for binding to the histone deacetylase core complex. 
Mutating these critical residues even in the context of full length MBD2 diminishes 
interaction with the histone deacetylase core complex.   A recent analysis of MBD2 
alternative splice variants revealed that dominant isoform in embryonic stem cells, 
MBD2c, lacks most of the C-terminus including the MBD2IDR and the coiled-coil 
domains.   Consistent with the role of these two domains in recruiting Mi2 and the 
histone deacetylase core complex, MBD2c fails to interact with any of the NuRD 
components and lacks repressive activity (Lu et al. 2014).  
MBD2-NuRD has been established as a transcriptional repressor of embryonic and fetal 
β-type globin genes in primary adult erythroid cells across different species 
(Gnanapragasam et al. 2011b; Kransdorf et al. 2006; Rupon et al. 2006a; Singal et al. 
2002) and of tumor suppressor genes in breast cancer cells (Esteller 2008; Mian et al. 
2011). We hypothesized that the Arg286 and Leu287 mutations of MBD2 that impair 
recruitment of the histone deacetylase core components of the NuRD complex would in 
turn abrogate repression of methylated target genes. To test this hypothesis, we 
assayed the expression of a previously identified highly methylated MBD2 target gene, 
PRSS8, in MDA-MB-435 breast cancer cells (Mian et al. 2011). PRSS8 encodes for 
prostasin, a member of the trypsin family of serine proteases that has been implicated in 
inhibition of metastasis of both breast and prostate cancer cells (Chen et al. 2001; Chen 
and Chai 2002).  A CpG-rich region in the promoter and exon 1 of PRSS8 is heavily 
methylated when this gene is repressed in MDA-MB-435 breast cancer cells (Chen and 
Chai 2002), while demethylation by 5-aza-2'-deoxycytidine combined with histone 
deacetylase inhibitor treatment reactivates expression of PRSS8. In our studies, 
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R286E/L287A double mutant MBD2 protein exerts diminished repression of PRSS8 
when compared to an equivalent amount of wild-type MBD2 protein, (Figure 17c) thus 
confirming the importance of these two amino acid residues in MBD2-NuRD function.  
Our results can be summarized into a dynamic working model for the architecture of the 
NuRD complex wherein the subunits carrying the chromatin remodeling enzymatic 
activities unique to the NuRD complex can be mapped to two separate domains of 
MBD2: the MBD2IDR which recruits the histone deacetylase core components and the 
coiled-coil domain which recruits the chromatin remodeling subunit Mi2β through its 
interaction with p66α (Figure 18). Delineating the multi-protein interactions within the 
MBD2-NuRD complex should enable future attempts to decouple the distinct enzymatic 
activities of the complex, in isolation or combination, to disrupt the repressive functions 
of each and dissect their potentially independent roles in regulating specific sets of 
genes.  
Understanding the role of IDRs in the assembly of multi-protein complexes like MBD2-
NuRD adds valuable insight to their function in epigenetic regulation.  IDRs have been 
well-recognized as hubs for interaction of many proteins due to their malleability and 
fluctuating structures. MBD1-c was recently shown to selectively interact with different 
binding partners through its intrinsically disordered transcriptional repression domain 
(Hameed et al. 2014). Structural characterization of intrinsically disordered regions of 
other proteins such as p53 (Dawson et al. 2003; Wells et al. 2008), PTP1B (Krishnan et 
al. 2014), androgen receptor (Myung et al. 2013), α-synuclein (Toth et al. 2014; 
Uversky, Li, Fink 2001) and oncoprotein c-myc (Berg et al. 2002; Hammoudeh et al. 
2009) has elucidated the function of these proteins in pathological pathways and lead to 
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successful efforts developing small molecule inhibitors for therapeutic drug targeting. 
The work presented here sets the stage for further biochemical and functional 
characterization of the MBD2-NuRD complex and raises the possibility of selectively 
abrogating NuRD dependent silencing of specific sets of genes by disrupting the 
MBD2IDR mediated interactions with the HDAC complex. Exploitation of such 
mechanistic findings could ultimately lead to improved treatment of hemoglobin 
disorders and cancer. 
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Figure 18. A working model of the architecture of the MBD2-NuRD co-repressor complex.Our 
model maps interactions between MBD2 and the histone deacetylase core subunits to the MBD2IDR, 
wherein mutation of the two contiguous residues comprising the critical interaction site (shown as red 
asterisks in the IDR) impairs binding. The previously characterized coiled-coil domain of MBD2 recruits 
the chromatin remodeler Mi-2β through p66α and the MBD recruits the co-repressor complex to sites of 
dense CpG methylation. 
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CHAPTER 3: Role of the MBD2-NuRD complex in developmental regulation of the 
fetal γ–globin gene 
 
I. Introduction: 
   The  γ-globin gene lies on chromosome 11 within the β-globin gene cluster, which 
contains the genes 5’-LCR-ε-Gγ-Aγ-δ-β-3’. These β-type globin genes are expressed in 
ontogeny in the order in that they appear on the chromosome. Several cis-acting 
sequences and trans-acting factors have been identified to regulate the fetal-to-adult 
hemoglobin switch (Sankaran, Xu, Orkin 2010b). Our lab previously identified MBD2, an 
epigenetic regulator, to be involved in developmental silencing of the fetal γ-globin gene 
in adult erythroid cells (Amaya et al. 2013; Gnanapragasam et al. 2011b; Rupon et al. 
2006a). Methyl CpG binding domain protein 2 (MBD2) belongs to the family of proteins 
characterized by the presence of the MBD domain. This domain enables these proteins 
to preferentially bind to methylated DNA. MBD2 binds to densely methylated CpG 
islands and recruits the Nucleosomal Remodeling and Histone Deacetylase (NuRD) co-
repressor complex, to cause chromatin compaction and transcriptional silencing 
(Meehan et al. 1989; Wade 2001).  
      We previously demonstrated that MBD2 knockout in β-YAC transgenic mice leads to 
at least a ten-fold induction of human fetal γ-globin in adult erythroid cells (Rupon et al. 
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2006a). This level of induction is very similar to that which is obtained with the treatment 
of a DNA methylation inhibitor, 5-Azactydine. During the switch to definitive  
erythropoiesis in the β-YAC transgenic mice embryos, the absence of MBD2 causes an 
inability to fully silence the fetal γ-globin. Knockdown of MBD2 in primary human adult 
erythroid cells caused significantly increased expression of the fetal γ-globin gene by 
~9-fold as compared to the scramble shRNA control cells, without affecting their normal 
terminal differentiation into red cells. Although MBD2 was shown to have a role in the 
silencing of the γ-globin gene, it did not bind to the gene to mediate its silencing (Rupon 
et al. 2006a). This was not entirely surprising because there are no CpG islands within 6 
kb of the γ-globin gene. In fact, no region in the promoter contains more than 4 CpGs in 
a span of 70 bp DNA. While MBD2 has been shown to bind to a sequence containing as 
few as three CpGs in vitro (Fraga et al. 2003), MeCP1 complex as a whole seems to 
require at least 15 CpGs per the complex in vivo (Meehan et al. 1989; Wade 2001). 
Moreover, in vivo, MBD2 binds only to methylated CpG island sequences (Ginder, 
Gnanapragasam, Mian 2008).  
Because MBD2 does not bind to the γ-globin gene to cause its silencing in adult 
erythrocytes, we postulated that the loss of MBD2 results in transcriptional activation of 
a gene or genes that are normally silent in adult erythroid cells. The product of this 
gene(s) could in turn result in the transcriptional activation of the γ-globin gene. To 
recognize indirect downstream effectors of MBD2, we conducted gene and microRNA 
expression microarrays in MBD2-/- and wild-type mice adult erythroblasts to identify 
genes/miRNAs that would be differentially regulated in the absence of MBD2.  
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Figure 19. Gene expression microarray in erythroid cells of MBD2-/- mice (A) Heat map showing 
differential expression of genes in erythroid cells of MBD2
-/-
 and wild-type mice. 93 were found to be up-
regulated and 50 genes were down-regulated in MBD2
-/-  
mice compared to the control wild-type mice. (B) 
Ingenuity Pathway Analysis of the 93 differentially regulated genes to identify genes involved in 
hematological pathways yielded the lists of genes listed here. Prioritization based on genes having a CpG 
island identified these four genes as candidates: Zinc-finger and BTB domain containing 32 (Zbtb32), 
YY1-associated factor 2 (YAF2), BRG1-associated factor 57 (Baf57) and Itchy E3 ubiquitin protein ligase 
homolog (ITCH). (Part B on next page) 
(Unpublished data by Rupon JW and Gnanapragasam MN) 
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The gene expression microarray was performed on an Affymetrix Genechip 430A 2.0 to 
recognize differentially regulated genes in MBD2-/- and wild type adult erythroid cells. To 
this end, MBD2-/- and wild type mice were intraperitoneally injected with 1- 
acetyl-2-phenylhydrazine to induce hemolytic anemia, causing extra-medullary 
hematopoiesis. This makes the spleen the primary site of erythropoiesis and it 
populates to have >90% erythroid cells. Total RNA was isolated from the spleens and 
sent for microarray analysis on an Affymetrix 430A2.0 platform with probe-sets for over 
14,000 well-characterized mouse genes. To generate the list of genes which are 
differentially expressed between MBD2-/- and wild type adult mouse erythroid cells, a 
statistical cut off p-value of < 0.01 was used. 93 genes were found to be up-regulated 
and 50 genes were down-regulated in MBD2-/- mice compared to wild type mice adult 
erythroid cells (Figure 19A). For the statistical analysis, we collaborated with Dr. Kellie 
J. Archer (Department of Biostatistics, VCU). Since MBD2 serves as an epigenetic 
repressor of its target genes, we focused on identifying genes with increased 
expression in MBD2-/- erythroid cells. The 93 up-regulated genes were prioritized as 
candidate genes by Ingenuity Pathway Analysis of genes relevant in hematological 
pathways and we focussed on those genes with a CpG island. Ingenuity Pathway 
Analysis dynamically computes a large “global” molecular network based on published 
physical interactions (direct as well as indirect) as well as functional interactions 
between orthologous genes using an extensive database. From the 93 genes studied, 
the following four hits populated our analyses: Zinc-finger and BTB domain containing 
32 (Zbtb32), YY1-associated factor 2 (YAF2), BRG1-associated factor 57 (Baf57) and 
Itchy E3 ubiquitin protein ligase homolog (ITCH) (Figure 19B).  
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Figure 20. Validation of candidate genes by Q-RT PCR. (A) RNA from spleen of three anemic MBD2 
knock down (MBD2-/-) and wild type (MBD2+/+) mice was analyzed by Q-RT PCR to verify the differential 
expression of Zbtb32; n=3, Error bars indicate mean ±SD. Mouse erythroleukemia cell line was 
transfected with pSuperior-MBD2 shRNA and empty vector control to validate expression of the candidate 
gene Zbtb32. Western analysis was performed to determine of (B) MBD2 knockdown levels; (C) ZBTB32 
protein levels in the MBD2 knockdown cells. Q-RT PCR was performed to determine (D) Zbtb32 mRNA 
levels in the MBD2 knockdown cells. CyclophilinA was used for normalization in Q-RT PCR. Error bars 
indicate mean ±SE.  
(Unpublished data by Gnanapragasam MN) 
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   Of the 4 genes mentioned above, Zbtb32 was the only gene successfully validated by 
qPCR, with a 4-fold increased expression in adult erythrocytes of MBD2-/- mice as 
compared to wild type mice (Figure 20A). For in vitro validation of the candidate gene 
Zbtb32, we used the mouse erythroleukemia (MEL) cell line. Mbd2 was stably knocked 
down using the shRNA system in MEL cells by upto 90%, both at the mRNA and protein 
level (Figure 20B). In the absence of Mbd2, gene expression of Zbtb32 protein was 
increased by ~2.5 fold as compared to the shScramble control cells (Figure 20C).   
      ZBTB32 contains a CpG island in the body of the gene which could potentially be 
bound by MBD2 when methylated. Studies have identified the regions to be 
preferentially occupied by MBD2 which include -700 to +200 base-pairs relative to a 
transcription start site (TSS) when regulating the expression of the target gene through 
binding methylated DNA (Chatagnon et al. 2011). We investigated whether MBD2 binds 
this CpG island through chromatin immunoprecipitation (ChIP). ChIP assays were 
performed on adult erythroid cells from spleen of anemic MBD2-/- and wild-type mice. 
MBD2 showed enrichment at the CpG islands of the Zbtb32 and Ugt8 genes in wild-
type mice but not in MBD2-/- mice (Figure 21). The CpG island in the promoter of the 
Ugt8 gene serves as a positive control for the binding of MBD2. This observation 
demonstrates that MBD2 binds directly to the Zbtb32 gene in adult erythrocytes.   
To study the biological functional effect of increased expression of ZBTB32 as observed 
in cells deficient for MBD2, our experimental strategy involved enforced expression of 
ZBTB32 in adult hematopoietic cells. We hypothesized that enforced expression of 
ZBTB32 would reactivate the silenced γ-globin gene. Chemical inducer of dimerization 
(CID) dependent multipotential β–YAC mouse bone marrow cells were used as a   
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Figure 21. Chromatin Immunoprecipitation of MBD2 in ZBTB32 gene. ChIP assays were performed 
using anti-MBD2 and goat IgG control antibodies in adult erythroblasts from MBD2 wild type and 
knockout mice. DNA was analyzed using real-time PCR the Ugt8 gene CpG island and ZBTB32 gene 
CpG island. Data was normalized to endogenous amylase gene levels to account for loading errors and 
IgG controls to account for non-specific pull-downs. Error bars indicate mean ±SD. 
(Unpublished data by Rupon JW and Gnanapragasam MN) 
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murine cell system of functional validation. These cells primarily express adult human 
and murine β–type globin genes and hence serve as a valuable system to study 
activators of the fetal γ-globin gene (Blau et al. 2005). Knockdown of Mbd2 in CID cells 
lead to elevated expression of Zbtb32 (Figure 22B), which makes it a valid system to 
study functional effects of Zbtb32. Transient over-expression of Zbtb32 from a plasmid 
carrying the coding sequence of human ZBTB32 was achieved by nucleofection and 
desired level of expression was observed (Figure 22C). Over-expression of ZBTB32 
caused elevation of the γ-globin gene expression by ~2.5 fold at 72 hours post-
transfection (Figure 22D). 
In the studies presented in Chapter 3, we validate the function of ZBTB32 in γ-globin 
gene activation in primary adult human erythroid cells. Since miRNAs are also important 
epigenetic regulators of gene expression through post-transcriptional mechansims, we 
carried out a miRNA microarray analysis of differentially regulated miRNAs in erythroid 
cells of adult MBD2 knockout mice. We identify a single miRNA, miR-210, which 
regulates the expression of the fetal γ-globin gene through a direct or indirect 
mechanism. Understanding the mechanism of MBD2-mediated fetal globin gene 
regulation gives insight into the role of epigenetics in the fetal-to-adult globin switch and 
hematopoietic development in general. 
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Figure 22. Validation of candidate genes in CID β-YAC cells. CID dependent β-YAC bone marrow 
cells were transiently transfected with siMBD2 and siNeg control (n=3). They were analyzed for (A) MBD2 
protein levels by western analysis; and (B) ZBTB32 protein level by western analysis. All the experiments 
were performed at 72h post transfection. Error bars represent mean ±SE. (C) Functional studies in CID β-
YAC cells: CID dependent β-YAC bone marrow cells were transiently transfected with the coding region 
of ZBTB32 (n=3) along with their corresponding empty vector control. The over-expression of ZBTB32 
was verified using western analysis. Error bars indicate mean ± SE (D) mRNA levels of γ-globin was 
calculated using Q-RT PCR in the ZBTB32 over-expressing cells. Gamma globin expression was 
normalized to GlycophorinA.  
(Unpublished data by Gnanapragasam MN) 
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II. Methods: 
 
Lentiviral knockdown and expression:  
shMBD2 (GGGTAAACCAGACTTGAA), hsa-miR-210 (CTGTGCGTGTGACAGCGGCTGA) 
and shScramble sequences were cloned into the pRRL.H1 shRNA vector and packaged 
into lentivirus by calcium phosphate transfections in HEK 293T cells as described 
earlier. The coding sequence of human TZFP cloned in the pCEP-Flag plasmid was a 
generous gift from Dr. Maureen Hoatlin (Oregon Health and Science University, 
Portland, Oregon, USA). To be used for stable over expression studies, this sequence 
was later cloned into the pTRIPZ lentiviral vector with an enhanced green fluorescent 
protein (eGFP) as the reporter gene. This sequence of TZFP was subcloned into a TA 
cloning vector using PCR amplification to introduce restriction cut sites for Mlu1-Cla1 
and followed by ligation into the TA vector using the TA Cloning® kit (Life 
Technologies). A clone verified by sequencing was cloned into the pTRIPZ lentiviral 
expression vector (ThermoScientific) by Mlu1-Cla1 restriction digestion of the respective 
TA vector, gel purification of the desired band and ligation into pTRIPZ lentiviral vector. 
This stable expression vector was packaged into lentivirus as mentioned above and 
used to infect CD34+ hematopoietic progenitor cells.  
 
CD34+ cell isolation: 
CD34+ cells were isolated from de-identified apheresis packs donated by the VCU Bone 
Marrow Transplant Clinic. Cells were thawed in a 37ºC incubator and then poured into a 
50 mL tubes. Cells were mixed with 1 volume of 1X PBS containing 2% FBS. ~30 mL 
volume of cells were then added to a 50 mL tube containing 15 mL of Ficoll-paque-plus 
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(StemCell Technologies Inc). The mix was spun at 400xg for 30 minutes at room 
temperature with no brakes. The middle layer containing the mononuclear cells was 
extracted and placed on a fresh tube, where 40 mL of 1X PBS with 2% FBS was then 
added. Mononuclear cells were then filtered through a 70 uM nylon filter () and spun at 
250xg for 6 minutes at room temperature. Th epaulet was resuspended in 4-5 mL of 
DNaseI solution (StemCell Technologies Inc.)  and incubated at room temperature for 
15 minutes. Following DNaseI incubation, 40 mL of 1X PBS with 2% FBS and 1mM 
EDTA was added  to dilute the solution, followed by spinning the cells at 250xg for 6 
minutes at room temperature. The cell pellet was resuspended in 1X PBS with 2% FBS 
and 1mM EDTA to a density of 2x108 cells/mL. EasySep kit (StemCell Technologies 
Inc.) was used for positive selection of CD34+ cells as per the manufacturer’s protocol. 
Cells were then grown in an expansion medium consisting of StemSpan SFEM II 
medium (StemCell Technologies Inc.) with 1X CC100 cytokine cocktail (StemCell 
Technologies Inc.) and 2% penicillin and streptomycin.  
 
CD34+ cell infection and culture: 
2x105 CD34+ cells were plated per well on a 12-well tissue culture plate in 50 uL of 
expansion medium on the day of infection. The medium containing lentivirus was then 
mixed with 4 ug/mL of polybrene and 650 uL of the lentiviral solution was added per 
well. The cells were incubated overnight in 37ºC and 5% CO2  and the following day, 2X 
expansion medium was added to the cells. 96 hours post-infection, GFP+ cells were 
selected by flow cytometry on a BD FACSAria™ II flow cytometer instrument and 
maintained after in a growth medium containing IMDM supplemented with 20% FBS 
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(Hyclone), 10 ng/mL stem cell factor (SCF), 1 u/mL of erythropoietin (EPO), 1 ng/mL IL-
3, 1 uM dexamethasone, 1 uM estradiol and 2% penicillin and streptomycin for three 
days. The cells were then washed 2 times with IMDM and grown in a differentiation 
medium containing IMDM supplemented with 20% FBS (Hyclone), 1 u/mL of 
erythropoietin (EPO), 10 ng/mL insulin, and 2% penicillin and streptomycin. Cells were 
grown in the differentiation medium for 10 days and changed to a fresh medium once in 
every two days.  
 
Cell surface marker analysis by flow cytometry:  
On day 10 of differentiation, the differentiated erythroid cells were washed with upto 10 
mL of cell staining buffer containing 1X PBS with 10% FBS and spun at 300xg for 5 
minutes at room temperature. The cell pellet was then resuspended in 100 uL of the cell 
staining buffer and incubated with 0.06 ug of CD71 (Transferrin receptor) antibody and 
0.015 ug of CD235a (Glycophorin A) antibody for 30 minutes on ice in the dark. Cells 
were then washed twice with 1.5 mL of cell staining buffer by spinning at 300xg for 5 
minutes and resuspending in fresh buffer each time. After the final wash, cells were 
resuspended in 400 uL of buffer and analyzed and sorted by a BD FACSAria™ II 
machine. These sorted cells were used for gene and protein expression.    
 
RNA Isolation and Quantitative PCR (qPCR): 
Total RNA was isolated from transduced cells X days post-infection by phenol-
chloroform extractions (TRIzol, Life Technologies) as per the manufacturer’s protocol. 
Samples were then subjected to DNaseI digestion as follows: 
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1 uL of 10X DNaseI Buffer (Ambion) 
0.25 uL of DNaseI 
0.25 uL of SUPERase Inhibitor 
1 ug of total RNA 
The volume was made unto 10 uL with DEPC treated H2O.  
The DNaseI reaction was incubated at 37ºC for 30 minutes followed by 75ºC for 10 
minutes.  
5 uL (500 ng) of this RNA product was then converted to cDNA using the iScript cDNA 
synthesis kit (BioRad) as follows: 
2.0 uL of 5X reaction buffer 
0.5 uL of reverse transcriptase enzyme and  
2.5 uL of DEPC teated H2O 
This 10 uL reaction mix was subjected to following thermal cycling conditions: 25ºC for 5 
minutes, 42ºC for 30 minutes and 85ºC for 5 minutes. This cDNA was used for gene 
expression analysis using quantitative PCR on an ABI 7300 Real Time PCR system; 
FastStart Universal SYBR Green Master mix (Roche Diagnostics, Germany) or Taqman 
FastStart Universal Probe master mix (Roche Diagnostics, Germany) were used. 
Thermal cycling conditions for the PCR were: 1 cycle at 50ºC for 2 minutes and 95ºC for 
10 minutes followed by 40 cycles at 95ºC for 15 seconds and 60ºC for 1 minute. The 2-
ΔΔCt method was used for analysis. Relative quantification was determined using the 
SDS 1000 software. Primers used for qPCR are listed in Table 3.  
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MiRNA microarray analysis:  
MBD2-/- mice and wild type mice were made anemic by treatment for two days with 
intra-peritonial injection of 1-acetyl-2-phenylhydrazine (10 mg/ml; Sigma) at a dose of 
0.4 mg/10 g weight of mice. This was done so that spleen becomes greater than 90% 
erythroid. On the fifth day the spleens from four MBD2-/- and wild type mice were 
harvested and RNA was extracted using Trizol (Sigma) as explained earlier.  These 
RNA samples were sent to Dr. Catherine Dumur in the Department of Pathology at 
Virginia Commonwealth University for further processing. The Affymetrix GeneChip® 
miRNA array was used. This array covers miRNAs from with 71 organisms on a single 
array, including 609 murine miRNAs from the Sanger miRNA database v11. The 
FlashTag™ Biotin HSR RNA Labeling Kit (Genisphere Inc., Hatfield, PA) was used to 
label total RNA, containing low molecular weight RNA species. Briefly, 500 ng of total 
RNA from your samples was subjected to a brief Poly(A) tailing reaction followed by 
ligation of a biotinylated signal molecule to the target RNA sample. The labeled RNA 
was then hybridized onto GeneChip® miRNA arrays, and scanned on an Affymetrix 
GeneChip® Scanner 3000 G7 according to the GeneChip® Expression Analysis 
Technical Manual procedures (Affymetrix, Santa Clara, CA).  
For the statistical analysis, we used the following workflow for miRNA microarray data 
summarization: detection of each probe set above background (using a Wilcoxon Test); 
background adjustment (using the Robust Multiarray Analysis - RMA – algorithm); 
quantile normalization; and median polish probe set summarization. Prior to further 
statistical analysis, the dataset was restricted to probe sets representing murine 
miRNAs (609 mmu-miRNAs). I identified probe sets having average signals below 
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background (in grey). Thereafter, for each probe set, a two sample t-test will be used to 
compare MBD2+/+ to MBD2-/- samples. Resulting p-values were used to estimate the 
false discovery rate (FDR) using the Benjamini-Hochberg method.  
 
Quantitative-PCR validation of the miRNA, miR-210:  
TaqMan® miRNA assay kit was obtained from Life Technologies designed specifically 
to detect and quantify the mature form of miR-210 (hsa-miR-210). Briefly, total RNA was 
isolated from erythroid cells using TRIzol® reagent as previously described. In the 
reverse transcription step, cDNA was transcribed form total RNA samples using primers 
specific for miR-210 and reagents from the TaqMan® MicroRNA Reverse Transcription 
kit. In the PCR step, PCR products were amplified from the cDNA samples using the 
TaqMan MicroRNA Assay together with the TaqMan® Universal PCR master mix 
(Figure 23). U6-snRNA is a small non-coding RNA and is a component of the U6 small 
nuclear ribonucleoprotein complex, was used as the endogenous control for expression 
of small RNAs.  
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Figure 23 Two step miRNA qPCR. 1. In the reverse transcription (RT) step, cDNA is reverse transcribed 
from total RNA samples using specific miRNA primers from the TaqMan MicroRNA Assays and reagents 
from the TaqMan® MicroRNA Reverse Transcription Kit. 2. In the PCR step, PCR products are amplified 
from cDNA samples using the TaqMan MicroRNA Assay together with the TaqMan® Universal PCR 
Master Mix. 
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Western Blot Analysis: 
Cell pellets were resuspended in 4% SDS and sonicated for 5 minutes (30 seconds ON, 
30 seconds OFF setting). Total protein was quantitated using BioRad DC Protein assay 
(BioRad) followed by UV-Vis spectrophotometry. 100 ug of protein mixed with 2X 
laemmli buffer was run on a 10% SDS-PAGE gel. The protein was transferred onto a 
PVDF membrane (0.45 uM, Millipore) for 1 hour at a constant voltage of 100V. The 
membrane was then blocked in a blocking buffer consisting of 5% milk in 1X PBST for 
one hour at room temperature. Following this, the membrane was incubated with the 
primary antibody of interest at room temperature for 1 hour. The membrane was then 
washed 3 times by 1X PBST for 5 minutes each and incubated with the secondary 
antibody in a blocking buffer solution for 45 minutes at room temperature. The 
membrane was again washed 3 times with 1X PBST for 5 minutes each and then 
incubated with SuperSignal® West Pico Chemiluminescence substrate or SuperSignal®  
West Dura Extended duration substrate (Thermo Scientific) for 5 minutes according to 
the manufacturer’s protocol. The membrane was then exposed to an autoradiography 
film (Bio Express) and developed to study protein bands of interest. Alternatively, the 
membrane incubated with the chemiluminescent substrate was exposed in the Odyssey 
Infrared Imaging System (LI-COR Biosciences).  
 
Antibodies: Anti-MBD2 (Santa Cruz sc-1244), anti-TZFP (Abcam 26066), anti-CD235a 
(eBioscience # 12-9987-82), anti-CD71 (eBioscience # 14-0719-82). 
Primers: The sequences of the primers used in chapter 3 are in Table 3. 
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Table 3. List of primers used for qPCR in Chapter 3 
 Forward Reverse Probe 
Human ϒ-
globin 
GTG GAA GAT GCT 
GGA GGA GAA A 
TGC CAT GTG CCT 
TGA CTT TG 
AGG CTC CTG GTT 
GTC TAC CCA TGG 
ACC 
Human β-globin GCA AGG TGA ACG 
TGG ATG AAG T 
TAA CAG CAT CAG 
GAG TGG ACA GA 
CAG GCT GCT GGT 
GGT CTA CCC TTG 
GAC CC 
Human MBD2 AAG AGC GAG TAC 
AGC AAG TAC GCA 
TTC TGT ATC AGC 
AGC TCG CGA CAA 
TGG AAG AAG CAC 
TGA TGG CAG ACA TC 
Human TZFP GGA CAA AGG CTA 
CAG GAG AAG  
TTC ACT CAA GCA 
TCA GAT GGA G 
CAC TAC CGA GTC 
CAC ACA GGA GAG AA 
Human GAPDH TCG ACA GTC AGC 
CGC ATC TTC TTT 
ACC AAA TCC GTT 
GAC TCC GAC CTT 
AGC CAC ATC GCT 
CAG ACA CCA TGC 
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III. Results: 
 
A. Over-expression of ZBTB32 in CD34+ adult human erythroid cells activates the 
fetal γ–globin gene:  
A better model than the mouse bone marrow CID cells to study regulators of fetal γ-
globin gene silencing is an adult human progenitor derived erythroid cell system. As 
described earlier, these cells express <1-2% fetal hemoglobin out of the total globin at 
the end of their in vitro erythroid differentiation process. To validate this system to study 
the function of ZBTB32, we knocked down MBD2 in these cells and quantitated the 
increase in ZBTB32 expression. Knockdown of MBD2 by ~80% (Figure 24A) causes ~ 
1.5-fold increase in the expression of ZBTB32 in these cells (Figure 24B). Therefore, in 
line with our previous data, we hypothesized that over-expression of ZBTB32 in these 
primary adult cells will activate expression of the fetal γ-globin gene. The coding 
sequence of ZBTB32 was stably over-expressed in these cells through lentiviral 
transduction, followed by growth and erythroid differentiation of the cells. Over-
expression of ZBTB32 at the mRNA level was confirmed (Figure 24C). On day 10 of 
differentiation, erythroid cells were selected by sorting for CD71/CD235a double positive 
cells by flow cytometry. Analyses demonstrated that over-expression of ZBTB32 
increased the expression of the γ-globin gene by 2-fold compared to the empty vector  
control (Figure 24D). At the same time, over-expression of ZBTB32 did not cause a 
significant increase in adult β-globin gene expression, which suggests that the effect of 
ZBTB32 on fetal γ-globin gene expression is specific to that gene and not a non-specific 
effect on the β-globin gene locus (Figure 24E). Also, over-expression of ZBTB32 did not 
interfere with the normal differentiation of the erythroid  
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Figure 24. Validation and functional analysis of ZBTB32 in CD34+ adult erythroid cells. CD34+ 
primary adult human CD34
+
 erythroid progenitor cells were transduced with anti-MBD2 shRNA and SCR 
control expressing lentivirus. Western blot analysis shows (A) ~75% knockdown of MBD2 in these cells at 
the protein level and (B) increased expression of ZBTB32 at the protein level in the MBD2 knocked down 
CD34
+
 erythroid cells. The western blot is representative of three independent experiments. (C) (C) 
CD34
+
 erythroid progenitor cells were transduced with lentivirus expressing the coding sequence of 
hZBTB32 and the empty vector control. qPCR  analysis shows over-expression of hZBTB32 mRNA in 
these cells as compared to the empty vector control. (D) Human fetal γ-globin gene mRNA expression 
was quantitated using qPCR and normalized to GAPDH. hZBTB32 over-expressing CD34
+
 cells show ~2-
fold increased expression of the γ-globin gene (p-value < 0.05). (E). Human adult β-globin gene mRNA 
expression was quantitated using qPCR and normalized to GAPDH. hZBTB32 over-expressing CD34
+
 do 
not show a significant increase in the expression of β -globin gene (p-value > 0.05). Error bars denote 
standard deviation of three independent experiments.      
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Figure 25. ZBTB32 over-expressing CD34+ cells show normal erythroid differentiation profile. 
Expression of cell surface markers CD71 and CD235a was analyzed using flow cytometry to study the 
erythroid differentiation profile of the transduced cells. Both empty vector expressing control cells and 
hZBTB32 expressing cells show normal erythroid differentiation. Level of erythroid differentiation is similar 
in both the groups.   
ZBTB32 Vector 
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cells as can be seen from the CD71/CD235a cell-surface marker analysis. Up to 95% of 
the cell population consisted of double positive erythroid cells (Figure 25).    
 
B.  MicroRNA expression profile of MBD2 knockout mice: 
Three wild-type and three MBD2-/- mice were injected intra-peritoneally with 1-acetyl-2-
phenylhydrazine in order to induce hemolytic anemia, an event which results in extra 
medullary hematopoiesis in the spleen, making the spleen >90% erythroid. Total RNA 
from the spleen was harvested and sent over to our collaborator Dr. Catherine Dumur 
(Dept. of Pathology, VCU) for murine miRNA microarray analysis. This array covers 
miRNAs from 71 organisms on a single array, including 609 murine miRNAs from the 
Sanger miRNA database v11. Total RNA from our samples was ligated with a biotin 
label followed by hybridization onto GeneChip® miRNA arrays, and it was scanned on 
an Affymetrix GeneChip® Scanner 3000 G7.  
Statistical analysis was restricted to the 609 murine miRNA probe sets. A two sample 
student t-test was used to compare wild-type and MBD2-/- samples. The resulting p-
values were used to calculate the false discovery rate (FDR) using the Benjamini-
Hochberg method. Only one miRNA probe set, miR-210, showed a significant change 
(FDR<5%) with an ~3 fold induction in MBD2-/- compared to wild-type samples (Figure 
26).  
C.  Validation of miR-210 expression in adult erythrocytes from β-YAC transgenic 
mice: 
To validate the differentially expressed miR-210 identified from the microarray screen, 
we conducted miRNA quantitative PCR on the total RNA obtained from spleens of wild-  
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Figure 26. Validation of miR-210 expression in mouse splenic erythroblasts. Total RNA from   three 
wild-type and three MBD2 knockout (MBD2
-/-
) mice was analyzed for mature miR-210 expression by 
qPCR. MBD2
-/-
 mice show ~3-fold (p-value<0.05) increased expression of miR-210 in the splenic 
erythroblasts, validating the results obtained from the microarray screen. Error bars denoted standard 
deviation of three different mice for each group. 
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type and MBD2-/- mice. qPCR verification did show a 3-fold increase in the expression 
of miR-210, using U6 snRNA as an endogenous control (p-value<0.05,  
n=3). U6 snRNA is a non-coding small nuclear RNA (snRNA) component of the U6 
snRNP (small nuclear ribonucleoprotein) RNA-protein complex which is involved in the 
splicing of pre-mRNAs.  
miR-210 is located on chromosome 11p15.5 and is transcribed from the intron 1 of a 
non-protein coding processed RNA, the miR-210 host gene. The predicted size of the 
pri-miR-210 is 2927 bp which is almost the same as that of miR-210 host gene. The 
upstream regulatory region contains HIF-1α binding sites and several studies have 
reported miR-210 as a robust hypoxia-inducible miRNA. Analysis of the upstream 
regulatory region of the murine miR-210 host gene by the UCSC genome browser also 
shows the presence of a CpG-island between -586 and -19 bp of the promoter (Zhou et 
al. 2007) and differential methylation of this region has been reported in various 
pathophysiological conditions (Kiga et al. 2014; Lages et al. 2011; Xiong et al. 2012). 
This information suggests a potential direct role of MBD2 in epigenetic regulation of 
miR-210. 
D. Functional analyses of miR-210 expression in adult mouse bone marrow cells: 
Given that MBD2-/- mice show elevated γ-globin expression in adult erythrocytes as 
well as a concomitant increase in expression of the miR-210, we hypothesized that 
MBD2 might regulate γ-globin gene expression in part through miR-210. Hence we 
postulated that over-expression of miR-210 in mouse bone marrow CID cells and 
primary adult human erythroid cells will be able to induce γ-globin gene expression. 
Chemical inducer of dimerization (CID) dependent β-YAC mouse bone marrow cells are 
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widely used to study human γ-globin gene regulation. These cells are derived from the 
bone marrow of β-YAC transgenic mice and can be propagated in culture by liquid 
media containing an artificial chemical inducer of dimerization (Blau et al., 2005). This 
chemical induces thrombopoietin signaling through homodimerization of FKBP (FK506 
binding protein) binding domains which are in turn fused to thrombopoietin signaling 
domain. The resultant signaling pathway enables indefinite proliferation of these bone 
marrow cells. These cells predominantly express adult human β-globin and very low 
levels of fetal γ-globin (<1% of β-globin), akin to adult human erythroid cells, thus 
making it a good in vitro system to study regulators of the fetal γ-globin gene.  
  Stable over-expression of miR-210 was achieved by lentiviral delivery of the mature 
miR-210 in these cells. Up to 2-fold ectopic expression of mature miR-210 was 
achieved in these cells as quantitated by qPCR. Quantitation of human fetal γ-globin 
and adult β-globin mRNA levels was further carried out in these cells. Fetal γ-globin 
gene showed an increased trend in expression by ~2.4 fold when normalized to 
glycophorin A gene expression, however this was not statistically significant (n=3, p-
value>0.05) (Figure 27A ). Interestingly, quantitation of the human β-globin gene also 
showed a similar but significant increase in expression by ~ 3.1-fold (n=3, p-
value<0.01), thus indicating an overall increased β-type globin gene expression, 
possibly brought about by induced erythroid differentiation of the multi-potent bone 
marrow cells (Figure 27B).  
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Figure 27. mir-210 regulates human β-type globin gene expression in β-YAC mouse bone marrow 
cells.    CID-dependent β-YAC mouse bone marrow cells were transduced with lentivirus expressing miR-
210 and SCR control. Human fetal γ-globin and adult β-globin gene mRNA expression was quantitated by 
qPCR and normalized to mouse Glycophorin A expression. (A) Human γ-globin gene shows an increased 
expression with miR-210 expression, although it is not statistically significant (n=3, error bars denoted 
standard deviation). (B) miR-210 over-expressing CID cells show ~3-fold increased expression of human 
adult β-globin gene as compared to SCR control infected cells (p-value<0.05, error bars denote standard 
deviation of 3 independent experiments).  
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E.  Validation of miR-210 expression in MBD2 knockdown CD34+ hematopoietic 
progenitor cells: 
Following a preliminary functional analysis of miR-210 in the murine erythroid system, 
we investigated the role of miR-210 in the human erythroid system. To this end, we  
quantitated mature miR-210 expression in stable MBD2 knocked down CD34+ cells by 
qPCR. Knockdown of MBD2 in CD34+ cells causes a modest 2-fold increase in 
expression of mature miR-210. However, due to a large variability in the fold-change, 
the increase in miR-210 expression was not found to be statistically significant over 
multiple repeats (n=8, p-value>0.05) (Figure 28). This observation may arise from the 
fact that erythroid cells harvested for mRNA analysis are often a heterogeneous 
population. Although the differentiated cells are sorted for CD71/CD235a double 
positive populations only, within this erythroid population one may envision cells at 
different stages of erythroid differentiation and hence have different miRNA expression 
levels.  
    Alternately, we hypothesized that a significant increase in miR-210 expression may 
require very high levels of MBD2 knockdown, which would also indicate high level of γ-
globin gene expression. For each experiment conducted on the same sample of CD34+ 
cells, in Table 4 we have plotted values of the percentage of MBD2 knockdown, 
gamma/(gamma+beta) globin fold change in MBD2 knockdown vs. SCR cells and the 
increase in miR-210 expression as compared to the SCR controls. It can be observed 
that with highest level of MBD2 knockdown and γ-globin gene induction, miR-210 
expression is significantly higher as compared to its SCR control. As the percentage of  
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Figure 28. miR-210 expression in MBD2 knockdown CD34+ erythroid cells. MBD2 was knocked 
down by about 75% in CD34
+
 erythroid cells, followed by their in vitro erythroid differentiation. miR-210 
expression was quantitated by qPCR and normalized to U6RNA expression. miR-210 expression was not 
statistically significant in MBD2 knockdown erythroid cells (n=8, error bars denote standard deviation). 
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MBD2 knock down and γ-globin gene expression reduces, the fold-change in 
expression of miR-210 becomes variable and less consistent. Since the most robust  
induction of miR-210 was observed in MBD2 knockout erythroid cells, our data suggests 
that increased expression of miR-210 in erythroid cells may require >90% elimination of 
MBD2. 
 
Table 4. miR-210 expression in a background of varying MBD2 knockdown and γ-globin gene 
expression in erythroid cells. Expression of miR-210, MBD2 and γ-globin gene was measured by 
qPCR. Percentage of MBD2 knockdown positively correlates with percentage of absolute γ-globin gene 
expression i.e. ↑MBD2 knockdown ∝ ↑γ-globin gene expression and this is statistically significant. miR-
210 expression does not consistently show increased expression with higher MBD2 knockdown and 
higher γ-globin gene expression. 
% MBD2 Knockdown  Gamma/(gamma+beta) fold 
change compared to SCR 
Increase in miR210 expression 
compared to SCR 
90% 135 fold (14.29% HbF) 9.43 
66% 15.65 2.14 
51% 14.14 0.97 
45% 7.62 1.03 
— 9.28 0.67 
no kd 4.84 no change 
11% 2.87 no change 
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F. Functional analysis of miR-210 in CD34+ hematopoietic progenitor cells: 
Although we were limited in validating the expression of miR-210 in MBD2 knockdown 
CD34+ cells, we nevertheless proceeded with validating the function of miR-210 in 
primary human erythroid cells. We over-expressed mature miR-210 in the primary 
human erythroid cells through lentiviral expression. CD34+ human erythroid cells were 
transduced with SCR and miR-210 expressing lentivirus and transduced cells were 
selected by flow cytometry based on their expression of green fluorescent protein 
(GFP). We achieved a very robust expression of mature miR-210 in the erythroid cells 
as quantitated by qPCR (n=6, p-value<0.01) (Figure 29A). Following growth and 
differentiation of the transduced CD34+ cells in vitro to erythrocytes, we quantitated the 
expression of the fetal γ-globin gene on day 10 of differentiation. We observe an 
increased trend in expression of the fetal γ-globin gene relative to total γ-and β-globin 
gene expression in miR-210 over-expressing cells as compared to SCR control cells 
(n=6, p-value>0.05) (Figure 29B). Given the role of miR-210 in erythroid differentiation 
and its effect on both γ-and β-globin gene induction in mouse erythroid cells, we 
analyzed absolute expression of γ-and β-globin gene expression by normalizing its 
expression to an endogenous gene - GAPDH in SCR and miR-210 over-expressing 
cells.  MiR-210 over-expressing erythroid cells show ~ 2 fold increase in γ-globin gene 
(n=3, p-value>0.05) and a parallel 3-fold increase in β-globin gene expression (n=3, p-
value<0.05) (Figure 29C,D), similar to the observation in CID mouse bone marrow cells. 
Over-expression of miR-210 does not affect the differentiation profile of the cells, as can 
be seen from the similar cell surface marker expression by shSCR and miR-210 
expressing cells (Figure 30). These results lead us to an understanding of the function  
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Figure 29 Functional analysis of miR-210 over-expression in CD34+ cells. miR-210 was stably over-
expressed in adult erythroid progenitors followed by their in vitro erythroid differentiation. miR-210 and 
globin gene expression was quantitated using qPCR. (A) Over-expression of miR-210 by upto 23-fold as 
compared to SCR controls was achieved by lentiviral delivery of mature miR-210 (p-value<0.01, n=6, 
error bars denote standard deviation). (B) Absolute gamma globin gene expression 
(gamma/gamma+beta) shows an increased expression trend in miR-210 over-expressing erythroid cells 
as compared to SCR controls. However, the fold change is not statistically significant (n=6, error bars 
denote standard deviation). (C) Human fetal γ-globin gene mRNA expression was quantitated using 
qPCR and normalized to GAPDH. miR-210 over-expressing CD34
+
 cells show increased expression of 
the γ-globin gene, but it is not statistically significant (p-value > 0.05). (D). Human adult β-globin gene 
mRNA expression was quantitated using qPCR and normalized to GAPDH. miR-210 over-expressing 
CD34
+
 show a significant increase in the expression of β -globin gene by ~2-fold as compared to SCR 
control (p-value < 0.05). Error bars denote standard deviation of three independent experiments. 
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Figure 30. Over-expression of miR-210 in erythroid cells does not affect their normal 
differentiation profile. Percentage of CD71+/CD235a+ erythroid cell population (Quadrant Q2) is similar 
in (A) SCR expressing control cells and (B) miR-210 over-expressing cells. (Percentage values denote 
average and standard deviation of 6 independent experiments). 
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of miR-210 in β-type globin gene expression in erythroid cells, possibly through 
modulation of erythroid differentiation and a general effect on transcription of genes 
belonging to the β-globin gene locus. It also sheds light on a novel downstream effector 
of MBD2 through which it may mediate its effect on γ-globin gene expression.  
 
IV. Discussion: 
Methyl CpG-binding domain protein 2 (MBD2) mediates developmental silencing of the 
fetal γ-globin gene, although without direct interaction with cis-regulatory sequences 
near the γ-globin gene promoter (Rupon et al. 2006a). In fact, MBD2 does not bind to 
any promoter sequences within the β-globin gene locus. This result could be anticipated 
given that the entire human β-globin gene locus is CpG sparse and the MBD2-NuRD 
complex requires at least 12 methylated CpG dinucleotides for binding methylated DNA 
in vitro (Ginder, Gnanapragasam, Mian 2008; Meehan et al. 1989; Mian et al. 2011; 
Wade 2001). In vivo MBD2 binds only to densely methylated CpG islands. Hence, we 
set out to define the mechanism of action for developmental silencing of the fetal γ-
globin gene by MBD2.  
  We hypothesized that MBD2 may regulate silencing of γ-globin gene expression in 
adult erythrocytes by an indirect mechanism which may involve other gene(s) or 
miRNA(s). MiRNAs have recently evolved as vital small non coding RNAs that play 
important roles in regulating gene expression. Loss of MBD2 would activate expression 
of a gene or a miRNA, which would in turn activate the expression of the fetal γ-globin 
gene. To test our hypothesis and identify downstream effectors of MBD2, we carried out 
gene and miRNA expression microarrays in splenic erythrocytes of MBD2-/- and wild 
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type mice. 93 genes were found to be up-regulated in MBD2-/- mice compared to wild-
type mice; a single miRNA, miR-210 was found to be increased in expression in MBD2-/- 
erythrocytes.  
  So far MBD2 has been shown to regulate a limited set of genes in normal 
development. MBD2-/- mice show disrupted expression of IL-4 and interferon-γ in helper 
T cells (Kersh 2006), abnormal expression of exocrine pancreatic genes in the colon 
(Berger et al. 2007), elevated expression of the Xist gene (Barr et al. 2007) and 
dysregulation of olfactory receptor neuron differentiation (Macdonald et al. 2010). Mbd2-
/- mice also show reduced adenoma formation in Apcmin/+ mice by attenuating the Wnt 
signaling pathway (Phesse et al. 2008). Limited studies have been performed to 
understand the function of MBD2 in normal development. In the erythroid system in 
mice, our studies identify a new set of protein coding genes that are regulated by MBD2 
in normal physiology. They indicate that loss of MBD2 disrupts the expression of just a 
few hundred genes rather than a large set of thousands of genes in the erythroid 
compartment. Similarly, miRNA microarray results showed a single differentially 
regulated miRNA, miR-210, in MBD2-/- adult erythrocytes. MBD2 has been shown to 
regulate expression of miR-373 in hilar cholangiocarcinoma (Chen et al. 2011). 
However, miR-210 is so far the only miRNA recognized to be regulated by MBD2 in 
normal tissues.  
  We used Ingenuity pathway analysis (IPA) to identify candidate genes for a potential 
role in regulation of the γ-globin gene in adult erythrocytes. IPA analysis helped to 
categorize the differentially regulated genes based on their functions and we focused on 
genes involved in hematological pathways. Four genes were identified as candidates 
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based on increased expression in MBD2-/- erythrocytes and presence of a CpG Island in 
its promoter region: Zbtb32, YAF2, Baf57 and ITCH. Of these, only Zbtb32 was 
validated for its increased expression in the MBD2-/- adult erythrocytes by qPCR. Zbtb32 
was further validated for its increased expression in MBD2 knock down mouse 
erythroleukemia cell line (MEL), CID-dependent β-YAC mouse bone marrow cells and 
primary adult human CD34+ erythroid cells. A high number of false positives may arise 
due to variability in modifier genes brought about by the mixed background of the mice 
used in this study. Although this can be a limitation, the advantage of using mixed 
background mice as compared to inbred mice is that the former better represent the 
variation present in human populations.  
   We further validated the functional role of ZBTB32 in human γ-globin gene expression 
in CID β-YAC mouse bone marrow cells and primary adult human CD34+ erythroid cells.  
Both of these in vitro cell systems have an adult β-globin gene expression profile and 
minimal expression (<1%) of fetal hemoglobin (Blau et al. 2005; Pope et al. 2000). 
Over-expression of ZBTB32 showed a modest increase in the expression of γ-globin 
gene (~2-fold), indicating that ZBTB32 may comprise one of the many different ways in 
which MBD2 regulates the γ-globin gene. Also, as described earlier, the repression of 
the γ-globin gene in adult erythrocytes is a complex interplay between many different 
cis-acting sequences and trans-acting factors. Over-expression of a single positive 
regulator may not be able to offset effects of other repressor proteins present in these 
cells. At this stage, the mechanism of ZBTB32 mediated activation of the γ-globin gene 
in adult erythrocytes is conjectural. ZBTB32 has not been shown to be directly involved 
in the regulation of the γ-globin gene. However, it has been reported to interact with 
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GATA2 which is known to be involved in γ-globin gene regulation in human 
erythroleukemia K562 cells (Ikonomi et al. 2000; Tsuzuki and Enver 2002). Study of the 
expression profile of ZBTB32 in human erythroid progenitor cells displayed high 
expression levels of ZBTB32 in the progenitor stage when the γ-globin gene expression 
is also higher, followed by a significant decline in expression of ZBTB32 as well as γ-
globin in the differentiated erythroid cells (Dai et al. 2002). This could be consistent with 
the role of ZBTB32 as a potential activator of the γ-globin gene.    
     We validated miR-210 expression in MBD2-/- mouse splenic erythrocytes and also 
carried out functional analyses in CID mouse bone marrow cells by over-expressing 
miR-210. Our results showed a modest increase in γ-globin gene expression, but a 
more significant increase in adult β-globin gene expression, suggesting induced 
erythroid differentiation of these cells caused by miR-210 over-expression. In primary 
adult human erythroid cells, we were unable to report a consistent increase in miR-210 
expression in MBD2 knocked down cells. However, our experimental strategy may be 
limited by the fact that the differentiated cells used for analysis are a heterogeneous 
population of erythroid cells. Although these cells are sorted for their expression of both 
CD71 and CD235a cell surface markers, they may represent several different stages of 
erythroid differentiation. This could in turn dictate the expression of miR-210 which has 
been implicated in erythroid maturation of progenitor cells (Bianchi et al. 2009; Bianchi 
et al. 2012). To address this concern, we could alternately sort different stages of 
erythroblasts by categorizing the CD71+/CD235a+ cells in the R1-R5 sub groups, of 
which R3-R5 sub-groups represent later stages of erythroid differentiation. Recent 
studies have also introduced band 3 and α4 integrin expression as markers to the 
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studies of erythropoiesis to isolated specific stages of erythroblasts through flow 
cytometry (Hu et al. 2013). 
   Functional analysis of ɣ-globin gene expression in miR-210 over-expressing cells 
showed an increase in expression of the fetal γ-globin as well adult β-globin gene 
compared to the scramble expressing control cells, similar to results observed in mouse 
bone marrow CID cells. The increase in γ-globin gene expression however was not 
statistically significant which may be due to the fact that each experiment in primary 
human erythroid cells is conducted on cells from an individual bone marrow donor. 
Hence part of the variability in our results represents the variability seen in a mixed 
human population with various genetic backgrounds. Increasing the sample size of the 
experiments might bring the increased fold change of ɣ-globin gene expression in miR-
210 over-expressing cells in a statistically significant range.  
Thus, taken together, both the murine and the human erythroid cell systems display an 
effect of miR-210 over-expression on γ- and β-globin gene expression. Several other 
groups have reported a role of miR-210 in erythroid differentiation. miR-210 expression 
is increased in a cell culture model which induces ɣ-globin gene expression and 
erythroid differentiation (Bianchi et al. 2009). Moreover, miR-210 levels are also 
elevated during mouse fetal liver erythroid cell differentiation in vitro (Kosaka et al. 
2008). miR-210 has been shown to be up-regulated in erythroid cells of patients with β-
thalassemia and high HbF levels (Bianchi et al. 2009). Hence, miR-210 expression has 
been correlated with increased ɣ-globin gene expression and erythroid maturation, 
however the mechanism has not yet been identified. No known targets of miR-210 have 
been shown to be involved in erythropoiesis, nor have bioinformatic analyses through 
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miRNA target prediction algorithms identified any known regulators of β-type globin 
expression as targets of miR-210.  
   However, miR-210 is also predominantly a hypoxia induced miRNA and hypoxia 
response of erythroid cells has been shown to induce erythroid differentiation in part 
through miR-210 (Sarakul et al. 2013). Thus miR-210 may be an indirect regulator of β-
type globin gene expression through pathways that involve induced erythroid 
differentiation or hypoxia mediated stress erythropoiesis. The role of miR-210 in 
erythroid differentiation could be further evaluated in conditions of ineffective 
erythropoiesis caused by a maturation blockade example congenital dyserythropoietic 
anemia and β-thalassemias. It would be worthwhile to investigate whether over-
expression of miR-210 can restore normal erythroid differentiation of immature erythroid 
cells.  
          In conclusion, our studies have identified two novel targets of MBD2 in the adult 
erythroid system: ZBTB32 and miR-210. We tested the function of both of these factors 
individually in adult mouse bone marrow cells and primary adult human erythroid cells. 
ZBTB32 and miR-210 modestly contribute to the induction of γ-globin gene expression 
in MBD2 deficient erythroid cells. Given the current literature and our data, we believe 
that ZBTB32 and miR-210 function in independent pathways to induce γ-globin gene 
expression. Co-expression of ZBTB32 and miR-210 in primary adult human erythroid 
cells would be anticipated to produce at least an additive increase in γ-globin gene 
expression. Optimization of the lentiviral transduction method will be required to perform 
co-transduction of both downstream effectors of MBD2 in primary erythroid cells.    
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CHAPTER 4: Summary, Future Directions and Perspectives 
 
 
 
           Sickle cell disease and β-thalassemia are among the most common monogenic 
disorders worldwide. Sickle cell disease is characterized by “sickle” shaped red blood 
cells caused by polymerization of deoxygenated HbS. Sickling of red cells leads to 
vaso-occlusion and ischemia in small vessels causing painful crises and multiple organ 
damage. Hydroxyurea is the only therapeutic option for patients with sickle cell disease, 
however, its effects are often variable. β-thalassemia is characterized by reduced 
synthesis of the β-globin chains. Cooley’s anemia or β-thalassemia major is the most 
severe form of the disease and blood transfusions are the standard course of treatment 
for these patients. Iron chelation therapy is required to deplete the iron deposits in 
organs due to regular blood transfusions. Reactivation of fetal hemoglobin in patients 
with sickle cell disease and β-thalassemia can alleviate symptoms of the disease. 
Understanding the regulators involved in the fetal-to-adult hemoglobin switch can 
provide new avenues for search of molecular drug targets with higher efficacy and lower 
side-effects. 
            Research over the past 6 decades has added valuable information to the 
understanding of the hemoglobin switching process. DNA methylation has emerged as 
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an important  regulator of embryonic and fetal globin gene expression (Gnanapragasam 
et al. 2011b; Rupon et al. 2006b; Rupon et al. 2011b). The MBD2-NuRD co-repressor 
complex directly represses the expression of the chicken ρ-globin gene in avian adult 
erythroid cells whereas it indirectly regulates γ-globin gene expression in human cells 
(Rupon et al. 2006b). MBD2 knockout mice carrying the human β-globin gene locus (β-
YAC) display higher than normal expression of the human fetal γ-globin gene in adult 
erythroid cells (Rupon et al. 2006b). Primary adult human erythroid cells deficient for 
MBD2 also exhibit significant reactivation of the γ-globin gene (Gnanapragasam et al. 
2011b). Partial knockdown of the Mi2β subunit of the NuRD complex has an even larger 
effect on de-repression of the fetal γ-globin gene, through additionally down-regulating 
BCL11A and KLF1 proteins which are repressors of the γ-globin gene in adult erythroid 
cells. KLF1 and BCL11A have been shown to play a major role in γ –globin gene 
expression. KLF1 is a positive regulator of the adult β-globin gene and the BCL11A 
gene. BCL11A binds to the β-globin gene in the γ-δ intergenic region and brings about 
repression of the γ-globin gene, through its interaction with co-repressor complexes that 
include the MBD3-NuRD complex, LSD1/CoREST complex, Sin3A, NCoR/SMRT, and 
DNMT1 (Bauer, Kamran, Orkin 2012). The NuRD complex with its various binding 
partners has been identified as an important network point in regulation of fetal γ-globin 
gene expression. However, further work is required to elucidate the assembly and 
functional organization of the various subunits of the NuRD complex.
           In our studies presented in Chapter 2, we have pursued the structural and 
functional characterization of a previously uncharacterized domain of MBD2, MBD2IDR. 
This domain of MBD2 lies between the N-terminus methyl-binding domain (MBD) and 
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the C-terminus coiled-coil (CC) interaction domain. MBD2, as a whole protein, has been 
difficult to express in vitro, which limits its biophysical characterization. Therefore, we 
strategized to characterize the structure of MBD2 domain by domain. We have 
previously described the structure of chicken MBD2, which is 96% identical to human 
MBD2 in protein sequence (Scarsdale et al. 2011b). We also studied the coiled-coil 
domain of MBD2 and described its interaction with the conserved region 1 (CR1) of 
p66α component of the NuRD complex (Gnanapragasam et al. 2011b). In collaboration 
with the research group lead by Dr. David Williams, we conducted NMR studies that 
identified the MBD2IDR to be an intrinsically disordered region. Our results outline that 
despite the inherent disorder, MBD2IDR is involved in two important functions: 1) 
modifying the kinetics of DNA binding and MBD2’s affinity for methylated DNA through 
ionic interactions mediated by the positively charged N-terminal region of  MBD2IDR and 
2) mediating interaction of MBD2 with the histone deacetylase core of the NuRD 
complex. In pursuit of refining the former function, we mapped two contiguous amino 
acid residues, Arg286 and Leu287 to form a critical region of interaction between MBD2IDR 
and the histone deacetylase core. Mutation of these key residues in full length MBD2 
protein significantly disrupted its interaction with RbAp48, HDAC2 and MTA2 subunits. 
To test the role of these critical amino acids in the repressive activity of MBD2, we 
mutated the two contiguous amino acids in the full length MBD2 protein and 
investigated its function in vivo. We designed an in vivo gene repression assay in a 
breast cancer cell line such that a tumor suppressor gene PRSS8 silenced by MBD2 
mediated repression was used as a reporter of MBD2 function (Chen et al. 2001). To 
this end, endogenous MBD2 was stably knocked down in MDA-MB-435 breast cancer 
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cells and wild type as well as double mutant MBD2 was re-introduced in the cells 
through a lentiviral expression system. In this system, we could attain about 50% 
knockdown of endogenous MBD2 protein and a comparable level of enforced 
expression of wild-type and double mutant MBD2 protein. We observed that add back of 
wild-type MBD2 repressed the PRSS8 gene beyond the baseline expression level set 
by the control cells, whereas the double mutant MBD2 failed to do so. This resulted in a 
2-fold higher expression of PRSS8 in the double mutant MBD2 expressing cells as 
compared to the wild-type MBD2 expressing cells.  This observation reflected an 
impaired repressor function of the MBD2 protein due to its disrupted interaction with the 
histone deacetylase core of the NuRD complex. 
          For de-repression of a gene silenced by MBD2, at least a 75% knockdown of the 
MBD2 protein is required (Amaya et al. 2013; Gnanapragasam et al. 2011b). Since we 
were able to achieve only a 50% knockdown of endogenous MBD2 in our assay due to 
technical limitations, we did not observe a complete de-repression of the gene PRSS8. 
Also, genes known to be repressed by MBD2 have been identified either in MBD2 
knockout mice or through knockdown of MBD2 in various cell systems. Functionally, this 
entails loss of function of all the domains of MBD2. While our assay interferes with the 
interaction of MBD2 with the histone deacetylase core, the double mutant MBD2 still 
carries a functional MBD and CC domain. These domains will allow for the mutant 
MBD2 to occupy sites of CpG methylation as well as recruit the p66α and Mi2β proteins, 
which bring about chromatin remodeling activities at the respective locus. A combined 
effect of both of these events may prevent complete de-repression of the target gene of 
MBD2, even in the absence of interaction with the histone deacetylase core 
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components. Thus, complete de-repression of a methylated target gene may require de-
coupling of both histone deacetylase and chromatin remodeling activities from the 
MBD2-NuRD complex. This hypothesis will be tested by introducing mutations in the 
key residues of coiled-coil domain of MBD2, which are critical for its interaction with 
p66α and Mi2β proteins, in addition to the key residue mutations in the IDR.  
       An ideal experimental design to study the function of mutant MBD2 protein will be 
to introduce these critical mutations in the endogenous MBD2 gene in a cell line of 
interest, followed by testing gene expression changes. Although this idea would have 
been perceived as too far-fetched in the past, the field of genomic editing has been 
revolutionized with the advent of the CRISPR/Cas9 technology. The CRISPR (Clustered 
Regularly Interspaced Short Palindromic Repeats)/Cas9 system has been adapted from 
the prokaryotic immune system which allows them resistance against foreign genetic 
elements such as plasmids and phages in the form of adaptive immunity. This 
technology has enabled generation of gene knockout cell lines and transgenic animals 
at an unprecedented speed and greatly empowered genetic research (Maddalo et al. 
2014; Platt et al. 2014; Swiech et al. 2014). A stunning application of the CRISPR/Cas9 
system was recently reported in the correction of HBB mutations in β-thalassemia 
patient-derived induced pluripotent stem cells (iPSCs). These “corrected” iPSCs 
showed restored expression of the HBB gene post the gene editing when differentiated 
into erythroblasts in vitro (Xie et al. 2014).  
           In the context of MBD2 function, the CRISPR/Cas9 system could be employed to 
introduce the critical amino acid mutations in the endogenous MBD2 gene in a cell line 
such as MDA-MB-435 where the function of MBD2 has been well characterized (Mian et 
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al. 2011). Introducing mutations at critical sites in the MBD2IDR or the coiled-coil domain 
or in combination will enable us to dissect the specific role(s) of the histone deacetylase 
core and the chromatin remodeling components in MBD2 mediated repression of 
methylated target genes. Gene expression microarray analysis will be employed in such 
a system to understand regulation of specific sets of genes by the histone deacetylase 
core or the chromatin remodeling components of NuRD. Such an experiment where the 
interaction of MBD2 with both histone deacetylase and chromatin remodeling 
components of the NuRD complex is disrupted will also shed light on the function of 
MBD2 as an independent methylation-mediated transcriptional repressor. 
        The fetal γ-globin gene has been extensively studied by our lab as a target of the 
MBD2-NuRD co-repressor complex in murine as well as human systems. Studying the 
function of critical residues of the MBD2IDR in the context of developmental silencing of 
the γ-globin gene by MBD2 is an ongoing project in the lab. Knockdown of MBD2 in 
adult human erythroid cells causes a robust de-repression of the fetal γ-globin gene, 
which provides a bigger dynamic range to study the function of mutant MBD2 protein in 
these cells. A functional assay similar to that in the MDA-MB-435 breast cancer cells is 
being pursued; endogenous MBD2 is knocked down followed by introduction of wild-
type or double mutant MBD2 in sequential lentiviral transductions. Preliminary studies in 
CD34+ adult erythroid cells have generated encouraging results. However, the feasibility 
of such an experiment is significantly limited by the low infection efficiency of primary 
cells and reduced viability of the cells due to double lentiviral infections. If the design of 
experiment works successfully in CD34+ cells, future studies will be planned to introduce 
critical residue mutations in the coiled-coil domain of MBD2 in combination with the 
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mutant MBD2IDR and study its effect on γ-globin gene expression. We anticipate that 
expression of MBD2 carrying mutations in both IDR and CC domains may lead to de-
repression of the γ-globin gene at levels comparable to those in MBD2 knockdown 
CD34+ cells. 
      A long standing goal of the lab has been to inhibit the repressor activity of the 
MBD2/NuRD complex. The repressor activity of MBD2 is mediated through interactions 
with other co-repressor proteins, suggesting that disruption of these protein-protein 
interactions can serve as a potential avenue to inhibit its function. Intrinsically 
disordered proteins have recently been identified as attractive drug targets for inhibiting 
protein-protein interactions because of their over-representation in disease pathways 
and characteristic high specificity-low affinity interaction networks (Metallo 2010).  
However, leads to such inhibitors have been limited by the fact that protein-protein 
interactions involving unstructured regions often span large flat contact areas and lack 
short binding pockets which are ideal for drug targets. Alternately, inhibitors targeting 
disordered regions can be designed to prevent interaction between the unstructured 
region and its structured ligand/interaction partner. Recent work has indicated that 
protein-protein interactions based on disorder-to-order transition of an intrinsically 
disordered protein can be disrupted (Dawson et al. 2003; Klein and Vassilev 2004; 
Stauffer 2007). Few studies of intrinsically disordered proteins have led to the discovery 
of successful small molecule inhibitors. Examples include, inhibitor of interaction 
between tumor suppressor p53 and its binding partner Mdm2; Mdm2 by binding to an 
intrinsically disordered region of p53 targets p53 for ubiquitination and causes it to be 
transported out of the nucleus. Small molecule inhibitors called “nutlins" have been 
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identified which associate with Mdm2 and thus prevent its interaction with p53 (Klein 
and Vassilev 2004). The interaction between oncoprotein c-myc and its binding partner 
Max has been inhibited by by small molecules which bind c-myc and stabilize its 
disordered conformation. This in turn prevents its interaction with Max protein 
(Hammoudeh et al. 2009). Characterization of the MBD2IDR adds valuable insight to 
understanding interactions within the multi-protein NuRD complex. Identification of the 
two contiguous amino acid residues critical for the interaction between MBD2IDR and the 
histone deacetylase core subunits provides an exciting avenue to target these protein-
protein interactions within the NuRD complex through small molecule/peptide inhibitors.        
     An important step towards identifying small molecule/peptide inhibitors of the MBD2-
NuRD complex will be to better define the structure of MBD2 protein. We have 
previously reported the structure of the chicken MBD bound to methylated DNA 
sequence (Scarsdale et al. 2011a) and the helical coiled-coil interaction between CC 
domain of MBD2 and the conserved region 1 (CR1) of p66α protein (Gnanapragasam et 
al. 2011b). We have now also characterized the structure of the MBD2IDR as an 
intrinsically disordered region in isolation and in the context of its interaction with 
methylated DNA. However, many intrinsically disordered regions often fold into a well-
defined conformation in the presence of their binding partners (Tompa 2002). This 
refolding of the region is guided by principles of thermodynamics that dictate that 
binding will stabilize and strengthen binding interactions. Our studies suggest an 
interaction between MBD2IDR and RbAp48, HDAC2 and MTA2 proteins. To understand 
the structure of the MBD2IDR in presence of its binding partners, MBD2IDR will need to be 
co-expressed along with RbAp/HDAC/MTA proteins and purified as a complex. NMR 
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spectroscopy of this complex will better define the structure of MBD2IDR in the presence 
of its functional interactions.    
            MBD2 and MBD3 are highly similar proteins and are both involved in regulatory 
functions through interactions with the NuRD complex. MBD2IDR and the homologous 
region of MBD3 are 79% identical in protein sequence and this amino acid sequence 
can be a strong determinant of the protein structure. To extend the information gained 
through our work on MBD2, we will hypothesize that the region of MBD3 homologous to 
MBD2IDR will also be intrinsically disordered and be involved in recruiting the histone 
deacetylase core of the NuRD complex. In the absence of the functional methyl-binding 
domain, the positively charged N-terminal region of MBD3, which is homologous to 
MBD2IDR, may facilitate non-specific ionic interactions of MBD3 protein with the DNA.  
The MBD3/NuRD complex is involved in many important biological processes, in 
particular embryonic development as well as reprogramming of iPSCs and pluripotency 
of embryonic stem cells (dos Santos et al. 2014; Hendrich et al. 2001; Rais et al. 2013).  
         In the work detailed in Chapter 3, we investigated the mechanism of MBD2 
mediated repression of the fetal γ-globin gene. Through microarray analysis of protein-
coding genes and miRNAs differentially regulated in MBD2-/- mice, we identified two 
new targets of MBD2: ZBTB32 and miR-210. We successfully validated the function of 
ZBTB32 in various murine and human erythroid cell systems, wherein over-expression 
of ZBTB32 modestly induced the expression of the fetal γ-globin gene in adult erythroid 
cells. Similarly, enforced expression of miR-210 in adult erythroid cells displayed an 
effect on increasing the expression of the fetal γ-globin gene. Taking into account our 
current understanding of the biological functions of ZBTB32 and miR-210, we believe 
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that both of these factors regulate γ-globin gene expression through independent 
pathways. Simultaneous enforced expression of ZBTB32 and miR-210 will be 
hypothesized to have an additive effect on the induction of the fetal γ-globin gene in 
adult erythroid cells. The execution of this experiment has been limited by technical 
difficulties involved in maintaining optimum transduction efficiency and viability of CD34+ 
primary human erythroid cells transduced with two lentiviral vectors. Two approaches 
will be used to overcome this limitation: 1. Improving lentiviral transduction efficiency 2. 
Use of a lentiviral expression vector allowing high expression of the gene of interest 
followed by selection of transduced cells through a method other than FACS. 
Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) complexes, can 
improve lentiviral transduction of hematopoietic stem cells by increasing cytoplasmic 
entry of lentiviruses by endocytic events (Wang et al. 2014). Through careful design of 
experiments to ensure minimum cytotoxicity, introduction of rapamycin in the lentiviral 
transduction mixture will be used to improve transduction efficiency of CD34+ cells. For 
the second approach, lentiviral expression vectors that carry a cell surface antigen gene 
instead of GFP or a drug selection marker will enable selection of transduced cells 
through magnetic bead sorting, a technique that is easier to perform and does not affect 
viability of the transduced CD34+ cells.  
      Given the modest fold changes in γ-globin gene expression by over-expression of 
either ZBTB32 or miR-210, we anticipate that there exist other effectors of MBD2, which 
also contribute to its repressive effect. Long non-coding RNAs have gained increasing 
significance in transcriptional regulation and various biological processes (Wilusz, 
Sunwoo, Spector 2009). Regulation of non-coding RNAs by MBD2 is an unexplored 
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area, which holds great potential and will enable identification of yet unknown 
mechanisms of transcriptional regulation by MBD2.  
 
Perspectives: 
Several potential molecular targets for reactivation of fetal hemoglobin in adult cells 
have been identified. Of these, BCL11A is one of the prime candidates that have been 
pursued due to its impressive therapeutic potential as observed in Bcl11a knockout 
sickle cell disease transgenic mice. These transgenic mice show a dramatic elevation of 
fetal hemoglobin expression in adult erythroid cells and an almost curative effect on 
sickle cell disease pathophysiology. Though initial studies were encouraging, studies in 
primary human adult erythroid cells showed a relatively less dominant effect of BCL11A 
on γ–globin gene expression. This result arises from the fact that regulation of the 
transgenic human γ-globin gene in mice has differences in regulation in mice compared 
to humans due to the absence of a fetal β–type globin gene in mice. Nevertheless, 
targeting BCL11A has been a challenge since its exact mechanism of action is not very 
clear and it does not harbor an enzymatically active functional domain, which could be 
targeted through small molecule inhibitors. BCL11A may function through a multi-
protein complex and targeting the protein-protein interactions may be imperative to 
inhibit its activity as a repressor of fetal γ-globin gene. Besides, given the role of 
BCL11A in normal lymphoid development, systemic effects of pharmacologically 
targeting BCL11A remains a concern.  
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   The MBD2-NuRD co-repressor complex serves as an attractive epigenetic target for 
induction of fetal hemoglobin in adult erythrocytes of patients with β-
hemoglobinopathies. In contrast to other known regulators of fetal hemoglobin, MBD2 
stands out as a target of clinical significance due to its minimal involvement in 
processes of normal development and erythroid differentiation. MBD2-/- knockout mice 
are viable and fertile and display a minimally abnormal phenotype. MBD2 deficient 
primary human erythroid cells also show normal cellular proliferation and differentiation. 
This underscores the therapeutic potential of targeting MBD2 since it would not affect 
normal physiological processes. However, the road to developing inhibitors of the 
MBD2-NuRD complex has been wrought with many obstacles.  
          The first challenge is the need for a robust in vitro system that can provide a 
dynamic read-out for the repressor function of the MBD2-NuRD complex. The most well 
defined role of MBD2 is in developmental silencing of the fetal γ-globin gene. Many in 
vitro systems are available today to study the hemoglobin switch in murine and human 
adult erythroid cells, but these systems have their limitations. β-YAC mouse bone 
marrow CID cells primarily express adult mouse and human globin genes; the 
embryonic and fetal globin genes are very tightly repressed in these cells (Blau et al. 
2005). Although MBD2 knockdown increases γ-globin gene expression in these cells, 
the tight transcriptional repression provides a small dynamic range to study the function 
of MBD2. Recently, CID cells engineered with a γ-globin promoter-firefly luciferase (γ-
luc) and β-globin promoter-Renilla luciferase (β-luc) fusions from γ-luc β-luc β-YAC 
transgenic mice were developed for high-throughput screening of inducers of fetal γ-
globin gene (Peterson et al. 2014). This system would allow the identification of 
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compounds that specifically induce the firefly luciferase (γ-globin), but not Renilla 
luciferase (β-globin). A similar system would be required to screen large number of 
compounds that inhibit the function of MBD2 and activate the γ-globin gene promoter.  
Primary adult human erythroid cells offer the advantage of a large dynamic range of γ-
globin gene repression by MBD2; however the technical difficulties involved in genetic 
manipulation of these cells are a challenge. Additionally, although primary adult human 
erythroid cells have become a valuable and standard system to identify and 
characterize regulators of the hemoglobin switch, there is lack of a consistency in the 
extent of erythroid differentiation and relative γ/(γ+β) expression level achieved in 
studies performed by different groups. Having a comparable quantitative end-point for 
experiments involving primary human erythroid cells will add value to this system as 
well as aide comparison of effects of various factors on the hemoglobin switch.      
   The feasibility of targeting the function of MBD2 is another challenge. Unlike most 
“druggable” targets that possess enzymatic activities or well-defined binding pockets for 
ligands that can be bound by small molecules, MBD2 functions as a repressor in co-
operation with the multiple proteins of NuRD complex. Protein-protein interactions and 
protein-DNA interactions are challenging drug targets. However, recent advances have 
been made in developing covalently stapled peptides and small molecules, which can 
disrupt protein-protein interactions. A stabilized alpha-helical peptide was synthesized to  
interfere with the assembly of the active NOTCH transcriptional complex (Moellering et 
al. 2009); a small-molecule inhibitor that disrupted the BCL6/corepressor complex by 
binding at the binding groove of BCL6 BTB domain (Cerchietti et al. 2010), and a 
hydrocarbon-stapled peptide modeled after the BIM BH3 helix which broadly targeted all 
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BCL2 family proteins (LaBelle et al. 2012) are all examples of successful applications of 
therapeutic targeting of protein-protein interactions. Our studies have identified two 
critical interaction surfaces on the MBD2 protein, which can be targeted to disrupt 
binding with the histone deacetylase and chromatin remodeling components of the 
NuRD complex. In the future, this information will be employed to test a library of small 
molecule inhibitors or to design synthetic peptides that can specifically target the critical 
regions of MBD2. Targeting the function of MBD2 will have therapeutic value in 
treatment of β-hemoglobinopathies as well as various cancers where tumor suppressor 
genes are silenced by MBD2. 
 
  
  
 140 
Literature Cited 
 
Abdulmalik O, Safo MK, Chen Q, Yang J, Brugnara C, Ohene-Frempong K, Abraham DJ, Asakura T. 
2005. 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red 
blood cells. Br J Haematol 128(4):552-61. 
Adams VH, McBryant SJ, Wade PA, Woodcock CL, Hansen JC. 2007. Intrinsic disorder and autonomous 
domain function in the multifunctional nuclear protein, MeCP2. J Biol Chem 282(20):15057-64. 
Alqarni SS, Murthy A, Zhang W, Przewloka MR, Silva AP, Watson AA, Lejon S, Pei XY, Smits AH, Kloet 
SL, et al. 2014. Insight into the architecture of the NuRD complex: STRUCTURE OF THE RbAp48-
MTA1 SUBCOMPLEX. J Biol Chem 289(32):21844-55. 
Amaya M, Desai M, Gnanapragasam MN, Wang SZ, Zu Zhu S, Williams DC,Jr, Ginder GD. 2013. 
Mi2beta-mediated silencing of the fetal gamma-globin gene in adult erythroid cells. Blood 
121(17):3493-501. 
Angelucci E. 2010. Hematopoietic stem cell transplantation in thalassemia. Hematology Am Soc Hematol 
Educ Program 2010:456-62. 
Ardekani AM and Naeini MM. 2010. The role of MicroRNAs in human diseases. Avicenna J Med 
Biotechnol 2(4):161-79. 
Atweh G and Fathallah H. 2010. Pharmacologic induction of fetal hemoglobin production. Hematol Oncol 
Clin North Am 24(6):1131-44. 
Bader S, Walker M, Harrison D. 2000. Most microsatellite unstable sporadic colorectal carcinomas carry 
MBD4 mutations. Br J Cancer 83(12):1646-9. 
Barr H, Hermann A, Berger J, Tsai HH, Adie K, Prokhortchouk A, Hendrich B, Bird A. 2007. Mbd2 
contributes to DNA methylation-directed repression of the xist gene▿. Mol Cell Biol 27(10):3750-7. 
Baubec T, Ivanek R, Lienert F, Schubeler D. 2013. Methylation-dependent and -independent genomic 
targeting principles of the MBD protein family. Cell 153(2):480-92. 
Bauer DE, Kamran SC, Orkin SH. 2012. Reawakening fetal hemoglobin: Prospects for new therapies for 
the beta-globin disorders. Blood 120(15):2945-53. 
Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, Lin C, Shao Z, Canver MC, Smith EC, Pinello L, et 
al. 2013. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin 
level. Science 342(6155):253-7. 
Behringer RR, Ryan TM, Palmiter RD, Brinster RL, Townes TM. 1990. Human gamma- to beta-globin 
gene switching in transgenic mice. Genes Dev 4(3):380-9. 
Bell SG. 1999. An introduction to hemoglobin physiology. Neonatal Netw 18(2):9-15. 
Bender MA, Bulger M, Close J, Groudine M. 2000. Beta-globin gene switching and DNase I sensitivity of 
the endogenous beta-globin locus in mice do not require the locus control region. Mol Cell 5(2):387-
93. 
Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, Boger DL, Vogt PK. 2002. 
Small-molecule antagonists of myc/max dimerization inhibit myc-induced transformation of chicken 
embryo fibroblasts. Proc Natl Acad Sci U S A 99(6):3830-5. 
Berger J, Sansom O, Clarke A, Bird A. 2007. MBD2 is required for correct spatial gene expression in the 
gut. Mol Cell Biol 27(11):4049-57. 
Bianchi N, Zuccato C, Lampronti I, Borgatti M, Gambari R. 2009. Expression of miR-210 during erythroid 
differentiation and induction of gamma-globin gene expression. BMB Rep 42(8):493-9. 
Bianchi N, Zuccato C, Finotti A, Lampronti I, Borgatti M, Gambari R. 2012. Involvement of miRNA in 
erythroid differentiation. Epigenomics 4(1):51-65. 
  
 141 
Bjellqvist B, Hughes GJ, Pasquali C, Paquet N, Ravier F, Sanchez JC, Frutiger S, Hochstrasser D. 1993. 
The focusing positions of polypeptides in immobilized pH gradients can be predicted from their 
amino acid sequences. Electrophoresis 14(10):1023-31. 
Blau CA, Barbas CF,3rd, Bomhoff AL, Neades R, Yan J, Navas PA, Peterson KR. 2005. {Gamma}-globin 
gene expression in chemical inducer of dimerization (CID)-dependent multipotential cells established 
from human {beta}-globin locus yeast artificial chromosome ({beta}-YAC) transgenic mice. J Biol 
Chem 280(44):36642-7. 
Borg J, Papadopoulos P, Georgitsi M, Gutierrez L, Grech G, Fanis P, Phylactides M, Verkerk AJ, van der 
Spek PJ, Scerri CA, et al. 2010. Haploinsufficiency for the erythroid transcription factor KLF1 causes 
hereditary persistence of fetal hemoglobin. Nat Genet 42(9):801-5. 
Boyer SH, Belding TK, Margolet L, Noyes AN. 1975. Fetal hemoglobin restriction to a few erythrocytes (F 
cells) in normal human adults. Science 188(4186):361-3. 
Brackertz M, Gong Z, Leers J, Renkawitz R. 2006. p66alpha and p66beta of the mi-2/NuRD complex 
mediate MBD2 and histone interaction. Nucleic Acids Res 34(2):397-406. 
Bradner JE, Mak R, Tanguturi SK, Mazitschek R, Haggarty SJ, Ross K, Chang CY, Bosco J, West N, 
Morse E, et al. 2010. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and 
HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A 107(28):12617-22. 
Cai M, Williams DC,Jr, Wang G, Lee BR, Peterkofsky A, Clore GM. 2003. Solution structure of the 
phosphoryl transfer complex between the signal-transducing protein IIAGlucose and the cytoplasmic 
domain of the glucose transporter IICBGlucose of the escherichia coli glucose phosphotransferase 
system. J Biol Chem 278(27):25191-206. 
Campbell AD, Cui S, Shi L, Urbonya R, Mathias A, Bradley K, Bonsu KO, Douglas RR, Halford B, 
Schmidt L, et al. 2011. Forced TR2/TR4 expression in sickle cell disease mice confers enhanced 
fetal hemoglobin synthesis and alleviated disease phenotypes. Proc Natl Acad Sci U S A 
108(46):18808-13. 
Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, 
Westerman K, et al. 2010. Transfusion independence and HMGA2 activation after gene therapy of 
human beta-thalassaemia. Nature 467(7313):318-22. 
Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Fares C, 
Arrowsmith CH, et al. 2010. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. 
Cancer Cell 17(4):400-11. 
Chang CJ and Bouhassira EE. 2012. Zinc-finger nuclease-mediated correction of alpha-thalassemia in 
iPS cells. Blood 120(19):3906-14. 
Chang KH, Nelson AM, Cao H, Wang L, Nakamoto B, Ware CB, Papayannopoulou T. 2006. Definitive-
like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and 
fetal globins with little or no adult globin. Blood 108(5):1515-23. 
Charache S, Dover G, Smith K, Talbot CC,Jr, Moyer M, Boyer S. 1983. Treatment of sickle cell anemia 
with 5-azacytidine results in increased fetal hemoglobin production and is associated with 
nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex. Proc Natl 
Acad Sci U S A 80(15):4842-6. 
Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. 1995. 
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. investigators of the 
multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 332(20):1317-22. 
Chatagnon A, Perriaud L, Nazaret N, Croze S, Benhattar J, Lachuer J, Dante R. 2011. Preferential 
binding of the methyl-CpG binding domain protein 2 at methylated transcriptional start site regions. 
Epigenetics 6(11):1295-307. 
Chen LM and Chai KX. 2002. Prostasin serine protease inhibits breast cancer invasiveness and is 
transcriptionally regulated by promoter DNA methylation. Int J Cancer 97(3):323-9. 
  
 142 
Chen LM, Hodge GB, Guarda LA, Welch JL, Greenberg NM, Chai KX. 2001. Down-regulation of 
prostasin serine protease: A potential invasion suppressor in prostate cancer. Prostate 48(2):93-103. 
Chen Y, Gao W, Luo J, Tian R, Sun H, Zou S. 2011. Methyl-CpG binding protein MBD2 is implicated in 
methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. Oncol Rep 25(2):443-51. 
Chen Z, Luo HY, Basran RK, Hsu TH, Mang DW, Nuntakarn L, Rosenfield CG, Patrinos GP, Hardison 
RC, Steinberg MH, et al. 2008. A T-to-G transversion at nucleotide -567 upstream of HBG2 in a 
GATA-1 binding motif is associated with elevated hemoglobin F. Mol Cell Biol 28(13):4386-93. 
Collis P, Antoniou M, Grosveld F. 1990. Definition of the minimal requirements within the human beta-
globin gene and the dominant control region for high level expression. EMBO J 9(1):233-40. 
Cornilescu G, Delaglio F, Bax A. 1999. Protein backbone angle restraints from searching a database for 
chemical shift and sequence homology. J Biomol NMR 13(3):289-302. 
Costa FC, Fedosyuk H, Chazelle AM, Neades RY, Peterson KR. 2012. Mi2beta is required for gamma-
globin gene silencing: Temporal assembly of a GATA-1-FOG-1-Mi2 repressor complex in beta-YAC 
transgenic mice. PLoS Genet 8(12):e1003155. 
Cramer JM, Scarsdale JN, Walavalkar NM, Buchwald WA, Ginder GD, Williams DC,Jr. 2014. Probing the 
dynamic distribution of bound states for methylcytosine-binding domains on DNA. J Biol Chem 
289(3):1294-302. 
Cui S, Kolodziej KE, Obara N, Amaral-Psarris A, Demmers J, Shi L, Engel JD, Grosveld F, Strouboulis J, 
Tanabe O. 2011. Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional 
corepressors that associate specifically with the embryonic beta-type globin promoters in 
differentiated adult erythroid cells. Mol Cell Biol 31(16):3298-311. 
Dai MS, Chevallier N, Stone S, Heinrich MC, McConnell M, Reuter T, Broxmeyer HE, Licht JD, Lu L, 
Hoatlin ME. 2002. The effects of the fanconi anemia zinc finger (FAZF) on cell cycle, apoptosis, and 
proliferation are differentiation stage-specific. J Biol Chem 277(29):26327-34. 
David G. Nathan, David Ginsburg, Stuart H. Orkin, A. Thomas Look. 2003. Nathan and oski's 
hematology of infancy and childhood. 0721693172. 
Dawson R, Muller L, Dehner A, Klein C, Kessler H, Buchner J. 2003. The N-terminal domain of p53 is 
natively unfolded. J Mol Biol 332(5):1131-41. 
Deaton AM and Bird A. 2011. CpG islands and the regulation of transcription. Genes Dev 25(10):1010-
22. 
Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. 1995. NMRPipe: A multidimensional spectral 
processing system based on UNIX pipes. J Biomol NMR 6(3):277-93. 
Dijon M, Bardin F, Murati A, Batoz M, Chabannon C, Tonnelle C. 2008. The role of ikaros in human 
erythroid differentiation. Blood 111(3):1138-46. 
Dillon N and Grosveld F. 1991. Human gamma-globin genes silenced independently of other genes in the 
beta-globin locus. Nature 350(6315):252-4. 
dos Santos RL, Tosti L, Radzisheuskaya A, Caballero IM, Kaji K, Hendrich B, Silva JC. 2014. 
MBD3/NuRD facilitates induction of pluripotency in a context-dependent manner. Cell Stem Cell 
15(1):102-10. 
Dover GJ and Charache S. 1992. Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell 
disease. Semin Oncol 19(3 Suppl 9):61-6. 
Dumitriu B, Patrick MR, Petschek JP, Cherukuri S, Klingmuller U, Fox PL, Lefebvre V. 2006. Sox6 cell-
autonomously stimulates erythroid cell survival, proliferation, and terminal maturation and is thereby 
an important enhancer of definitive erythropoiesis during mouse development. Blood 108(4):1198-
207. 
Dunker AK, Cortese MS, Romero P, Iakoucheva LM, Uversky VN. 2005. Flexible nets. the roles of 
intrinsic disorder in protein interaction networks. FEBS J 272(20):5129-48. 
  
 143 
EDINGTON GM and LEHMANN H. 1955. Expression of the sickle-cell gene in africa. Br Med J 
1(4925):1308-11. 
Eisen JA, Sweder KS, Hanawalt PC. 1995. Evolution of the SNF2 family of proteins: Subfamilies with 
distinct sequences and functions. Nucleic Acids Res 23(14):2715-23. 
Ellis J, Tan-Un KC, Harper A, Michalovich D, Yannoutsos N, Philipsen S, Grosveld F. 1996. A dominant 
chromatin-opening activity in 5' hypersensitive site 3 of the human beta-globin locus control region. 
EMBO J 15(3):562-8. 
Enver T, Raich N, Ebens AJ, Papayannopoulou T, Costantini F, Stamatoyannopoulos G. 1990. 
Developmental regulation of human fetal-to-adult globin gene switching in transgenic mice. Nature 
344(6264):309-13. 
Esteghamat F, Gillemans N, Bilic I, van den Akker E, Cantu I, van Gent T, Klingmuller U, van Lom K, von 
Lindern M, Grosveld F, et al. 2013. Erythropoiesis and globin switching in compound Klf1::Bcl11a 
mutant mice. Blood 121(13):2553-62. 
Esteller M. 2008. Epigenetics in cancer. N Engl J Med 358(11):1148-59. 
Evans T and Felsenfeld G. 1989. The erythroid-specific transcription factor Eryf1: A new finger protein. 
Cell 58(5):877-85. 
Feng Q and Zhang Y. 2001. The MeCP1 complex represses transcription through preferential binding, 
remodeling, and deacetylating methylated nucleosomes. Genes Dev 15(7):827-32. 
Fibach E and Prus E. 2005. Differentiation of human erythroid cells in culture. Curr Protoc Immunol 
Chapter 22:Unit 22F.7. 
Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberg D, 
Linden J, et al. 2013. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by 
the adenosine A2A receptor agonist regadenoson. Blood 121(17):3329-34. 
Filion GJ, Zhenilo S, Salozhin S, Yamada D, Prokhortchouk E, Defossez PA. 2006. A family of human 
zinc finger proteins that bind methylated DNA and repress transcription. Mol Cell Biol 26(1):169-81. 
Fraga MF, Ballestar E, Montoya G, Taysavang P, Wade PA, Esteller M. 2003. The affinity of different 
MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic 
Acids Res 31(6):1765-74. 
Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, Taher A, Chaneim N, Boosalis M, 
Berenson R, et al. 2013. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene 
inducer, in beta-thalassaemia intermedia and HbE/beta-thalassaemia. Br J Haematol 161(4):587-93. 
Fujita N, Watanabe S, Ichimura T, Ohkuma Y, Chiba T, Saya H, Nakao M. 2003. MCAF mediates MBD1-
dependent transcriptional repression. Mol Cell Biol 23(8):2834-43. 
Fujiwara Y, Browne CP, Cunniff K, Goff SC, Orkin SH. 1996. Arrested development of embryonic red cell 
precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A 
93(22):12355-8. 
Fuxreiter M. 2012. Fuzziness: Linking regulation to protein dynamics. Mol Biosyst 8(1):168-77. 
Fuxreiter M and Tompa P. 2012. Fuzzy complexes: A more stochastic view of protein function. Adv Exp 
Med Biol 725:1-14. 
Gallienne AE, Dreau HM, Schuh A, Old JM, Henderson S. 2012. Ten novel mutations in the erythroid 
transcription factor KLF1 gene associated with increased fetal hemoglobin levels in adults. 
Haematologica 97(3):340-3. 
Ghosh RP, Nikitina T, Horowitz-Scherer RA, Gierasch LM, Uversky VN, Hite K, Hansen JC, Woodcock 
CL. 2010. Unique physical properties and interactions of the domains of methylated DNA binding 
protein 2. Biochemistry 49(20):4395-410. 
Ginder GD, Gnanapragasam MN, Mian OY. 2008. The role of the epigenetic signal, DNA methylation, in 
gene regulation during erythroid development. Curr Top Dev Biol 82:85-116. 
  
 144 
Gnanapragasam MN, Scarsdale JN, Amaya ML, Webb HD, Desai MA, Walavalkar NM, Wang SZ, Zu Zhu 
S, Ginder GD, Williams DC,Jr. 2011a. p66Alpha-MBD2 coiled-coil interaction and recruitment of mi-2 
are critical for globin gene silencing by the MBD2-NuRD complex. Proc Natl Acad Sci U S A 
108(18):7487-92. 
Gnanapragasam MN, Scarsdale JN, Amaya ML, Webb HD, Desai MA, Walavalkar NM, Wang SZ, Zu Zhu 
S, Ginder GD, Williams DC,Jr. 2011b. p66Alpha-MBD2 coiled-coil interaction and recruitment of mi-2 
are critical for globin gene silencing by the MBD2-NuRD complex. Proc Natl Acad Sci U S A 
108(18):7487-92. 
Grosveld F, van Assendelft GB, Greaves DR, Kollias G. 1987. Position-independent, high-level 
expression of the human beta-globin gene in transgenic mice. Cell 51(6):975-85. 
Guy J, Hendrich B, Holmes M, Martin JE, Bird A. 2001. A mouse Mecp2-null mutation causes 
neurological symptoms that mimic rett syndrome. Nat Genet 27(3):322-6. 
Hameed UF, Lim J, Zhang Q, Wasik MA, Yang D, Swaminathan K. 2014. Transcriptional repressor 
domain of MBD1 is intrinsically disordered and interacts with its binding partners in a selective 
manner. Sci Rep 4:4896. 
Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ. 2009. Multiple independent binding sites for 
small-molecule inhibitors on the oncoprotein c-myc. J Am Chem Soc 131(21):7390-401. 
Harju-Baker S, Costa FC, Fedosyuk H, Neades R, Peterson KR. 2008. Silencing of agamma-globin gene 
expression during adult definitive erythropoiesis mediated by GATA-1-FOG-1-Mi2 complex binding 
at the -566 GATA site. Mol Cell Biol 28(10):3101-13. 
Haynes C, Oldfield CJ, Ji F, Klitgord N, Cusick ME, Radivojac P, Uversky VN, Vidal M, Iakoucheva LM. 
2006. Intrinsic disorder is a common feature of hub proteins from four eukaryotic interactomes. PLoS 
Comput Biol 2(8):e100. 
Hendrich B and Bird A. 1998. Identification and characterization of a family of mammalian methyl-CpG 
binding proteins. Mol Cell Biol 18(11):6538-47. 
Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A. 2001. Closely related proteins MBD2 and MBD3 
play distinctive but interacting roles in mouse development. Genes Dev 15(6):710-23. 
Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. 1999. The thymine glycosylase MBD4 can bind to the 
product of deamination at methylated CpG sites. Nature 401(6750):301-4. 
Hong W, Nakazawa M, Chen YY, Kori R, Vakoc CR, Rakowski C, Blobel GA. 2005. FOG-1 recruits the 
NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J 24(13):2367-78. 
Hu J, Liu J, Xue F, Halverson G, Reid M, Guo A, Chen L, Raza A, Galili N, Jaffray J, et al. 2013. Isolation 
and functional characterization of human erythroblasts at distinct stages: Implications for 
understanding of normal and disordered erythropoiesis in vivo. Blood 121(16):3246-53. 
Ikonomi P, Noguchi CT, Miller W, Kassahun H, Hardison R, Schechter AN. 2000. Levels of GATA-
1/GATA-2 transcription factors modulate expression of embryonic and fetal hemoglobins. Gene 
261(2):277-87. 
Illingworth RS and Bird AP. 2009. CpG islands--'a rough guide'. FEBS Lett 583(11):1713-20. 
INGRAM VM. 1956. A specific chemical difference between the globins of normal human and sickle-cell 
anaemia haemoglobin. Nature 178(4537):792-4. 
Jabbari K and Bernardi G. 2004. Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. Gene 
333:143-9. 
Jiang CL, Jin SG, Pfeifer GP. 2004. MBD3L1 is a transcriptional repressor that interacts with methyl-CpG-
binding protein 2 (MBD2) and components of the NuRD complex. J Biol Chem 279(50):52456-64. 
Jiang CL, Jin SG, Lee DH, Lan ZJ, Xu X, O'Connor TR, Szabo PE, Mann JR, Cooney AJ, Pfeifer GP. 
2002. MBD3L1 and MBD3L2, two new proteins homologous to the methyl-CpG-binding proteins 
MBD2 and MBD3: Characterization of MBD3L1 as a testis-specific transcriptional repressor. 
Genomics 80(6):621-9. 
  
 145 
Jiang J, Best S, Menzel S, Silver N, Lai MI, Surdulescu GL, Spector TD, Thein SL. 2006. cMYB is 
involved in the regulation of fetal hemoglobin production in adults. Blood 108(3):1077-83. 
Jin SG, Jiang CL, Rauch T, Li H, Pfeifer GP. 2005. MBD3L2 interacts with MBD3 and components of the 
NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing. J Biol Chem 
280(13):12700-9. 
Jing H, Vakoc CR, Ying L, Mandat S, Wang H, Zheng X, Blobel GA. 2008. Exchange of GATA factors 
mediates transitions in looped chromatin organization at a developmentally regulated gene locus. 
Mol Cell 29(2):232-42. 
Jones PA and Baylin SB. 2007. The epigenomics of cancer. Cell 128(4):683-92. 
Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. 1998. 
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 
19(2):187-91. 
Kersh EN. 2006. Impaired memory CD8 T cell development in the absence of methyl-CpG-binding 
domain protein 2. J Immunol 177(6):3821-6. 
Kiga K, Mimuro H, Suzuki M, Shinozaki-Ushiku A, Kobayashi T, Sanada T, Kim M, Ogawa M, Iwasaki 
YW, Kayo H, et al. 2014. Epigenetic silencing of miR-210 increases the proliferation of gastric 
epithelium during chronic helicobacter pylori infection. Nat Commun 5:4497. 
Kim JK, Samaranayake M, Pradhan S. 2009. Epigenetic mechanisms in mammals. Cell Mol Life Sci 
66(4):596-612. 
Klein C and Vassilev LT. 2004. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 
91(8):1415-9. 
Kloet SL, Baymaz HI, Makowski M, Groenewold V, Jansen PW, Berendsen M, Niazi H, Kops GJ, 
Vermeulen M. 2014. Towards elucidating the stability, dynamics and architecture of the nucleosome 
remodeling and deacetylase complex by using quantitative interaction proteomics. FEBS J . 
Kosaka N, Sugiura K, Yamamoto Y, Yoshioka Y, Miyazaki H, Komatsu N, Ochiya T, Kato T. 2008. 
Identification of erythropoietin-induced microRNAs in haematopoietic cells during erythroid 
differentiation. Br J Haematol 142(2):293-300. 
Kransdorf EP, Wang SZ, Zhu SZ, Langston TB, Rupon JW, Ginder GD. 2006. MBD2 is a critical 
component of a methyl cytosine-binding protein complex isolated from primary erythroid cells. Blood 
108(8):2836-45. 
Krishnan N, Koveal D, Miller DH, Xue B, Akshinthala SD, Kragelj J, Jensen MR, Gauss CM, Page R, 
Blackledge M, et al. 2014. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. 
Nat Chem Biol 10(7):558-66. 
Kumita JR, Smart OS, Woolley GA. 2000. Photo-control of helix content in a short peptide. Proc Natl 
Acad Sci U S A 97(8):3803-8. 
LaBelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C, Fisher JK, Godes M, Pitter K, 
Kung AL, et al. 2012. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. 
J Clin Invest 122(6):2018-31. 
Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupre I, Rolland D, Salon C, Godfraind C, deFraipont F, 
et al. 2011. MicroRNA and target protein patterns reveal physiopathological features of glioma 
subtypes. PLoS One 6(5):e20600. 
Le Guezennec X, Vermeulen M, Brinkman AB, Hoeijmakers WA, Cohen A, Lasonder E, Stunnenberg 
HG. 2006. MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and 
functional properties. Mol Cell Biol 26(3):843-51. 
Lebowitz J, Lewis MS, Schuck P. 2002. Modern analytical ultracentrifugation in protein science: A tutorial 
review. Protein Sci 11(9):2067-79. 
Lettre G, Sankaran VG, Bezerra MA, Araujo AS, Uda M, Sanna S, Cao A, Schlessinger D, Costa FF, 
Hirschhorn JN, et al. 2008. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci 
  
 146 
associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S 
A 105(33):11869-74. 
Levasseur DN, Ryan TM, Pawlik KM, Townes TM. 2003. Correction of a mouse model of sickle cell 
disease: Lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic 
stem cells. Blood 102(13):4312-9. 
Levasseur DN, Ryan TM, Reilly MP, McCune SL, Asakura T, Townes TM. 2004. A recombinant human 
hemoglobin with anti-sickling properties greater than fetal hemoglobin. J Biol Chem 279(26):27518-
24. 
Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F, Bird A. 1992. Purification, 
sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. 
Cell 69(6):905-14. 
Ley TJ, Maloney KA, Gordon JI, Schwartz AL. 1989. Globin gene expression in erythroid human fetal liver 
cells. J Clin Invest 83(3):1032-8. 
Ley TJ, DeSimone J, Anagnou NP, Keller GH, Humphries RK, Turner PH, Young NS, Keller P, Nienhuis 
AW. 1982. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ 
thalassemia. N Engl J Med 307(24):1469-75. 
Li X, Romero P, Rani M, Dunker AK, Obradovic Z. 1999. Predicting protein disorder for N-, C-, and 
internal regions. Genome Inform Ser Workshop Genome Inform 10:30-40. 
Lin X and Nelson WG. 2003a. Methyl-CpG-binding domain protein-2 mediates transcriptional repression 
associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res 
63(2):498-504. 
Lin X and Nelson WG. 2003b. Methyl-CpG-binding domain protein-2 mediates transcriptional repression 
associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res 
63(2):498-504. 
Lopez RA, Schoetz S, DeAngelis K, O'Neill D, Bank A. 2002. Multiple hematopoietic defects and delayed 
globin switching in ikaros null mice. Proc Natl Acad Sci U S A 99(2):602-7. 
Lowrey CH and Nienhuis AW. 1993. Brief report: Treatment with azacitidine of patients with end-stage 
beta-thalassemia. N Engl J Med 329(12):845-8. 
Lu Y, Loh YH, Li H, Cesana M, Ficarro SB, Parikh JR, Salomonis N, Toh CX, Andreadis ST, Luckey CJ, 
et al. 2014. Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. Cell 
Stem Cell 15(1):92-101. 
Ma Q, Wyszynski DF, Farrell JJ, Kutlar A, Farrer LA, Baldwin CT, Steinberg MH. 2007. Fetal hemoglobin 
in sickle cell anemia: Genetic determinants of response to hydroxyurea. Pharmacogenomics J 
7(6):386-94. 
Macdonald JL, Verster A, Berndt A, Roskams AJ. 2010. MBD2 and MeCP2 regulate distinct transitions in 
the stage-specific differentiation of olfactory receptor neurons. Mol Cell Neurosci 44(1):55-67. 
Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, 
Rekhtman N, de Stanchina E, et al. 2014. In vivo engineering of oncogenic chromosomal 
rearrangements with the CRISPR/Cas9 system. Nature . 
Magdinier F and Wolffe AP. 2001. Selective association of the methyl-CpG binding protein MBD2 with the 
silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci U S A 98(9):4990-5. 
Martin DI, Tsai SF, Orkin SH. 1989. Increased gamma-globin expression in a nondeletion HPFH 
mediated by an erythroid-specific DNA-binding factor. Nature 338(6214):435-8. 
McGrath K and Palis J. 2008. Ontogeny of erythropoiesis in the mammalian embryo. Curr Top Dev Biol 
82:1-22. 
Meehan RR, Lewis JD, McKay S, Kleiner EL, Bird AP. 1989. Identification of a mammalian protein that 
binds specifically to DNA containing methylated CpGs. Cell 58(3):499-507. 
  
 147 
Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, Foglio M, Zelenika D, Boland A, Rooks H, 
et al. 2007. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on 
chromosome 2p15. Nat Genet 39(10):1197-9. 
Metallo SJ. 2010. Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol 
14(4):481-8. 
Mian OY, Wang SZ, Zhu SZ, Gnanapragasam MN, Graham L, Bear HD, Ginder GD. 2011. Methyl-
binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer 
Res 9(8):1152-62. 
Miccio A and Blobel GA. 2010. Role of the GATA-1/FOG-1/NuRD pathway in the expression of human 
beta-like globin genes. Mol Cell Biol 30(14):3460-70. 
Miccio A, Wang Y, Hong W, Gregory GD, Wang H, Yu X, Choi JK, Shelat S, Tong W, Poncz M, et al. 
2010. NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood 
development. EMBO J 29(2):442-56. 
Millar CB, Guy J, Sansom OJ, Selfridge J, MacDougall E, Hendrich B, Keightley PD, Bishop SM, Clarke 
AR, Bird A. 2002. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 
297(5580):403-5. 
Miller IJ and Bieker JJ. 1993. A novel, erythroid cell-specific murine transcription factor that binds to the 
CACCC element and is related to the kruppel family of nuclear proteins. Mol Cell Biol 13(5):2776-86. 
Miltenberger-Miltenyi G and Laccone F. 2003. Mutations and polymorphisms in the human methyl CpG-
binding protein MECP2. Hum Mutat 22(2):107-15. 
Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, 
Verdine GL, Bradner JE. 2009. Direct inhibition of the NOTCH transcription factor complex. Nature 
462(7270):182-8. 
Mohan A, Oldfield CJ, Radivojac P, Vacic V, Cortese MS, Dunker AK, Uversky VN. 2006. Analysis of 
molecular recognition features (MoRFs). J Mol Biol 362(5):1043-59. 
Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt 
K, et al. 2013. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J 
Clin Invest 123(7):2948-60. 
Nakao M, Matsui S, Yamamoto S, Okumura K, Shirakawa M, Fujita N. 2001. Regulation of transcription 
and chromatin by methyl-CpG binding protein MBD1. Brain Dev 23 Suppl 1:S174-6. 
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. 1998. Transcriptional 
repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. 
Nature 393(6683):386-9. 
Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, Tempst P, Reinberg D, 
Bird A. 1999. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase 
complex. Nat Genet 23(1):58-61. 
Nuez B, Michalovich D, Bygrave A, Ploemacher R, Grosveld F. 1995. Defective haematopoiesis in fetal 
liver resulting from inactivation of the EKLF gene. Nature 375(6529):316-8. 
O'Neill DW, Schoetz SS, Lopez RA, Castle M, Rabinowitz L, Shor E, Krawchuk D, Goll MG, Renz M, 
Seelig HP, et al. 2000. An ikaros-containing chromatin-remodeling complex in adult-type erythroid 
cells. Mol Cell Biol 20(20):7572-82. 
Palis J. 2014. Primitive and definitive erythropoiesis in mammals. Front Physiol 5:3. 
Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale 
A, et al. 2011. Genomic safe harbors permit high beta-globin transgene expression in thalassemia 
induced pluripotent stem cells. Nat Biotechnol 29(1):73-8. 
Patil A and Nakamura H. 2006. Disordered domains and high surface charge confer hubs with the ability 
to interact with multiple proteins in interaction networks. FEBS Lett 580(8):2041-5. 
  
 148 
Perkins AC, Gaensler KM, Orkin SH. 1996. Silencing of human fetal globin expression is impaired in the 
absence of the adult beta-globin gene activator protein EKLF. Proc Natl Acad Sci U S A 
93(22):12267-71. 
Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai SP, Vichinsky EP, Olivieri NF. 
1993. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin 
disorders. N Engl J Med 328(2):81-6. 
Perumbeti A, Higashimoto T, Urbinati F, Franco R, Meiselman HJ, Witte D, Malik P. 2009. A novel human 
gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse 
model: Critical determinants for successful correction. Blood 114(6):1174-85. 
Peschle C, Mavilio F, Care A, Migliaccio G, Migliaccio AR, Salvo G, Samoggia P, Petti S, Guerriero R, 
Marinucci M. 1985. Haemoglobin switching in human embryos: Asynchrony of zeta----alpha and 
epsilon----gamma-globin switches in primitive and definite erythropoietic lineage. Nature 
313(5999):235-8. 
Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA. 2009. Correction of murine sickle cell 
disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. 
Mol Ther 17(2):245-52. 
Peterson KR, Costa FC, Fedosyuk H, Neades RY, Chazelle AM, Zelenchuk L, Fonteles AH, Dalal P, Roy 
A, Chaguturu R, et al. 2014. A cell-based high-throughput screen for novel chemical inducers of fetal 
hemoglobin for treatment of hemoglobinopathies. PLoS One 9(9):e107006. 
Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Stoerker J, Genuardi M, Yeung AT, Matsumoto Y, 
Bellacosa A. 2000. Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-
specific DNA N-glycosylase. J Biol Chem 275(42):32422-9. 
Phesse TJ, Parry L, Reed KR, Ewan KB, Dale TC, Sansom OJ, Clarke AR. 2008. Deficiency of Mbd2 
attenuates wnt signaling▿†. Mol Cell Biol 28(19):6094-103. 
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. 1994. Mortality in sickle 
cell disease. life expectancy and risk factors for early death. N Engl J Med 330(23):1639-44. 
Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, 
Jovanovic M, et al. 2014. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 
159(2):440-55. 
Pontius BW. 1993. Close encounters: Why unstructured, polymeric domains can increase rates of specific 
macromolecular association. Trends Biochem Sci 18(5):181-6. 
Pope SH, Fibach E, Sun J, Chin K, Rodgers GP. 2000. Two-phase liquid culture system models normal 
human adult erythropoiesis at the molecular level. Eur J Haematol 64(5):292-303. 
Powars DR, Weiss JN, Chan LS, Schroeder WA. 1984. Is there a threshold level of fetal hemoglobin that 
ameliorates morbidity in sickle cell anemia? Blood 63(4):921-6. 
Prokhortchouk A, Hendrich B, Jorgensen H, Ruzov A, Wilm M, Georgiev G, Bird A, Prokhortchouk E. 
2001. The p120 catenin partner kaiso is a DNA methylation-dependent transcriptional repressor. 
Genes Dev 15(13):1613-8. 
Radmilovic M, Zukic B, Petrovic MS, Bartsakoulia M, Stankovic B, Kotur N, Dokmanovic L, Georgitsi M, 
Patrinos GP, Pavlovic S. 2013. Functional analysis of a novel KLF1 gene promoter variation 
associated with hereditary persistence of fetal hemoglobin. Ann Hematol 92(1):53-8. 
Raich N, Enver T, Nakamoto B, Josephson B, Papayannopoulou T, Stamatoyannopoulos G. 1990. 
Autonomous developmental control of human embryonic globin gene switching in transgenic mice. 
Science 250(4984):1147-9. 
Rais Y, Zviran A, Geula S, Gafni O, Chomsky E, Viukov S, Mansour AA, Caspi I, Krupalnik V, Zerbib M, 
et al. 2013. Deterministic direct reprogramming of somatic cells to pluripotency. Nature 
502(7469):65-70. 
  
 149 
Rank G, Cerruti L, Simpson RJ, Moritz RL, Jane SM, Zhao Q. 2010a. Identification of a PRMT5-
dependent repressor complex linked to silencing of human fetal globin gene expression. Blood 
116(9):1585-92. 
Rank G, Cerruti L, Simpson RJ, Moritz RL, Jane SM, Zhao Q. 2010b. Identification of a PRMT5-
dependent repressor complex linked to silencing of human fetal globin gene expression. Blood 
116(9):1585-92. 
Riccio A, Aaltonen LA, Godwin AK, Loukola A, Percesepe A, Salovaara R, Masciullo V, Genuardi M, 
Paravatou-Petsotas M, Bassi DE, et al. 1999. The DNA repair gene MBD4 (MED1) is mutated in 
human carcinomas with microsatellite instability. Nat Genet 23(3):266-8. 
Rodriguez-Paredes M and Esteller M. 2011. Cancer epigenetics reaches mainstream oncology. Nat Med 
17(3):330-9. 
Romero, Obradovic, Dunker K. 1997. Sequence data analysis for long disordered regions prediction in 
the calcineurin family. Genome Inform Ser Workshop Genome Inform 8:110-24. 
Romero Z, Urbinati F, Geiger S, Cooper AR, Wherley J, Kaufman ML, Hollis RP, de Assin RR, 
Senadheera S, Sahagian A, et al. 2013. Beta-globin gene transfer to human bone marrow for sickle 
cell disease. J Clin Invest . 
Rupon JW, Wang SZ, Gnanapragasam M, Labropoulos S, Ginder GD. 2011a. MBD2 contributes to 
developmental silencing of the human epsilon-globin gene. Blood Cells Mol Dis 46(3):212-9. 
Rupon JW, Wang SZ, Gnanapragasam M, Labropoulos S, Ginder GD. 2011b. MBD2 contributes to 
developmental silencing of the human epsilon-globin gene. Blood Cells Mol Dis 46(3):212-9. 
Rupon JW, Wang SZ, Gaensler K, Lloyd J, Ginder GD. 2006a. Methyl binding domain protein 2 mediates 
gamma-globin gene silencing in adult human betaYAC transgenic mice. Proc Natl Acad Sci U S A 
103(17):6617-22. 
Rupon JW, Wang SZ, Gaensler K, Lloyd J, Ginder GD. 2006b. Methyl binding domain protein 2 mediates 
gamma-globin gene silencing in adult human betaYAC transgenic mice. Proc Natl Acad Sci U S A 
103(17):6617-22. 
Saito M and Ishikawa F. 2002. The mCpG-binding domain of human MBD3 does not bind to mCpG but 
interacts with NuRD/Mi2 components HDAC1 and MTA2. J Biol Chem 277(38):35434-9. 
Sankaran VG, Xu J, Orkin SH. 2010a. Advances in the understanding of haemoglobin switching. Br J 
Haematol 149(2):181-94. 
Sankaran VG, Xu J, Orkin SH. 2010b. Advances in the understanding of haemoglobin switching. Br J 
Haematol 149(2):181-94. 
Sankaran VG, Menne TF, Scepanovic D, Vergilio JA, Ji P, Kim J, Thiru P, Orkin SH, Lander ES, Lodish 
HF. 2011. MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human 
trisomy 13. Proc Natl Acad Sci U S A 108(4):1519-24. 
Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, Mikkola HK, Hirschhorn JN, Cantor AB, 
Orkin SH. 2008. Human fetal hemoglobin expression is regulated by the developmental stage-
specific repressor BCL11A. Science 322(5909):1839-42. 
Sankaran VG, Xu J, Ragoczy T, Ippolito GC, Walkley CR, Maika SD, Fujiwara Y, Ito M, Groudine M, 
Bender MA, et al. 2009. Developmental and species-divergent globin switching are driven by 
BCL11A. Nature 460(7259):1093-7. 
Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. 2003. Deficiency of Mbd2 suppresses 
intestinal tumorigenesis. Nat Genet 34(2):145-7. 
Sarakul O, Vattanaviboon P, Tanaka Y, Fucharoen S, Abe Y, Svasti S, Umemura T. 2013. Enhanced 
erythroid cell differentiation in hypoxic condition is in part contributed by miR-210. Blood Cells Mol 
Dis 51(2):98-103. 
Sarraf SA and Stancheva I. 2004. Methyl-CpG binding protein MBD1 couples histone H3 methylation at 
lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol Cell 15(4):595-605. 
  
 150 
Satta S, Perseu L, Maccioni L, Giagu N, Galanello R. 2012. Delayed fetal hemoglobin switching in 
subjects with KLF1 gene mutation. Blood Cells Mol Dis 48(1):22-4. 
Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman 
R, DeSimone J. 2003. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell 
adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102(12):3865-
70. 
Saxonov S, Berg P, Brutlag DL. 2006. A genome-wide analysis of CpG dinucleotides in the human 
genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U S A 103(5):1412-7. 
Scarsdale JN, Webb HD, Ginder GD, Williams DC,Jr. 2011a. Solution structure and dynamic analysis of 
chicken MBD2 methyl binding domain bound to a target-methylated DNA sequence. Nucleic Acids 
Res 39(15):6741-52. 
Scarsdale JN, Webb HD, Ginder GD, Williams DC,Jr. 2011b. Solution structure and dynamic analysis of 
chicken MBD2 methyl binding domain bound to a target-methylated DNA sequence. Nucleic Acids 
Res 39(15):6741-52. 
Schuck P. 2000. Size-distribution analysis of macromolecules by sedimentation velocity 
ultracentrifugation and lamm equation modeling. Biophys J 78(3):1606-19. 
Sebastiano V, Maeder ML, Angstman JF, Haddad B, Khayter C, Yeo DT, Goodwin MJ, Hawkins JS, 
Ramirez CL, Batista LF, et al. 2011. In situ genetic correction of the sickle cell anemia mutation in 
human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 
29(11):1717-26. 
Shen Y and Bax A. 2013. Protein backbone and sidechain torsion angles predicted from NMR chemical 
shifts using artificial neural networks. J Biomol NMR 56(3):227-41. 
Shen Y, Delaglio F, Cornilescu G, Bax A. 2009. TALOS+: A hybrid method for predicting protein 
backbone torsion angles from NMR chemical shifts. J Biomol NMR 44(4):213-23. 
Shenoy S. 2013. Hematopoietic stem-cell transplantation for sickle cell disease: Current evidence and 
opinions. Ther Adv Hematol 4(5):335-44. 
Shi L, Cui S, Engel JD, Tanabe O. 2013. Lysine-specific demethylase 1 is a therapeutic target for fetal 
hemoglobin induction. Nat Med 19(3):291-4. 
Singal R, Wang SZ, Sargent T, Zhu SZ, Ginder GD. 2002. Methylation of promoter proximal-transcribed 
sequences of an embryonic globin gene inhibits transcription in primary erythroid cells and promotes 
formation of a cell type-specific methyl cytosine binding complex. J Biol Chem 277(3):1897-905. 
Singal R, Ferris R, Little JA, Wang SZ, Ginder GD. 1997. Methylation of the minimal promoter of an 
embryonic globin gene silences transcription in primary erythroid cells. Proc Natl Acad Sci U S A 
94(25):13724-9. 
Singleton BK, Frayne J, Anstee DJ. 2012. Blood group phenotypes resulting from mutations in erythroid 
transcription factors. Curr Opin Hematol 19(6):486-93. 
Smits AH, Jansen PW, Poser I, Hyman AA, Vermeulen M. 2013. Stoichiometry of chromatin-associated 
protein complexes revealed by label-free quantitative mass spectrometry-based proteomics. Nucleic 
Acids Res 41(1):e28. 
Sripichai O, Kiefer CM, Bhanu NV, Tanno T, Noh SJ, Goh SH, Russell JE, Rognerud CL, Ou CN, Oneal 
PA, et al. 2009. Cytokine-mediated increases in fetal hemoglobin are associated with globin gene 
histone modification and transcription factor reprogramming. Blood 114(11):2299-306. 
Stadhouders R, Aktuna S, Thongjuea S, Aghajanirefah A, Pourfarzad F, van Ijcken W, Lenhard B, Rooks 
H, Best S, Menzel S, et al. 2014. HBS1L-MYB intergenic variants modulate fetal hemoglobin via 
long-range MYB enhancers. J Clin Invest 124(4):1699-710. 
Stamatoyannopoulos G, Majerus PW, Perimutter RM, Varmus H. 2001. The molecular basis of blood 
diseases. 3rd ed. Philadelphia, PA: WB Saunders. 
  
 151 
Stauffer SR. 2007. Small molecule inhibition of the bcl-X(L)-BH3 protein-protein interaction: Proof-of-
concept of an in vivo chemopotentiator ABT-737. Curr Top Med Chem 7(10):961-5. 
Stefanska B, Suderman M, Machnes Z, Bhattacharyya B, Hallett M, Szyf M. 2013. Transcription onset of 
genes critical in liver carcinogenesis is epigenetically regulated by methylated DNA-binding protein 
MBD2. Carcinogenesis 34(12):2738-49. 
Steinberg MH. 2008. Sickle cell anemia, the first molecular disease: Overview of molecular etiology, 
pathophysiology, and therapeutic approaches. ScientificWorldJournal 8:1295-324. 
Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. 1997. Fetal hemoglobin in sickle cell 
anemia: Determinants of response to hydroxyurea. multicenter study of hydroxyurea. Blood 
89(3):1078-88. 
Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, Benvenisty N, Simon I, Yakhini Z, Cedar H. 
2009. Developmental programming of CpG island methylation profiles in the human genome. Nat 
Struct Mol Biol 16(5):564-71. 
Sun N and Zhao H. 2014. Seamless correction of the sickle cell disease mutation of the HBB gene in 
human induced pluripotent stem cells using TALENs. Biotechnol Bioeng 111(5):1048-53. 
Suzuki M, Yamazaki H, Mukai HY, Motohashi H, Shi L, Tanabe O, Engel JD, Yamamoto M. 2013. 
Disruption of the Hbs1l-myb locus causes hereditary persistence of fetal hemoglobin in a mouse 
model. Mol Cell Biol 33(8):1687-95. 
Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F. 2014. In vivo 
interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat Biotechnol . 
Takahashi S, Onodera K, Motohashi H, Suwabe N, Hayashi N, Yanai N, Nabesima Y, Yamamoto M. 
1997. Arrest in primitive erythroid cell development caused by promoter-specific disruption of the 
GATA-1 gene. J Biol Chem 272(19):12611-5. 
Tanabe O, Katsuoka F, Campbell AD, Song W, Yamamoto M, Tanimoto K, Engel JD. 2002. An 
embryonic/fetal beta-type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer. 
EMBO J 21(13):3434-42. 
Tanabe O, McPhee D, Kobayashi S, Shen Y, Brandt W, Jiang X, Campbell AD, Chen YT, Chang C, 
Yamamoto M, et al. 2007. Embryonic and fetal beta-globin gene repression by the orphan nuclear 
receptors, TR2 and TR4. EMBO J 26(9):2295-306. 
Tanimoto K, Liu Q, Grosveld F, Bungert J, Engel JD. 2000. Context-dependent EKLF responsiveness 
defines the developmental specificity of the human epsilon-globin gene in erythroid cells of YAC 
transgenic mice. Genes Dev 14(21):2778-94. 
Thein SL, Menzel S, Lathrop M, Garner C. 2009. Control of fetal hemoglobin: New insights emerging from 
genomics and clinical implications. Hum Mol Genet 18(R2):R216-23. 
Thein SL, Menzel S, Peng X, Best S, Jiang J, Close J, Silver N, Gerovasilli A, Ping C, Yamaguchi M, et 
al. 2007. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on 
chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A 
104(27):11346-51. 
Tompa P. 2012. Intrinsically disordered proteins: A 10-year recap. Trends Biochem Sci 37(12):509-16. 
Tompa P. 2002. Intrinsically unstructured proteins. Trends Biochem Sci 27(10):527-33. 
Toth G, Gardai SJ, Zago W, Bertoncini CW, Cremades N, Roy SL, Tambe MA, Rochet JC, Galvagnion C, 
Skibinski G, et al. 2014. Targeting the intrinsically disordered structural ensemble of alpha-synuclein 
by small molecules as a potential therapeutic strategy for parkinson's disease. PLoS One 
9(2):e87133. 
Tsai SF, Martin DI, Zon LI, D'Andrea AD, Wong GG, Orkin SH. 1989. Cloning of cDNA for the major DNA-
binding protein of the erythroid lineage through expression in mammalian cells. Nature 
339(6224):446-51. 
  
 152 
Tsang AP, Fujiwara Y, Hom DB, Orkin SH. 1998. Failure of megakaryopoiesis and arrested 
erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev 12(8):1176-88. 
Tsuzuki S and Enver T. 2002. Interactions of GATA-2 with the promyelocytic leukemia zinc finger (PLZF) 
protein, its homologue FAZF, and the t(11;17)-generated PLZF-retinoic acid receptor alpha 
oncoprotein. Blood 99(9):3404-10. 
Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, Usala G, Busonero F, Maschio A, Albai 
G, et al. 2008. Genome-wide association study shows BCL11A associated with persistent fetal 
hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A 
105(5):1620-5. 
Uversky VN. 2011. Intrinsically disordered proteins from A to Z. Int J Biochem Cell Biol 43(8):1090-103. 
Uversky VN, Li J, Fink AL. 2001. Evidence for a partially folded intermediate in alpha-synuclein fibril 
formation. J Biol Chem 276(14):10737-44. 
Vacic V, Oldfield CJ, Mohan A, Radivojac P, Cortese MS, Uversky VN, Dunker AK. 2007. 
Characterization of molecular recognition features, MoRFs, and their binding partners. J Proteome 
Res 6(6):2351-66. 
Vakoc CR, Letting DL, Gheldof N, Sawado T, Bender MA, Groudine M, Weiss MJ, Dekker J, Blobel GA. 
2005. Proximity among distant regulatory elements at the beta-globin locus requires GATA-1 and 
FOG-1. Mol Cell 17(3):453-62. 
van Dijk TB, Gillemans N, Pourfarzad F, van Lom K, von Lindern M, Grosveld F, Philipsen S. 2010. Fetal 
globin expression is regulated by friend of Prmt1. Blood 116(20):4349-52. 
Vegiopoulos A, Garcia P, Emambokus N, Frampton J. 2006. Coordination of erythropoiesis by the 
transcription factor c-myb. Blood 107(12):4703-10. 
Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, Llinas M, Ulrich EL, Markley JL, Ionides J, 
Laue ED. 2005. The CCPN data model for NMR spectroscopy: Development of a software pipeline. 
Proteins 59(4):687-96. 
Wade PA. 2001. Methyl CpG binding proteins: Coupling chromatin architecture to gene regulation. 
Oncogene 20(24):3166-73. 
Wahlberg K, Jiang J, Rooks H, Jawaid K, Matsuda F, Yamaguchi M, Lathrop M, Thein SL, Best S. 2009. 
The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a 
distal regulatory region in erythroid cells. Blood 114(6):1254-62. 
Walavalkar NM, Gordon N, Williams DC,Jr. 2013. Unique features of the anti-parallel, heterodimeric 
coiled-coil interaction between methyl-cytosine binding domain 2 (MBD2) homologues and GATA 
zinc finger domain containing 2A (GATAD2A/p66alpha). J Biol Chem 288(5):3419-27. 
Wang CX, Sather BD, Wang X, Adair J, Khan I, Singh S, Lang S, Adams A, Curinga G, Kiem HP, et al. 
2014. Rapamycin relieves lentiviral vector transduction resistance in human and mouse 
hematopoietic stem cells. Blood 124(6):913-23. 
WATSON J. 1948. A study of sickling of young erythrocytes in sickle cell anemia. Blood 3(4):465-9. 
Weatherall DJ and Clegg JB. 2001. Inherited haemoglobin disorders: An increasing global health 
problem. Bull World Health Organ 79(8):704-12. 
Wells M, Tidow H, Rutherford TJ, Markwick P, Jensen MR, Mylonas E, Svergun DI, Blackledge M, Fersht 
AR. 2008. Structure of tumor suppressor p53 and its intrinsically disordered N-terminal 
transactivation domain. Proc Natl Acad Sci U S A 105(15):5762-7. 
Wijgerde M, Gribnau J, Trimborn T, Nuez B, Philipsen S, Grosveld F, Fraser P. 1996. The role of EKLF in 
human beta-globin gene competition. Genes Dev 10(22):2894-902. 
Wilusz JE, Sunwoo H, Spector DL. 2009. Long noncoding RNAs: Functional surprises from the RNA 
world. Genes Dev 23(13):1494-504. 
  
 153 
Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, Kan YW. 2014. Seamless gene correction of 
beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome 
Res 24(9):1526-33. 
Xiong L, Wang F, Huang X, Liu ZH, Zhao T, Wu LY, Wu K, Ding X, Liu S, Wu Y, et al. 2012. DNA 
demethylation regulates the expression of miR-210 in neural progenitor cells subjected to hypoxia. 
FEBS J 279(23):4318-26. 
Xu J, Sankaran VG, Ni M, Menne TF, Puram RV, Kim W, Orkin SH. 2010. Transcriptional silencing of 
{gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes 
Dev 24(8):783-98. 
Xu J, Bauer DE, Kerenyi MA, Vo TD, Hou S, Hsu YJ, Yao H, Trowbridge JJ, Mandel G, Orkin SH. 2013. 
Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci U 
S A 110(16):6518-23. 
Yi Z, Cohen-Barak O, Hagiwara N, Kingsley PD, Fuchs DA, Erickson DT, Epner EM, Palis J, Brilliant MH. 
2006. Sox6 directly silences epsilon globin expression in definitive erythropoiesis. PLoS Genet 
2(2):e14. 
Yildirim O, Li R, Hung JH, Chen PB, Dong X, Ee LS, Weng Z, Rando OJ, Fazzio TG. 2011. Mbd3/NURD 
complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. 
Cell 147(7):1498-510. 
Zhao Q, Zhou W, Rank G, Sutton R, Wang X, Cumming H, Cerruti L, Cunningham JM, Jane SM. 2006. 
Repression of human gamma-globin gene expression by a short isoform of the NF-E4 protein is 
associated with loss of NF-E2 and RNA polymerase II recruitment to the promoter. Blood 
107(5):2138-45. 
Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ, Cerruti L, Curtis DJ, Patel DJ, Allis CD, et al. 
2009a. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA 
methylation in gene silencing. Nat Struct Mol Biol 16(3):304-11. 
Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ, Cerruti L, Curtis DJ, Patel DJ, Allis CD, et al. 
2009b. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA 
methylation in gene silencing. Nat Struct Mol Biol 16(3):304-11. 
Zhao X, Ueba T, Christie BR, Barkho B, McConnell MJ, Nakashima K, Lein ES, Eadie BD, Willhoite AR, 
Muotri AR, et al. 2003. Mice lacking methyl-CpG binding protein 1 have deficits in adult 
neurogenesis and hippocampal function. Proc Natl Acad Sci U S A 100(11):6777-82. 
Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM. 2010. KLF1 regulates BCL11A expression and gamma- 
to beta-globin gene switching. Nat Genet 42(9):742-4. 
Zhou W, Zhao Q, Sutton R, Cumming H, Wang X, Cerruti L, Hall M, Wu R, Cunningham JM, Jane SM. 
2004. The role of p22 NF-E4 in human globin gene switching. J Biol Chem 279(25):26227-32. 
Zhou X, Ruan J, Wang G, Zhang W. 2007. Characterization and identification of microRNA core 
promoters in four model species. PLoS Comput Biol 3(3):e37. 
  
  
 154 
Vita 
 
 
 
Megha Anupam Desai was born on April 11, 1987 in Vadodara, Gujarat, India, and is an 
Indian citizen. She graduated from Baroda High School, Vadodara, India in 2005. She 
received her Bachelor of Engineering in Biotechnology from NMAM Institute of 
Technology, Nitte, Karnataka, India in 2009.  
